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ABSTRACT 
 
Food poisoning incidences relating to marine biotoxins are a global phenomenon and have 
the potential to severely impact the aquaculture industry. As a result, and as a legislative 
requirement in the European Union (EU), many countries have implemented monitoring 
programmes for these compounds but their success relies on the availability of certain quality 
assurance tools, two of which are reference materials (RMs) and proficiency testing. The 
limited amounts of RMs, in particular matrix certified reference materials (CRMs) for 
paralytic shellfish poisoning (PSP) toxins has been a limiting factor in the implementation of 
alternatives to the mouse bioassay for routine monitoring programmes. Various stabilisation 
procedures were investigated to ascertain the applicability of each for preparing RMs for 
various uses including internal QA/QC, proficiency testing and as candidates for certification. 
The beginning of these studies coincided with a large PSP toxic event in Icelandic waters. 
During that period mussels from two production sites on the north and north-west coasts of 
Iceland accumulated PSP toxins to levels many times over the EU regulatory limit. Mussels 
sampled during this period were characterised and presented along with phytoplankton data 
from the same period and presented as a first report of PSP toxins from Icelandic waters. 
Large quantities of naturally contaminated mussel tissues were harvested during this period 
for use in these studies. 
Various stabilisation procedures were investigated, such as thermal treatment, the use of 
preserving additives, high pressure processing (HPP) and freeze drying, for their applicability 
in preparing RMs for PSP toxins. Extensive characterisation of the materials was performed 
through homogeneity and short and long-term stability studies using two LC-FLD methods to 
evaluate each technique in reducing levels of degradation, biotransformations or 
epimerization. Freeze drying proved the most effective technique evaluated and this 
ABSTRACT 
 
 
 
ii 
 
procedure was used to prepare RMs in two shellfish species, Pacific oyster (Crassostrea 
gigas) and blue mussels (Mytilus edulis). The technique improved the stability of all toxins 
assessed compared to untreated controls. A successful feasibility study was carried out in a C. 
gigas matrix which resulted in the production of a medium scale RM as a candidate CRM. 
Certification of this material was not carried out during the course of these studies however. 
Although freeze drying proved the most effective in stabilising both the tissue matrix and the 
PSP toxins themselves, the labour intensive nature of the procedure as well as the significant 
per unit production costs led to alternative RM techniques being investigated. HPP of a C. 
gigas tissue matrix was performed and it provided an extremely effective technique for 
stabilising the toxins through a reduction of microbial activity. Stability studies showed the 
technique reduces or eliminates toxin degradation and epimerisation compared to untreated 
control materials with the technique potentially having applications in CRM development, 
although a full feasibility study was not conducted.  
The use of heat treatment and preserving additives provided the simplest and most cost 
effective stabilisation procedure investigated with both techniques, particularly when 
combined, improving toxin and matrix stability compared to untreated controls. Each 
technique was evaluated separately and combined in one tissue matrix, M. edulis and 
applications for materials prepared by this procedure were examined. Combining the use of 
preserving additives with a thermal pre-treatment step provided sufficiently stable and 
homogenous RMs which were used as an internal QA/QC tool in the Irish National 
Monitoring Programme (NMP) and in proficiency testing (PT) schemes operated by 
QUASIMEME and VEREFIN. 
Data from a RM prepared by the combined techniques above and used in the Irish NMP over 
a two year period provided evidence for the long-term stability of the material using a 
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classical stability model and was used to calculate an expanded uncertainty of measurement 
for the method used for official control purposes at the Marine Institute. 
Materials prepared by these combined techniques were also used to develop the first 
commercially available PT scheme for PSP toxins. Data is presented from the first six years 
of this development exercise from participants using a wide array of methodologies. Data 
showed the improvement of participants over this period but found statistical differences in 
the datasets of both LC-FLD methods employed by some subscribers in determining dcSTX 
and GTX2,3. A material was also prepared for use in a separate PT scheme operated by 
VEREFIN which highlights the wide applicability of these RMs. 
The techniques investigated during these studies have multiple applications in method 
development, as QA/QC tools, in CRM preparation and in proficiency testing schemes. 
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Chapter 1  
BACKGROUND AND OBJECTIVES 
 
1.1 HARMFUL ALGAL BLOOMS, BIOTOXINS AND SHELLFISH POISONING  
Phytoplankton are microscopic, single-celled plants that can grow in both marine and 
freshwater environments, providing a critical food supply for filter feeding bivalve shellfish 
such as mussels, oysters, clams and scallops. There are approximately 5000 known species of 
marine phytoplankton, a small proportion of which, less than 2%, can produce toxins that can 
find their way through the food chain to humans [1]. Dense concentrations of these cells can 
manifest as Harmful Algal Blooms (HABs), frequently referred to as “red tides”. 
 
Figure 1-1: From phytoplankton to food poisoning. 
 
Phytoplankton are a vital food source for filter feeding bivalve shellfish such as mussels, 
oysters, clams and scallops. Biotoxins can accumulate in the flesh of shellfish through filter 
feeding of toxin producing phytoplankton species, with the highest toxin concentrations 
generally found in the digestive gland (hepatopancreas) of the shellfish (Figure 1-2) [2]. 
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Figure 1-2: Internal anatomy of a mussel. 
 
There are approximately 2000 cases of human poisoning reported each year through the 
consumption of fish and shellfish and results in an approximate 15% mortality rate. Impacts 
on public health and potential economic damage through reduced consumption and 
exportation can therefore be extensive [3]. Whilst the shellfish generally remain unaffected 
following accumulation of these phycotoxins, human consumption of contaminated seafood 
products can lead to a variety of symptoms experienced after as little as 30 minutes, and can 
include nausea, vomiting, abdominal pain, diarrhoea, memory loss, paralysis and in extreme 
cases death. 
There are 5 internationally recognised syndromes of shellfish poisoning, namely: 
 Paralytic Shellfish Poisoning (PSP) 
 Amnesiac Shellfish Poisoning (ASP) 
 Diarrhetic Shellfish Poisoning (DSP) 
 Azaspiracid Shellfish Poisoning (AZP) and 
 Neurotoxic Shellfish Poisoning (NSP) 
 
The research undertaken in these studies was on the PSP group of biotoxins. 
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1.2 HYDROPHILIC BIOTOXINS 
1.2.1 PARALYTIC SHELLFISH POISONING (PSP) 
PSP is caused by a group of closely related compounds all based on a tetrahydropurine 
skeleton (Figure 1-3), with saxitoxin (STX) being the parent toxin and the first to be isolated 
in this group [4,5]. 
 
Figure 1-3: Structure of the principal PSP toxins. 
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These potent neurotoxins are mainly produced by marine dinoflagellates, in particular, 
Alexandrium spp. (Figure 1-4), Gymnodinium catenatum and Pyrodinium bahamense var. 
compressum [6] but have also been found to be produced by some freshwater cyanobacteria 
[7,8]. 
Saxitoxin and its congeners differ substantially in their toxicity (Table 1-1) and can be 
categorised into several subgroups based on their substituent sidechains, the most important 
of which are the carbamoyl, decarbamoyl and N-sulfo-carbamoyl groups (Figure 1-3). 
Saxitoxin is an inhibitory neurotoxin which has a high affinity for binding site 1 of the 
voltage-gated sodium ion channel  in mammalian nerve cells, thus inhibiting conductance of 
signals along the neuron [9].  Depending on the dose, symptoms can include tingling 
sensation or numbness around the lips, face, neck and extremities, headache, dizziness, 
nausea, vomiting, diarrhoea, muscular paralysis, respiratory difficulties and in severe cases 
death through respiratory paralysis [10]. Shellfish contaminated with PSP toxins pose severe 
risks to human consumers and numerous accounts of intoxications leading to illness or death 
have been recorded from around the world [11–15]. 
 
Figure 1-4: Alexandrium tamarense using a) fluorescence in situ hybridisation (FISH) probes and b) calcofluor white 
staining using a compound microscope with epi-flourescence microscopy (Olympus BX53, 100Mag). 
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STX comprises a 3,4-propinoperhydropurine tricyclic system together with two guanidino 
functional groups, which account for its high polarity and is soluble in water, methanol and 
ethanol but not in other organic solvents [4]. Paralytic Shellfish Toxins (PSTs) are prone to 
pH dependent conversions, are heat stable under mildly acidic conditions with the exception 
of the N-sulfo-carbamoyl toxins and are readily oxidised under alkaline conditions [16]. The 
N-sulfo-carbamoyl toxins such as GTX5 and C1,2 may be partially converted to the 
corresponding carbamate group toxins through hydrolysis if heated at low pH. These 
conversions can take place when PSTs are boiled with a strong acid such as HCl and can 
result in STX analogues with lower toxicity factors being chemically converted into ones 
with higher toxicities. Conversions do not take place in weak acids such as acetic acid even 
under boiling conditions [6]. 
Table 1-1: Toxicity equivalency factors (TEFs) of the principal PSP toxins. 
Toxin 
Toxicity Equivalency Factors 
Oshima
a 
EFSA
b 
STX 1.00 1.00 
GTX2 0.36 0.40 
GTX3 0.64 0.60 
NEO 0.92 1.00 
GTX1 0.99 1.00 
GTX4 0.73 0.70 
GTX5 0.06 0.10 
C1 0.01 - 
C2 0.10 0.10 
C3 0.01 - 
C4 0.06 0.10 
GTX6 0.06 0.10 
dcSTX 0.51 1.00 
dcGTX2 0.15 0.20 
dcGTX3 0.38 0.40 
dcNEO - 0.40 
11-hydroxy-STX - 0.30 
a TEFs calculated based on relative potency data by Oshima et al. [17]. 
b TEFs proposed by the CONTAM panel (EFSA) [6]. 
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STX-group toxins, also referred to as PSTs are not detectable by either UV or fluorescence 
owing to the lack of a chromophore. They therefore require alkaline oxidation into 
fluorescent imino purine derivatives for detection [6]. 
The first recorded fatal incidence of shellfish poisoning occurred in 1793 during Captain 
George Vancouver’s expedition into British Columbia. Upon landing in an area now known 
as Poison Cove, shellfish were collected by some of his crew for breakfast. This toxic 
banquet resulted in the death of one crew member five and a half hours after ingestion and 
severe PSP like symptoms experienced by four others; although they subsequently made a 
full recovery [18]. STX producing algae have been found to occur worldwide in both tropical 
and moderate climate zones [6], with detection of phytoplankton and contaminated shellfish 
tissues confirmed throughout regions of Europe, the Americas, Asia, Africa and Australasia. 
The EU regulatory limit for PSTs is set at 800 micrograms per kilogram (800 µg/kg) [19] and 
the reference method is the mouse bioassay (MBA) [20]. A named alternative to the MBA, 
the so called “Lawrence method”, was first cited in EU legislation in 2006 [21] which is 
based on high performance liquid chromatography with fluorescence detection (LC-FLD). 
 
1.2.2 AMNESIC SHELLFISH POISONING (ASP) 
Domoic acid (DA) (Figure 1-5), the amnesic shellfish poisoning toxin, belongs to a group of 
amino acids called the kainoids. They are classified as neuroexcitants or excitotoxins as they 
interfere with neurotransmission mechanisms in the brain [22].  
 
Figure 1-5: Structure of domoic acid. 
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The toxin can be accumulated in shellfish feeding on a number of toxic Pseudo-nitzschia 
diatom species. Consumption of shellfish contaminated with ASP toxins can lead to 
intoxication with symptoms including, abdominal cramps, nausea, vomiting, diarrhoea, 
decreased reaction to deep pain, disorientation, hallucinations, confusion, short-term memory 
loss (amnesia) and seizures [23]. 
The EU regulatory limit is set at 20 milligrams of domoic acid per kilogram (20 mg/kg) [19] 
and the reference method [20] is based on that published by Quilliam et. al., in 1995 for the 
quantitative determination of domoic acid in unsalted seafood [24]. 
 
1.3 LIPOPHILIC BIOTOXINS 
1.3.1 DIARRHETIC SHELLFISH POISONING (DSP) 
The class of toxins causing DSP includes okadaic acid (OA) and the dinophysistoxins DTX1, 
DTX2 and DTX3 (Figure 1-6). The first documented occurrence of DSP was in 1976 in 
Japan where numerous intoxications were reported [25].  
 
Figure 1-6: Structure of the OA group toxins. 
DSP is caused by certain Dinophysis and Prorocentrum species and has a worldwide 
geographical distribution [2]. No deaths have ever been attributed to DSP with patients 
Toxin R1 R2 R3
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generally recovering within three days from symptoms which may include nausea, vomiting, 
diarrhoea and abdominal cramps [3]. In addition the polyether toxins OA and DTX1 may 
promote stomach tumours [26]. 
For many years, the EU reference method for the regulatory testing of DSP toxins was a 
qualitative rodent-based assay [19,20], usually implemented as a mouse bioassay (MBA). As 
of the 1
st
 January 2015 the EU reference method was changed from the MBA to a liquid 
chromatography-mass spectrometry (LC-MS/MS) method as described by the EU- reference 
laboratory for marine biotoxins (EU-RLMB) [27]. The method must be capable of detecting 
at least OA, DTX1, DTX2, DTX3 and their esters and the EU regulatory limit is set at 160 
micrograms of okadaic acid equivalents per kilogram (160 µg/kg) [19]. 
 
1.3.2 AZASPIRACID SHELLFISH POISONING (AZP) 
Azaspiracids (AZAs)(Figure 1-7) are a recently discovered class of shellfish toxin, first 
implicated in human poisoning in 1995 in the Netherlands through consumption of mussels 
originating from Killary Harbour, Ireland [28]. Seven official poisoning incidents attributed 
to AZP have been reported to date with all originating from shellfish harvested in Ireland 
[29]. 
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Figure 1-7: Structure of the AZA group toxins. 
 
The first causative organism of AZP was only recently discovered in 2009 and named 
Azadinium spinosum [30], with many more Azadinium and related species being subsequently 
discovered [31]. Symptoms are similar to those described for DSP and include nausea, 
vomiting, abdominal cramps and diarrhoea and no deaths have been attributed to AZP [28]. 
As in the case of the DSP group toxins described above, the reference method in the EU for 
AZAs is the EU-RLMB LC-MS/MS method which must be capable of detecting at least 
AZA1, AZA2 and AZA3 [27]. The regulatory limit in the EU is 160 micrograms of 
azaspiracid equivalents per kilogram (160 µg/kg) [19]. 
 
1.3.3 YESSOTOXINS (YTXS) AND PECTENOTOXINS (PTXS) 
Neither YTX nor PTX toxins have been implicated in shellfish poisoning in humans to date 
and there has been much debate on the toxicity of both groups with evidence showing PTXs 
(Figure 1-8) to be of no risk to humans [32] and the oral toxicity of YTXs (Figure 1-9) to be 
extremely low compared to its intraperitoneal toxicity [33]. 
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Figure 1-8: Structure of the PTX group toxins. 
 
Both groups are named after the genus of scallop they were first isolated from, Patinopecten 
yessoensis [34,35] and the reference method in the EU for their detection is the EU-RLMB 
LC-MS/MS method described above [27]. 
 
Figure 1-9: Structure of yessotoxin. 
The regulatory limit in the EU is set at 160 micrograms of okadaic acid equivalents per 
kilogram for PTXs (160 µg/kg) [19]; owing to their general co-occurrence with DSP group 
toxins, and at 3.75 milligrams of YTX equivalents per kilogram (3.75 mg/kg) [36]. The 
causative organisms of PTXs are Dinophysis and Protoperidinium species and YTXs are 
caused by  Lingulodinium polyedrum and Protoceratium reticulatum [34,35]. 
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1.4 IRISH SHELLFISH INDUSTRY AND IMPACTS OF HABS 
Azaspiracids are the most problematic toxin group in terms of farm closures for the Irish 
shellfish industry and they have been detected every year since the inception of the biotoxin 
monitoring programme in 2001 (Figure 1-10) [31]. Shellfish farm closures have occurred 
every year except 2004, due to AZP toxicity over the EU regulatory limit. Toxicity typically 
occurs in the mid to late summer months with those sites affected sometimes remaining 
closed for long periods due to the apparent slow depuration rates of these toxins from 
shellfish [37]. Ireland is the worst affected country for AZAs with Norway and the UK being 
the only other countries to report AZA levels over the EU regulatory limit. There have been 
seven official poisoning incidents associated with AZA toxins reported to date but numerous 
others have also been linked to this toxin group, with the source of all incidents traced back to 
shellfish harvested in Ireland [29]. 
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Figure 1-10: Shellfish farm closures from 2012-2014 caused by DSP and AZP toxins. 
2012 2012
2013 2013
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DSP is caused by the OA-group toxins and they represent the next most problematic for the 
Irish shellfish industry causing significant economic hardship to shellfish farmers due to toxin 
related farm closures. They have been detected in various shellfish species in Ireland since 
2002. Toxicity typically occurs during the early to mid-summer months from Dinophysis 
acuta or Dinophysis acuminata blooms producing OA and DTX2 predominantly [38]. 
Depuration rates of OA-group toxins are faster than AZAs but both toxin groups regularly co-
occur in Irish shellfish which compounds the problem for farmers [38]. PTXs have only 
recently been detected in Irish shellfish (since 2014), although regular monitoring of this 
toxin group has only been in effect since 2011. YTXs have never been detected in any Irish 
shellfish species to date. 
Another problematic toxin group, although impacting far less is ASP caused by DA. Until 
recently scallops were the only species to be monitored year round for DA with levels in the 
main edible parts (posterior adductor muscle and gonad) rarely rising above the regulatory 
limit of 20 mg/kg, although it takes a long time for DA to depurate from scallops [39]. 
During large blooms of the causative organism, Pseudo-nitzchias, other species are regularly 
tested for this toxin group. Levels in these other species, mainly mussels can rise many times 
above the regulatory limit within a couple of weeks but fortunately toxicity quickly subsides 
due to apparently quick depuration rates. 
PSP toxins have not been problematic for the Irish shellfish industry to date with only one 
location in the South of the country, Cork Harbour experiencing shellfish harvesting area 
closures as a result of PSTs over the EU regulatory limit of 800 µg/kg STX equivalents. 
Monitoring of PSP was carried out using the MBA [40] until 2011 at the Marine Institute 
(MI), after which a pre-column oxidation (preCOX) liquid chromatography with fluorescence 
detection (LC-FLD) method also called the “Lawrence method” resulting in AOAC Official 
Method (OM) 2005.06 was used [41].  
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Figure 1-11: Locations where PSP toxins have been detected in shellfish 2012-2014. 
 
Since the implementation of this method PSTs have been detected, albeit at low levels, in 
other locations along the west coast of Ireland (Figure 1-11). It is unclear whether the 
occurrence of these toxins in other locations is due to the spread of the toxin producing algal 
2012 2013
2014
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species or, as is more likely, their detection is due to the improved sensitivity the preCOX 
LC-FLD method provides in comparison with the PSP MBA. The causative organism for 
PSP toxins in Irish waters are the Alexandrium species tamarense and minutum, which 
produce a toxin profile consisting predominantly of the gonyautoxins 2 & 3 (GTX2,3) as well 
as saxitoxin (STX). In samples close to or above the regulatory limit the gonyautoxins 1 & 4 
(GTX1,4) are also typically detected. Toxin accumulation in shellfish from Cork Harbour is 
very predictable with the onset of toxin uptake typically taking place during the first two 
weeks of June each year. Toxin levels quickly rise to concentrations around the regulatory 
limit or above but drop within a couple of weeks, although very low levels of GTX2,3 can 
typically be detected for many months thereafter. Although Alexandrium species are detected 
in phytoplankton samples all along the West coast of Ireland, particularly during the summer 
months, toxin levels in shellfish remain low. This is thought to be because both toxic and 
non-toxic variants of Alexandrium exist in Irish waters with the non-toxic variant 
predominating outside Cork Harbour at present [42]. 
 
1.5 EU REGULATORY FRAMEWORK 
There have been a number of EU Directives and Regulations relating to the production and 
placing on the market of live bivalve molluscs for human consumption. Two underlying 
Council Directives played an important role in setting out the goals to be achieved by a 
Member State (MS). First, Council Directive 91/492/EEC, last amended by Council Directive 
97/79/EC, which laid down the health conditions for the production and the placing on the 
market of live bivalve molluscs and second, Council Directive 86/609/EEC which related to 
the protection of animals used for experimental or other scientific purposes [43–45]. 
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In 2004 Council Regulations (EC) 853/2004 and 854/2004 were passed into law which 
brought together and replaced the existing hygiene regulations for the food sector [19,46]. 
Regulation (EC) No. 853/2004 lays down the maximum permissible levels of marine 
biotoxins in shellfish with PSP toxins for example set at a limit of 800 micrograms (µg) per 
kilogram (kg). Regulation (EC) No. 854/2004 gives the monitoring authorities in each MS 
the mandate to examine live molluscs for the presence of biotoxins. 
Council Regulation (EC) No. 2074/2005 amended by Regulation (EC) No. 1664/2006 
indicates the recognised testing methods for marine biotoxins for the purposes of Regulations 
(EC) No. 853/2004 and No. 854/2004 [20,21]. With regard to PSP toxins it follows previous 
directives in establishing the biological testing method as the reference method in the EU but 
for the first time lays down an alternative method that can be used for official control 
purposes. The so called “Lawrence Method”, as published in the Journal of the AOAC as OM 
2005.06 may also be used by MSs [41]. 
 
1.6 REFERENCE MATERIALS 
The need for and use of reference materials (RMs) in the analysis of foodstuffs is necessitated 
by the quality assurance requirements of official control laboratories in order to demonstrate 
the adequacy of their testing methods. The definition of a RM as set down in the International 
Standards Organisation (ISO) 2008 guide on the definitions of reference materials and 
certified reference materials is stated as [47]: 
“A material, sufficiently homogeneous and stable with respect to one or more specified 
properties, which has been established to be fit for its intended use in a measurement 
process.” 
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The nomenclature used in the area of RM production varies, with organisations and authors 
of literature using an assortment of different terms. Arguably the most important in terms of 
analytical capabilities are Certified Reference Materials (CRM). The characteristics of these 
materials allows the determination of the accuracy or trueness of a method providing valuable 
information on the performance of methods to both laboratories and accreditation bodies. 
Their effective use is highly dependent on the long-term stability of the material, so detailed 
feasibility studies on candidate CRMs must be undertaken to determine any potential 
degradation issues associated with the material through long-term or accelerated stability 
studies. The ISO 2008 guide further defines a CRM as [47]: 
“Reference material characterised by a metrologically valid procedure for one or more 
specified properties, accompanied by a certificate that provides the value of the specified 
property, its associated uncertainty, and a statement of metrological traceability.” 
 
1.6.1 REFERENCE MATERIAL TYPES AND CLASSIFICATION 
RMs may be categorised in a number of different ways with two distinct types described as 
calibrant RMs and matrix RMs, the latter of which is dealt with in these studies [48,49]. The 
primary uses of these categories of RM are for analytical instrument calibration and the 
validation of entire analytical methods respectively, although they can be interchangeable. 
RMs can also be categorised based on their intended use and this will form the basis for how 
materials are defined herein. 
These categories are described as follows  [50]: 
1. Certified Reference Material (CRM):  
As detailed in the definition above, a CRM must be accompanied by or be traceable to a 
certificate or other piece of documentation issued by a certifying body. The material will 
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have one or more property values certified by a technically valid procedure together with 
uncertainty and traceability to the primary unit or standard [51]. 
Certification and the statistical principles involved in this process are detailed in various ISO 
documents. 
2. Laboratory Reference Materials (LRMs):  
These materials are generally used in the day-to-day quality control (QC) of official control 
sample testing. They are extracted and analysed alongside routine samples and thereby form 
one of the primary tools for the acceptance or rejection of a batch of samples. LRMs can also 
serve as a powerful and significantly cheaper tool, compared to the sole use of CRMs, in the 
in-house validation of a test method, particularly for parameters such as precision and 
ruggedness. As these materials are typically not transported to other laboratories, 
confirmation of stability under frozen conditions is usually sufficient for demonstration of 
fitness for purpose, in addition to homogeneity being adequately proven [50]. 
3. Interlaboratory Reference Materials (ILRMS):  
The last category of matrix RMs were first defined by Hess et al. in 2007 [50] and are 
intended to check the comparability of testing methods through interlaboratory exercises, 
such as collaborative trials and proficiency testing. The stability of these materials during 
transportation internationally to participant laboratories can be demonstrated through stability 
studies using elevated temperatures to mimic adverse conditions potentially encountered 
during transit. This requirement typically necessitates the use of stabilising techniques in the 
preparation of these materials as well as adequate homogenisation techniques, a requirement 
of any RM production procedure. 
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1.6.2 PRODUCTION 
The production of any RM requires a level of technical and organisational competence to 
ensure the key requirements of homogeneity and stability are adequately fulfilled [52]. 
Chapters 4 and 5 detail the various RM preparation techniques investigated in these studies 
but generically any RM procedure follows the basic key steps detailed in ISO guide 80:2014 
and illustrated in Figure 1-12 [52]. This document gives guidance for the in-house 
preparation of what are termed quality control materials (QCMs), a category defined by ISO 
to encompass both LRMs and ILRMs. 
 
Figure 1-12: Key steps in the preparation of RMs (reproduced from ISO guide 80 [52]. 
 
The specification of the RM in general is that the materials prepared should be as close as 
possible to real life samples and be available in sufficient quantities. In the area of biotoxin 
monitoring the large variety of shellfish species covered in these programmes means, in 
general, choosing the species most frequently analysed; which in the case of the Irish NMP 
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blue mussels (Mytilus edulis) are. In the area of ILRM production (described in Chapter 6) a 
systematic approach was followed which sought to prepare materials from as many shellfish 
species as possible, although this was dictated by the authors’ access to large enough 
quantities of naturally contaminated material. Other factors to consider in the material 
specification are the unit size required, an estimate of the total units required and the 
preparation yield [52]. Materials can then be sourced through various means including 
purchase from another organisation, collection of contaminated shellfish during toxic events, 
through toxin spiking or even shellfish feeding experiments [53]. 
One of the most important steps in this procedure is material processing which can involve a 
number of different steps aimed at ensuring appropriate homogeneity and stability for the 
final materials. Stabilising the material is discussed in detail in further chapters but the 
processing techniques for the wet tissue RMs, aimed at improving homogeneity, were 
developed and refined by McCarron in 2007 [54]. These techniques involved the use of 
various industrial blenders and grinders purchased during this period and further used during 
the course of these studies. 
Sub-division and particularly packaging is another important factor to consider, with 
appropriate techniques having been shown to improve toxin stability. Sealing the final 
product under an inert gas, for example, prevents or minimises oxidative reactions from 
taking place as well as creating an environment inhospitable for microbial growth [54]. 
Once the material is prepared and dispensed, an assessment of its homogeneity and stability 
must be undertaken in addition to RM characterisation and value assignment. Homogeneity is 
determined by analysing a representative quantity of RMs from the entire production batch 
with a statistical evaluation of the data. For the RMs described in this thesis this involved 
calculating the coefficient of variation from the homogeneity data with comparison to 
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expected levels of method variability determined through validation of the test method, below 
which the RM was deemed sufficiently homogenous.  
Depending on the final use of the materials, an assessment of stability in the short and/or 
long-term must also be undertaken. The stability studies contained in this thesis followed a 
reverse isochronous design which negates day-to-day instrumental variations through the 
analysis of all samples at the end of the study in one chromatographic sequence [55]. Material 
characterisation and value assignment are also important in establishing toxin profiles in the 
final product, as changes can occur during the processing steps. This is particularly important 
for ILRM preparation where PT organisers require the information to assess which toxins or 
toxin profiles are covered by their schemes and for the preparation of LRMs under private 
contract. 
The last steps involve the preparation of accompanying documentation which generally 
include homogeneity and stability results, material characterisation and a description of the 
preparation techniques employed and the recommended storage conditions of the product 
determined through stability studies. 
 
1.6.3 STABILISATION TECHNIQUES 
In terms of the stability of biological matrices, microbial or biological activity is the most 
important influence to consider during preparation. Chemical activity and physical effects 
from, for example light and temperature are also important influences to consider, but 
microbial activity presents the biggest potential problem in RM preparation [56]. Various 
procedures to stabilise the matrix and therefore the analyte(s) have been described in the 
literature and the techniques used to prepare the RMs contained in this thesis are briefly 
described below.  
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1.6.3.1 PRESERVING ADDITIVES 
The use of preserving additives to stabilise the biological matrix is a relatively easy and cost 
effective technique to employ in RM production. The use of the antioxidant ethoxyquin has 
been used previously in the preparation of CRMs for marine biotoxins [57–59] and its 
combined use with antibiotics in the preparation of marine biotoxin RMs [54]. Their 
combined use was shown to improve the stability of DA [60] and to a lesser extent AZA3 
[54]. To date the combined use of these additives has not been reported for their stabilising 
effects on PSTs in shellfish matrices. 
As in the case of most stabilisation techniques for biological matrices the use of preserving 
additives aims to reduce or eliminate biological activity and oxidative degradation from 
taking place in the final product. This is particularly important given the fact that processing 
and dispensing steps are not carried out aseptically in the procedures described in this thesis 
so any technique aimed at reducing or eliminating bacterially induced reactions in the final 
product may be beneficial. 
 
1.6.3.2 THERMAL TREATMENT 
Another relatively simple stabilisation technique is sterilization through heat treatment which 
aims to destroy bacteria present in the source tissues. As this step is usually performed prior 
to material processing and dispensing bacteria may still play a part in toxin stability due to 
the septic nature of further processing steps. The heat treatment step should however, 
significantly reduce bacteria colony numbers in the source tissues. Although the thermal 
stability of the analytes must be sufficient to withstand the high temperatures applied, to 
minimise degradation during this step [52]. 
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1.6.3.3 FREEZE DRYING 
Removal of water through drying is another technique to stabilise, in particular biological 
tissue matrices, improving both short and long-term stability as well as making the material 
easier to handle [52]. Freeze drying is a technique ideally suited to the preparation of 
thermally sensitive analytes owing to the relatively gentle freeze drying process. The process 
involves the removal of water from the matrix through a process called sublimation, which is 
the transition of a substance directly from the solid to the gas phase without going through the 
intermediate liquid phase [61]. This transition takes place at temperatures and pressures 
below the triple point of a substance, which is the temperature and pressure point where all 
three phases (solid, liquid and gas) exist in thermodynamic equilibrium [61]. The process 
involves reducing the pressure inside the freeze drying chamber while simultaneously 
increasing the temperature slowly through a series of ramp steps, typically 96 hours in the 
case of materials described herein. The removal of water reduces the likelihood of microbial 
growth formation [52]. 
 This technique has been used for many years in the area of preservation in the food industry 
[56], as well as in the preparation of RMs for DA and some lipophilic toxins [62–65]. It has 
also been investigated for the preparation of a CRM containing two PSTs, STX and dcSTX 
[66–68]. This PST freeze dried CRM was not made commercially available and could not be 
distributed by the Institute for Reference Materials and Measurement (IRMM). 
 
1.6.3.4 HIGH PRESSURE PROCESSING 
High Pressure Processing (HPP) or High Hydrostatic Pressure Processing (HHP) is a non-
thermal pasteurisation technique which has been used to produce food products free from 
microbial contamination for over a century [69]. The process is desirable not only for the 
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potential of decontaminating the food product but also because it minimises the impact on the 
nutritional and physical characteristics of the final product (Figure 1-13). 
 
Figure 1-13: Picture of a strawberry after HPP treatment 
 
The process generally involves subjecting the food product to pressures of between 150-600 
MPa for times of 1-15 min [70]. Pressure is applied through water which surrounds the 
product and allows an even distribution of pressure throughout the product. 
This process applied in the area of RM preparation has the potential advantage of leaving the 
final material and matrix practically intact and very close to real life samples generally 
analysed in a laboratory. However, prior to the work described in this thesis, such an 
approach has yet to be reported for RMs of any type. 
 
1.6.4 HOMOGENEITY TESTING 
Homogeneity is defined by ISO as the “uniformity of a specified property value throughout a 
defined portion of a reference material” [47]. The level of inhomogeneity of the material 
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should result in a smaller effect on the measurement result than the expected variation of the 
measurement process or should be below an established criterion value [52].  
In general homogeneity testing requires the selection of a sufficient number of units, which 
are representative of the entire batch and the analysis of selected properties within those 
units. There are two aspects to homogeneity testing, between-unit and within-unit. Within-
unit homogeneity is only a requirement where the RM has been dispensed with more than 
one portion, and it is essential that each portion taken yields similar results. Between-unit 
homogeneity seeks to determine if differences between the various units of a batch exist and 
if those differences are within acceptable limits. The RMs described in these studies were 
dispensed as single portions so within-unit homogeneity was not assessed. 
The number of samples taken for homogeneity testing has recently been covered in ISO guide 
80:2014 [52] and two sampling guidelines are described in the document. The first approach 
is to select samples from a stock comprising “n” individuals using the formula: 
3(n)
1/3
 
This approach can be excessive in the number of samples chosen, particularly when 
dispensing large quantities of RMs (>1000) and therefore represents a significant analytical 
effort including the associated costs involved. 
The second approach which is based on studies to determine the effects of reducing the 
number of units selected, concluded that in certain circumstances 10 units analysed in 
duplicate was sufficient in assessing homogeneity [51]. This approach, where ≥10 units are 
selected is deemed appropriate by ISO for materials used in proficiency testing schemes [71]. 
The use of either approach in selecting the number of units to be assessed is highly dependent 
upon the sampling approach taken, i.e. the selections are representative of the entire 
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production batch. The best way of ensuring representativeness is through stratified random 
sampling. This involves dividing the total population into smaller groups known as strata, 
from which simple random sampling or systematic sampling is applied to each stratum. 
 
1.6.5 STABILITY TESTING 
Stability is defined in ISO guide 30:2015 as the “characteristic of a reference material, when 
stored under specified conditions, to maintain a specified property value within specified 
limits for a specified period of time”.  
The stability and homogeneity of a RM are arguably the two most important factors to 
consider when preparing these materials. Depending on the final use of the material, different 
approaches to stability testing can be performed. For example if transportation of the RM is 
not required, such as an LRM for sole internal use at one site, then short-term stability testing 
would not be necessary and an assessment of its long-term stability would be sufficient. 
Where international dispatch of the materials may be required, such as the preparation of 
ILRMs, an assessment of the short-term stability is necessary as these materials need to be 
stable during potentially adverse transportation conditions. As RMs are often prepared in 
large enough quantities to enable their use over a number of years, a long-term stability 
assessment is necessary to determine storage conditions. 
There are two main approaches in assessing the stability of the RM, classical and isochronous 
stability studies [55]. The “classical” model involves the analysis of materials, stored at 
various temperatures, and at pre-defined times during the course of the study. As analysis is 
carried out on different days, this model is highly dependent upon the long-term 
reproducibility of the method as well as its repeatability. 
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An alternative approach described by Lamberty et al. in 1998 [55] sought to negate these 
reproducibility issues through an isochronous experimental design, which can be used when 
the total duration of the study is known. This design can have two main formats, isochronous 
and reverse isochronous measurements. In the standard isochronous design the required 
amount of materials are transferred to the various storage conditions at the beginning of the 
study. After specific time periods during the study, materials are transferred from the storage 
conditions to a reference storage temperature where stability is assumed. This format relies 
on the assumption that the degradation process ceases once materials are removed from the 
temperature condition being investigated and stored at the reference temperature. 
A reverse isochronous stability study involves transferring the required amount of materials 
to the reference temperature at the beginning of the study. At specific time periods during the 
study, materials are removed from the reference storage temperature and transferred to the 
storage conditions being investigated. 
In the case of both the isochronous and reverse isochronous stability studies, all materials are 
removed from the storage conditions at the end of the study and analysed immediately. The 
long-term method reproducibility is therefore inconsequential following this approach and 
only method repeatability is a factor in the analysis. 
 
1.6.6 CERTIFICATION 
There are a number of technically valid approaches to certifying a reference material, 
including measurement by one or more methods involving one or many laboratories. The 
requirements for a CRM are that it is “characterised by a metrologically valid procedure for 
one or more specified properties, accompanied by a certificate that provides the value of the 
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specified property, its associated uncertainty, and a statement of metrological traceability” 
[51]. 
Accuracy and the uncertainty of the values determined are two important aspects in the 
certification process. The certified value(s) of the material presents the best estimate of the 
“true” value and is not expected to differ by more than the measurement uncertainty. The 
uncertainty of the measurement value should take into account errors associated with the 
measurement process, such as systematic or random errors. All components of the uncertainty 
should be evaluated and taken into account when calculating this value, with data generated 
through the measurement process, as well as homogeneity and stability study data being used 
to produce the final uncertainty of the CRM. 
Measurement of the value can be carried out using a single definitive method, by two or more 
independent reference methods or by a network of qualified laboratories using one or more 
methods of demonstrated accuracy [51]. 
Certification of the RMs prepared during these studies was not carried out so the statistical 
approaches involved are not discussed further. 
 
1.7 PROFICIENCY TESTING 
The use of RMs is becoming increasingly important in the area of quality assurance (QA), 
particularly given the global nature of the shellfish industry. Implementing and running a 
robust quality system is of the upmost importance to any monitoring system in giving 
confidence to the analyst and industry as a whole. The use of proficiency testing (PT) as well 
as being a legislative requirement in the EU [72,73] is a powerful QA tool at the analyst’s 
disposal enabling laboratories to evaluate their results against a designated consensus. 
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QUASIMEME was founded in 1992 and initially funded by the EU under a three year quality 
assurance project [74]. The aim was to establish a comprehensive network of laboratories 
producing demonstrably reliable chemical information while providing a holistic approach to 
quality assurance. 
The determination of PSP toxins was added to the QUASIMEME scope in 2009 as a 
development exercise, and has been running each year since with one round organised 
annually. The wide array of methods available for determining PSP toxins gives choice to the 
analyst but does pose a problem to organisers of PT schemes in including as many of these 
methods as possible. The most widely used methods internationally for PSP analysis are the 
mouse bioassay (MBA) [40], liquid chromatography-fluorescence detection (LC-FLD) based 
on pre-column oxidation (preCOX) [41] and post-column oxidation (PCOX) [75], immuno-
based assays (ELISA) and liquid chromatography with tandem mass spectrometry (LC-
MS/MS). 
The Finnish Institute for Verification of the Chemicals Weapons Convention (VEREFIN), 
located in the University of Helsinki was established in 1994 continuing a research project on 
Chemical Weapons (CW) which had been operating since 1973. VEREFIN supports CW 
disarmament, of which STX is listed in schedule 1 of the Chemical Weapons Convention 
(CWC), through the development of analytical methodologies used to identify Chemical 
Warfare Agents (CWA). Under the 7
th
 EU Framework Programme for Research VEREFIN 
co-ordinated the EQuATox (Establishment of Quality Assurance for the Detection of 
Biological Toxins of Potential Bioterrorism Risk) project. As part of this project a PT scheme 
was organised which sought to evaluate existing methodologies for the determination of STX 
in real samples. A shellfish tissue RM prepared using one of the techniques described in 
chapter 4 was used in this PT scheme. 
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1.8 EVOLUTION OF METHODOLOGIES FOR PSP DETERMINATION 
As previously stated the MBA is the reference method in EU legislation for the determination 
of PSP toxins in Europe. It was first applied in the determination of PSP toxicity by Sommer 
and Meyer in 1937 [76]. Subsequently the procedure underwent standardisation, culminating 
in AOAC official method (OMA) 959.08 [40].  This is the reference method specified in EU 
legislation [21] and involves the extraction of the shellfish homogenate tissue in dilute 
hydrochloric acid followed by intraperitoneal injection of filtered extracts into replicate mice. 
The time taken from injection to mouse death is recorded and the toxicity determined from a 
conversion table developed by Sommer and Meyer [76]. Reported drawbacks of the method 
include underestimations of total toxicity caused by high salt concentrations or the presence 
of some metals in samples [10,77]. The presence of other metals, such as zinc, particularly 
evidenced in oyster tissues has been reported to increase the threat of false positives [78]. The 
method is also controversial in its use of large numbers of mice and in stipulating death as an 
endpoint. A further drawback of the MBA is that it only provides a total toxicity value and no 
information about the specific toxin profile of a sample. However, the method has been used 
globally for many years and has provided an excellent preventative method for the significant 
reduction of PSP intoxications worldwide. 
Due to method performance concerns, ethical issues regarding animal welfare, and as a 
legislative requirement to reduce, refine or replace animal based assays, an alternative 
method was written into EU legislation in 2011 which is based on the oxidation of extracts 
before separation and determination by LC-FLD [21]. PSP toxins do not exhibit natural 
ultraviolet absorption or fluorescence and must therefore be oxidised into iminopurine 
derivatives before analysis using fluorescence detection [79]. The method cited in legislation 
was developed by Lawrence & Ménard, 1991 [80] and underwent international validation in 
2004 before being approved as an AOAC official method in 2005 [41]. This method is based 
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on a two-step acetic acid extraction followed by solid phase extraction (SPE) cleanup using 
C18 reverse-phase cartridges to remove hydrophobic shellfish matrix interferences. Cleaned 
extracts are then oxidised using peroxide and/or periodate reagents before separation and 
analysis by LC-FLD (preCOX) to determine the qualitative or semi-quantitative presence of 
toxins. Full quantitation of samples containing N-hydroxylated toxins normally requires 
further sample extract clean-up using carboxylic acid ion-exchange SPE cartridges. This step 
separates the samples into three fractions each containing toxins in a different overall charge 
state, thereby enabling more accurate detection and quantitation of each toxin or epimeric 
pair [41]. 
The main drawbacks of the method relate to the complex chromatographic output as well as 
the lack of separation of epimeric pairs (GTX1 & GTX4, GTX2 & GTX3, C1 & C2, dcGTX2 
& dcGTX3 and C3 & C4) characteristic of this toxin group. Users of this method calculate 
summed toxin concentrations for each epimeric pair. Sample toxicities are estimated from the 
sum of toxin concentrations, which leads to a slight overestimation as the more toxic 
analogue for each epimeric pair is used to calculate total toxicity. This is in spite of the fact 
that the epimer ratio in bivalve tissues typically reaches an equilibrium of 3:1 predominated 
by the less toxic α-epimers (GTX1, 2) compared to the more toxic β-epimers (GTX3, 4) [81]. 
Pre-column derivatization can produce one to three oxidation product peaks per toxin, 
leading to difficulties in determining toxin profiles and accurate quantitation. This is 
particularly pertinent for samples often used in PT schemes that have either a complex toxin 
profile or a profile not routinely seen by the participant’s laboratory. Another drawback of 
using this method and all chemical based methods of analysis is the lack of certified reference 
standards for all the PSP toxins, most notably GTX6, C3, C4, dcGTX1 and dcGTX4. 
Although complex, the method has been refined and standardised since acceptance as a first 
action AOAC method, and in recent years has been implemented into routine official control 
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testing of shellfish in a number of countries including Ireland, UK, Portugal and New 
Zealand. 
Methods based on post-column derivatization were first utilised for shellfish monitoring by 
Sullivan and Wekell in 1984 [82]. Further developments were described by Oshima et al. in 
1989 [83] where the separation of the full suite of known PSP toxins was achieved using 
three separate chromatographic conditions. A method modified from those of Oshima, 1995 
[17] and Thomas et al. 2006 [84] was first published by Rourke et al., 2008 [85]. This 
method underwent international validation under the protocol of the AOAC in 2010 and was 
subsequently accepted as AOAC official method 2011.02 [75]. The extraction technique is 
based on that of the MBA, specifically involving boiling in HCl. Partial hydrolysis of certain 
PSP toxins into more toxic analogues occurs with the PCOX/MBA extraction method which, 
some argue, mimics the process of digestion in the stomach thereby more accurately 
reflecting sample potential toxicity [86]. The milder conditions of the preCOX extraction 
method do not cause hydrolysis of the toxins, with toxin profile consequently remaining 
unaffected. 
A distinct advantage the PCOX method has over the preCOX is the formers ability to 
separate the PSP epimers contained in this group [87]. One disadvantage with the PCOX 
methods are its inability to separate certain PSP toxins (dcNEO/NEO and GTX6/GTX4) 
unless a very long runtime is used [85]. OMA 2011.02 also requires two chromatographic 
runs in order to separate the full suite of PSP toxins. The method has recently been adopted 
into US legislation and has been implemented into official control monitoring programs 
within Canada, Norway and some US states. 
The use of mass spectrometry (MS) as a detection system for determining PSP toxins is 
desirable, based on the high sensitivity and selectivity this technique potentially gives the 
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user. Early LC-MS methods required the use of ion-pairing reagents in the mobile phase in 
order to ensure adequate retention of the charged PSP species [88,89]. This, along with the 
aqueous mobile phase these methods employed, led to poor ionization and signal suppression. 
Dell’Aversano et al., 2005 [90] developed an LC-MS/MS method based on hydrophilic 
interaction liquid chromatography (HILIC) which increased detection sensitivity compared to 
previous LC-MSMS methods. Despite comparable sensitivities for the majority of toxins to 
the other methods described above, the use of LC-MS/MS methods in routine monitoring and 
therefore PT schemes is limited, mainly due to matrix effects problems. Recent advances in 
this area were made by Boundy et al. 2015 [91] where the application of solid phase 
extraction using graphitised carbon prior to LC-MS/MS analysis eliminates or significantly 
reduces these matrix related issues. 
A number of functional and immunological assays have been developed for PSP toxins over 
the last 20 years although their use for routine monitoring purposes has been limited. This is 
mainly due to the lack of information these methods provide on the toxin profile of samples, 
the use and handling of radioisotopes or cross reactivity issues which may lead to false 
positives or false negatives. 
A receptor binding assay (RBA) was developed by Vieytes et al., in the early 90’s [92] and 
was further optimised by Doucette et al. [93]. This binding competition assay uses sodium 
channels isolated from rat brain membranes coated on to microtitre plates. Tritiated saxitoxin 
[
3
H]STX competes with unlabelled STX and its derivatives for binding to the available 
sodium channel receptor sites. Unbound tritiated STX is removed by filtration and bound 
triated STX is quantified by liquid scintillation counting. This method has undergone 
extensive single laboratory validation (SLV) and a collaborative study [94,95] and has been 
accepted as an official AOAC method of analysis (OMA AOAC 2011.27) [96]. 
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Several cytotoxicity assays have been developed and are based on the combined effect they 
exert in the presence of veratridine and ouabain on neuroblastoma cells [6]. The method, 
further developed by Jellet et al. in 1992 [97] yielded unsatisfactory results in an AOAC 
International collaborative study in 1999 however. A radioligand binding assay using a STX 
specific receptor, saxiphilin was developed by Llewellyn et al., in the late 90’s but has not 
been subjected to formal SLV or collaborative studies to date [98]. 
Immunological assays use antibodies to detect the toxin of concern which are raised either in 
animal or cell cultures. Two formats of immunological assays have been developed for PSPs, 
ELISA (Enzyme-Linked ImmunoSorbent Assays) and LFA (Lateral Flow Assays). These 
methods are based on the antibodies ability to recognise and bind the toxin of interest. The 
most common immunoassay technique in use for PSP testing is that of ELISA. A number of 
commercial testing kits are available with one utilised within the Quasimeme PT rounds sold 
under the name Ridascreen™ (R-Biopharm, Darmstadt, Germany). The high number of STX 
analogues has however posed problems for developers of this and other similar ELISA 
methods, with NEO and GTX-1,4 in particular exhibiting poor cross reactivity with the 
Ridascreen assay [99]. 
The development of biosensors using biological components, such as antibodies to recognise 
and bind the toxins, has advanced over the last number of years. These sensors use antibodies 
as the bio-recognition component and surface plasmon resonance (SPR) as the detection 
component. These methods involve the immobilisation of the toxin onto a chip. Samples are 
then mixed with the bio-recognition component and are injected over the surface of the chip. 
Toxins present in the sample compete with toxins on the chip for binding to the antibody 
which if present change the resonance angle of the light [100]. An SPR based immunoassay 
developed for PSP toxins was subjected to various validation studies but, as in the case of the 
ELISA above, showed poor cross reactivity for some analogues, in particular GTX1,4 and 
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dcNEO [101–104]. A multiplex SPR method has also been developed for the ASP, DSP and 
PSP groups which has the advantage of detecting three toxin groups in a single test, although 
their development is still at an early stage [105]. 
Alternative methods for PSP determination include capillary electrophoresis coupled to 
ultraviolet (UV) or MS detection, although limited research has been carried out in this area 
[106–111]. 
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1.9 RESEARCH AIMS AND OBJECTIVES 
The primary aims and objectives of this research were to investigate techniques aimed at 
stabilising PSTs in various shellfish tissue matrices. Each technique was evaluated for its 
applicability in preparing RMs for different uses including official control monitoring in the 
Irish NMP, for PT schemes operated by QUASIMEME and VEREFIN and feasibility studies 
into the production of a CRM. 
A further aim of this research was to characterise and present a first report of PSP toxins from 
shellfish harvested in Iceland. This toxic event occurred during the initial search for PSP 
contaminated materials for use in these studies. 
Using one of the techniques developed during these studies, multiple materials were prepared 
and used in the first commercially available PSP PT scheme operated by Quasimeme and in a 
separate PT exercise organised by VEREFIN. 
The major aims and objectives can be outlined as follows: 
 Characterise materials harvested during a large PSP toxin event in Iceland during the 
summer of 2009 and present a first report including toxin profile determination 
together with associated phytoplankton data. 
 Collect and characterise PSP contaminated material for use in these development 
exercises. 
 Investigate various stabilisation techniques and their effects on PSTs and shellfish 
tissue matrices including their applicability for RM production for various uses. The 
techniques investigated included: 
o Heat treatment 
o Use of preserving additives (antioxidant and antibiotics) 
o High Pressure Processing (HPP) 
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o Freeze drying 
o Combinations of the above 
 Assess data generated over six years of PT exercises operated by QUASIMEME to 
investigate potential method dependency issues and if they relate to the analysis of 
particular PSP analogues. 
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Chapter 2  
MATERIALS AND METHODS 
 
2.1  SOURCE OF TISSUES 
With the levels of PSP toxins in Irish shellfish rarely rising above the EU regulatory limit (MI 
unpublished data), coupled with a relatively simple toxin profile, it was necessary to source 
contaminated materials from collaborators of the MI for use in the RM investigations 
described in this thesis.  
Table 2-1: Description of whole flesh (WF) source tissues used in the preparation of materials for the studies contained in 
this thesis, including country of origin, species and toxins present as determined by preCOX LC-FLD (AOAC 2005.06). 
Country Species Predominant Toxin(s) Present 
Trace Toxin(s) 
Present 
Spain 
Mussel  
dcSTX GTX5 + STX 
(Mytilus galloprovancialis) 
Portugal 
Clam  
dcGTX2,3, dcSTX + dcNEO 
 (Spisula solida) 
UK 
Oyster  
GTX2,3, STX, GTX-1,4, NEO, C1,2 
 (Crassostrea gigas) 
Canada 
Mussel 
GTX2,3, STX, GTX1,4 + NEO 
 (Mytilus edulis) 
Ireland 
Mussel 
GTX2,3 + STX GTX1,4 
(Mytilus edulis) 
Iceland 
Mussel 
GTX2,3, STX + GTX-1,4 
 (Mytilus edulis) 
Norway 
Mussel 
GTX2,3, STX, GTX1,4 + NEO 
 (Mytilus edulis) 
 
The beginning of this research coincided with a large PSP event in Iceland, as detailed in 
Chapter 3, and a large quantity of contaminated blue mussels (Mytilus edulis) were harvested 
and transported on ice to the MI. Large amounts of Mediterranean mussels (Mytilus 
galloprovancialis) were harvested in Spain in 2009, after which it was discovered that PST 
levels were above the EU regulatory limit. A sub-sample of the tissue material was also sent 
to the MI on ice. 
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The Norwegian Veterinary Institute (NVI), Canadian Food Inspection Agency (CFIA), 
Centre for Environment Fisheries and Aquaculture Science (CEFAS), UK also all provided 
PST contaminated shellfish with various toxin profiles as detailed in Table 2-1. 
 
2.2  CONSUMABLES 
2.2.1 CHEMICALS 
All chemicals and solvents used were of analytical or HPLC grade. The deionised (DI) water 
was supplied from a reverse osmosis system (Barnstead Int., Dubuque, IA, USA). Acetic acid 
(HOAc), hydrochloric acid (HCl), nitric acid (HNO3), ortho-phosphoric acid (H3PO4) 
ammonium formate, ammonium acetate, sodium chloride (NaCl), sodium hydroxide (NaOH), 
ammonium hydroxide (NH4OH), hydrogen peroxide (H2O2), disodium hydrogenphosphate, 
1M tetrabutyl ammonium phosphate, erythromycin, ethoxyquin, trichloroacetic acid (TCA) 
and periodic acid (H5IO6) were purchased from Sigma-Aldrich (Steinheim, Germany). 
Ampicillin and oxytetracycline were purchased from Fisher Scientific (Waltham, MA, USA). 
Methanol (MeOH) and acetonitrile (MeCN) were purchased from Labscan (Stillorgan, 
Ireland). 
 
2.2.2 STANDARDS 
Certified reference toxins: gonyautoxin 1 and 4 (GTX1,4), neosaxitoxin (NEO), 
decarbamoylsaxitoxin (dcSTX), gonyautoxin 2 and 3 (GTX2,3), gonyautoxin 5 (GTX5), N-
sulfocarbamoyl-gonyautoxin 2 and 3 (C1,2), decarbamoylneosaxitoxin (dcNEO), 
decarbamoylgonyautoxin 2 and 3 (dcGTX2,3) and saxitoxin (STX) were obtained from the 
Institute of Biotoxin Metrology, National Research Council Canada (IMB, NRCC, Halifax, 
Nova Scotia, Canada).  
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For preCOX analysis, the CRMs were first diluted in water (adjusted to pH 4.0 ± 0.1 with 
0.1M HOAc) to prepare primary stock solutions. Further dilutions were performed in 0.1 mM 
HOAc to prepare working calibration solutions. Primary and working standards were stored 
following NRCC recommendations [112]. Standards were prepared in three separate mixes as 
the oxidation products of some toxins co-elute. The concentration ranges and toxins 
contained in each mix are detailed in Table 2-2. 
For PCOX analysis, the working standards were prepared as dilutions of NRC-CRMs, in 
0.003M HCl for the GTX/STX toxins and in de-ionised water (pH 5.0 ± 0.1) for the C-toxins 
as described in AOAC OM 2011.02 [75]. The concentration ranges used in PCOX analysis 
are detailed in Table 2-3. 
 
2.3 METHODS OF ANALYSIS 
2.3.1 AOAC OFFICIAL METHOD 2005.06 
 
Figure 2-1: Schematic diagram of AOAC OM 2005.06 procedure. 
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EXTRACTION 
Tissue samples (5.0 g ± 0.1 g) were extracted twice in 50 mL polypropylene (PP) centrifuge 
tubes with 3.0 mL volumes of 1% HOAc. The first extraction step was performed using a 
multi-tube vortex mixer (V400 Alpha Labs, UK) for 1 min on high power, before being 
placed into a boiling water bath (Grant SBB Aqua 26 plus) for 5 min. Sample tubes were 
removed from the boiling water bath and placed into a basin of cold water for 5 min. Sample 
tubes were then centrifuged (CR4-22 Jouan, Thermo Electron Corp., CA, USA) at 4500 rpm 
for 10 min, collecting the resultant supernatant in 15 mL PP test tubes. The remaining pellet 
was re-extracted using a multi-tube vortex mixer, as described above, before re-centrifugation 
at 4500rpm for 10 min. The supernatants from both extraction steps were combined in the 
graduated 15 mL PP test tubes and made up to 10 mL with de-ionised water. 
 
SOLID PHASE EXTRACTION (SPE) C18 
Sample clean-up was performed using Supelclean (Supelcosil, Bellefonte, PA, USA) C-18 
cartridges (500 mg/3  mL), following the method described by [41]. The cartridges were 
conditioned with 6.0 mL MeOH before being washed with 6.0 mL DI water. 1.0 mL of the 
crude extract was loaded onto the cartridge and eluted with 2.0 mL de-ionised water into 4.0 
mL PP collection tubes. The extract was then adjusted to pH 6.5 ± 0.1 (Orion pH meter, 
Thermo Scientific Inc., Waltham, MA, USA) using 1M NaOH (3.99 g ± 0.01 g made up to 
100 mL with DI water) before the total volume was made up to 4 mL with de-ionised water. 
Aliquots were then taken for oxidation with either peroxide or periodate reagent depending 
on the toxins present. The clean-up procedure was performed on an automated SPE unit 
(Gilson ASPEC XL4, UK), which was previously in-house validated (data not shown) unless 
otherwise stated in the analysis sections of each chapter. 
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SOLID PHASE EXTRACTION (SPE) CARBOXYLIC ACID 
Ion exchange clean-up was performed to fractionate the C18-cleaned extracts using 
Bakerbond (J.T. Baker, Phillipsburg, NJ, USA) COOH cartridges (500 mg/3 mL) [41]. The 
COOH SPE cartridges were conditioned with 10.0 mL 0.01M ammonium acetate (0.77 g ± 
0.01 g ammonium acetate made up to 1 L with DI water) before loading a 2.0 mL aliquot of 
the C18 SPE cleaned extract. Fraction 1 containing the neutrally charged C toxins was eluted 
with 4.0 mL water and collected in a 12 mL PP tube, adjusting the final volume to 6.0 mL 
with DI water. 4 mL of 0.05M NaCl (0.29 g ± 0.01 g NaCl made up to 100 mL with DI 
water) were then passed through the cartridge, collecting the eluant containing the singly-
charged gonyautoxins in a 4 mL PP tube, adjusting the final volume to 4 mL with DI water. 
Fraction 3, containing the double-charged carbamates, was collected by eluting 5 mL of 0.3M 
NaCl (1.75 g ± 0.01 g NaCl made up to 100 mL with DI water) through the cartridge and 
collecting in a 12 mL PP tube, ensuring the final volume was 5 mL through adjustment with 
DI water. The clean-up procedure was performed manually using a SPE manifold and pump 
from Sigma-Aldrich (Steinheim, Germany). 
 
MATRIX MODIFIER 
The matrix modifier, used in the periodate oxidation of standard and sample extracts as 
described in section 2.3.1 was prepared weekly. An oyster (Crassostrea gigas) WF tissue, 
confirmed to be <LOD for all EU regulated biotoxins by LC-MS/MS (for lipophilic toxins), 
LC-UV (for DA and epi-DA) and LC-FLD OM AOAC 2005.06 (for PSTs), was dispensed in 
5 g aliquots into PP tubes before being hermetically sealed and stored at -20°C. An aliquot 
was taken weekly, defrosted before being extracted, SPE C18 cleaned and adjusted to pH 6.5 
according to section 2.3.1. This solution was stored at +4°C and used in the periodate 
oxidations described below. 
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OXIDATION 
PSP toxins are not naturally fluorescent and must therefore be oxidised into a fluorescent 
form prior to analysis. Two oxidation reactions could be performed on the cleaned extracts 
depending on the toxin profile present in the tissue. Non-hydroxylated PSP toxins were 
oxidised using H2O2 while the N-hydroxylated toxins were oxidised using a periodate 
reagent. Oxidations were performed in 1.5 mL PP HPLC vials (Fisher Scientific, Waltham, 
MA, USA) using calibrated pipettes and multichannel timers (Fisher Scientific, Waltham, 
MA, USA). 
 
PEROXIDE OXIDATION 
250 µL of 1M NaOH was added to 25 µL 10% H2O2 in a 1.5 mL PP HPLC vial and vortex 
mixed. 100 µL of the standard solution or test extract, after C18 or COOH SPE clean-up, were 
added to the vial, mixed, and allowed to react at room temperature for 2 min. The reaction 
was stopped by adding 20 µL glacial HOAc. 50 µL of the oxidised solution were injected 
onto the HPLC system. 
 
PERIODATE OXIDATION 
The periodate oxidant was prepared daily by combining equal quantities of 0.03M H5IO6 
(0.68 g ± 0.01 g H5IO6 made up to 100 mL with DI water), 0.3M ammonium formate (1.89 g 
± 0.01 g ammonium formate made up to 100 mL with DI water) and 0.3M disodium 
hydrogen phosphate (4.26 ± 0.01 g disodium hydrogen phosphate) made up to 100 mL with 
DI water) and adjusted to pH 8.2 with 0.2M NaOH (0.79 g ± 0.01 g NaOH made up to 100 
mL with DI water). 
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100 µL of matrix modifier (blank toxin free C-18 cleaned oyster tissue extract) were added to 
100 µL of standard or test extract, after C18 or COOH SPE clean-up, in a 1.5 mL PP HPLC 
vial. 500 µL of periodate oxidant was added to the vial, mixed and allowed to react at room 
temperature for 1 min. The reaction was stopped through the addition of 5 µL glacial HOAc. 
50 µL of the oxidised solution was injected onto the HPLC system. 
 
LC-FLD ANALYSIS 
 
Figure 2-2: LC-FLD setup used for OMA AOAC 2005.06. 
 
A Shimadzu (Kyoto, Japan) HPLC system with a fluorescence (FLD) detector (ex 340 nm, 
em 395 nm) (Shimadzu RF-10AXL), cooled autosampler set to +4°C (Shimadzu SIL-20A)  
and a degasser was used. The HPLC column was a reverse phase C-18 Supelcosil (150 mm x 
4.6 mm, 5 µm) fitted with a C-18 Supelguard cartridge (20 mm) as recommended in the 
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official method [41]. The HPLC programme followed was a slightly modified gradient 
elution based on that published in AOAC 2005.06 [41] using a flow rate of 1.5  mL/min. MP 
A was prepared by dissolving ammonium formate (12.62 g ± 0.01 g) in DI water before 
making up to the mark with DI water in a 2L volumetric flask. MP B was prepared by 
dissolving ammonium formate (6.31 g ± 0.01 g) in DI water, adding 100 mL MeCN before 
making up to the mark with DI water in a 1 L volumetric flask. Both MPA and B were 
adjusted to pH6.0 ± 0.1 with 0.1M HOAc (572 µL glacial HOAc made up to 100 mL with DI 
water) before filtering through a 0.45 µm nylon filter. 
The gradient followed was 0 - 5% MP B over 5 min, 5 - 70% B over the next 4 min, back to 
0% B over 2 min, then keeping at this condition for 7 min before the next injection. PST 
concentrations in sample extracts were quantified against a five-point calibration for each 
toxin and were expressed in µmol/kg. The concentration range of the standards used during 
these studies are contained in Table 2-2. 
Table 2-2: Concentration range of standards used for OMA AOAC 2005.06 analysis. 
Mix Toxin Concentration Range (µmol/L) 
Mix 1 
STX 0.005 → 0.417 
dcSTX 0.003 → 0.399 
GTX2,3 0.003 → 0.973 
GTX5 0.003 → 0.295 
dcGTX2,3 0.008 → 0.819 
C1,2 0.013 → 0.859 
Mix 2 
NEO 0.009 → 0.349 
GTX1,4 0.027 → 0.423 
Mix 3 dcNEO 0.009 → 0.334 
 
CALCULATIONS 
PSTs produce between 1 – 3 oxidation products after peroxide or periodate oxidation, some 
of which co-elute. Identifying toxins present in samples and therefore quantification is 
complex, particularly when certain toxins are present in samples. The toxin dcSTX co-elutes 
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with both dcNEO and NEO and dcGTX2,3 co-elutes with the toxins GTX1,4 so a back 
calculation is required when these toxins are present in a sample together. Materials described 
in these studies only contained a combination of dcSTX and dcNEO so only this back 
calculation is described below. 
The toxin dcSTX produces two oxidation products after both peroxide and periodate 
oxidation, with the first peak after peroxide oxidation used for quantification. The toxin 
dcNEO produces two oxidation products after periodate oxidation with the first peak used for 
quantification. In a sample containing both toxins the first dcNEO peak also has a 
contribution of dcSTX present in the sample. A set of dcSTX standards are periodate 
oxidised and a calibration curve generated from the area of the first peak of dcSTX versus 
dcSTX concentration. The amount of dcSTX present in the sample is known from the 
peroxide oxidation of the SPE C18 cleaned extract. This value can then be used to estimate the 
area of the dcSTX peak to be subtracted from the first dcNEO peak. The net area of dcNEO 
is then used to calculate its concentration. 
PST concentrations in samples, as described in the following chapters were calculated as 
follows: 
- Response (toxin) / slope = µmol/L 
- Concentration (µmol/L) / Tissue weight x 10 (Final volume of extract)  x Dilution 
Factor SPE = µmol/kg 
Dilution Factors:  C18 cleaned extracts - 4 
   COOH fraction 1 – 12 
   COOH fraction 2 – 8 
   COOH fraction 3 – 10 
- µmol/kg x 372.2 g/mol (STX Mol. Wt. HCl form) x TEF = µgSTXdiHCl-eq/kg 
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The total toxicity of a sample was calculated by combining individual analogue 
concentrations and is expressed in µgSTXdiHCl-eq/kg. 
 
UNCERTAINTY OF MEASUREMENT 
An expanded uncertainty of measurement (U) was calculated for OMA AOAC 2005.06 
during validation studies. Data was generated through the use of an LRM (internal MI code 
LRM-09-02) using OMA AOAC 2005.06 as part of the Irish National Monitoring 
Programme (NMP) for marine biotoxins. An aliquot of LRM-09-02 was extracted and 
analysed per batch over a two year period and the mean (996 µgSTXdiHCl-eq/kg) and 
relative standard deviation (8.7%) of the total toxicity data was generated. 
The uncertainty of measurement was calculated as follows: 
UCM = k x C x RSD 
K = Coverage Factor = 2 (@ 95% confidence assuming a normal distribution) 
C = 996 µgSTXdiHCl-eq/kg 
RSD = 8.7% 
UCM = 2 x 996 µgSTXdiHCl-eq/kg x 0.087 
UCM = 173 µgSTXdiHCl-eq/kg 
UCM at 996 µgSTXdiHCl-eq/kg ± 173 µgSTXdiHCl-eq/kg 
UCM at 996 µgSTXdiHCl-eq/kg ± 17.4% 
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2.3.2 AOAC OFFICIAL METHOD 2011.02 
 
Figure 2-3: Schematic diagram of AOAC OM 2011.02 procedure. 
 
EXTRACTION 
Tissue samples (5.0 ± 0.1 g) were extracted in 50 mL PP centrifuge tubes with 5 mL of 0.1M 
HCl (40.0 mL of 5M HCl made up to 2.0 L with DI water. 5M HCl prepared as 413.2 mL 
HCl made up to 1.0 L with DI water). The mixture was vortex mixed for 1.0 min ± 0.1 min 
and the pH adjusted to pH 2-4 if necessary. The mixture was placed in a boiling water bath 
for 5.0 ± 0.1 min, before being cooled in a basin of cold water for 5.0 ± 0.1 min, rechecking 
the pH and adjusting if necessary. The tubes containing the material were then centrifuged at 
4500 rpm for 10 min. 500 µL of the resultant supernatant were transferred to a micro 
centrifuge tube, adding 25 µL 30% TCA (15.00 g ± 0.01 g TCA made up to 50.0 mL with DI 
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water) to deproteinate the extract, mixed well before centrifuging at 16000 x g for 5 min. 
Protein precipitation is induced by adding TCA which exposes more of the proteins 
hydrophobic structure, resulting in increased precipitation. This step is necessary as proteins 
could precipitate out in the reaction coil of the oxidation unit causing blockages. 20.0 ± 0.1 
µL 1M NaOH were added to the supernatant, mixed well and centrifuged at 16000 x g for 5 
min, before filtering through a 0.2 µm nylon disc filter into a PP HPLC vial. 
 
LC-FLD ANALYSIS 
The same LC-FLD system described in section 2.3.1 above was used for the PCOX analysis 
with fluorescence detector set to ex 330 nm, em 390 nm and fitted with an automated post-
column derivatisation unit (Pickering Laboratories Inc., CA, USA) (Figure 2-4).  
 
Figure 2-4: LC-FLD and post column derivatisation unit setup for OMA AOAC 2011.02. 
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The system was setup by connecting the LC tubing, just after the analytical column, into the 
derivatisation unit. Samples pass through the unit via two mixing chambers, the first used to 
oxidise the sample and the second to stop the reaction. The reactor coil (5 metres in length) is 
situated between both mixing chambers and this heats the sample to 85°C. After the reaction 
is stopped in mixing chamber 2 the LC tubing is plumbed back to the fluorescence detector. 
The materials were analysed using two chromatographic runs as per [75], the first to 
determine GTX/STX toxins and the second for the C-toxins. The HPLC columns used were a 
Zorbax Bonus RP (150mm x 4.6mm, 3.5µm) fitted with a Zorbax guard cartridge (20mm) for 
the GTX/STX separation and a Thermo Betabasic 8 (250mm x 4.6mm, 5µm), fitted with a 
Thermo Betabasic guard cartridge (20mm) for the C-toxins. The HPLC programmes followed 
were as published in AOAC Official Method 2011.02 [75].  
GTX/STX analysis: MP A was prepared by adding 44.0 mL 0.5M heptane sulphonate (11.01 
g ± 0.01 g heptane sulphonate made up to 100 mL with DI water) to ~ 1.8 L DI water. This 
solution was mixed before adding 22.0 mL 0.5M H3PO4 (33.9 mL H3PO4 made up to 1.0 L 
with DI water), adjusting the pH of the combined solution to pH7.1 ± 0.1 with concentrated 
NH4OH. The solution was transferred to a 2.0 L volumetric flask, made up to the mark with 
DI water before filtering through a 0.45 µm nylon filter. MP B was prepared by adding 22.0 
mL 0.5M heptane sulphonate to ~ 0.8 L DI water. This solution was mixed before adding 
33.0 mL 0.5M H3PO4, adjusting the pH of the combined solution to pH7.1 ± 0.1 with 
concentrated NH4OH. 115 mL MeCN was added before transferring the solution to a 1.0 L 
volumetric flask, making the final volume up with DI water before filtering through a 0.45 
µm nylon filter. 
C-toxin analysis: MP A was prepared by adding 4.0 mL 1.0M tetrabutyl ammonium 
phosphate to ~ 1.8 L DI water. The pH of the solution was adjusted to pH5.8 ± 0.1 through 
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the addition of 1% NH4OH before transferring to a 2.0 L volumetric flask, making up to the 
mark with DI water before filtering through a 0.45 µm nylon filter.  
For the GTX/STX run a flow rate of 0.8 mL/min was used and the step gradient followed was 
0 – 7.9 min, 0% MP B, 8.0 – 18.5 min, 100% MP B and back to 0% MP B for 5.4 min to re-
equilibrate the column. 
For the C-toxin analysis, a flow rate of 0.8 mL/min was used and the system was operated in 
isocratic mode. 
 
POST-COLUMN DERIVITISATION 
The PCOX unit was operated at 0.4 mL/min for both the oxidant and acid solutions with the 
reactor coil set to 85°C (reaction coil 5m x 0.5mm id). The oxidant solution was prepared by 
adding 400.0 mL 0.5M H3PO4 to ~1.2 L DI water. 200 mL 0.05M H5IO6 (11.40 g ± 0.01 g 
H5IO6 made up to 1.0 L with DI water) was added before adjusting to pH 7.8 ± 0.1 with 5M 
NaOH (20.0 g ± 0.01 g NaOH made up to 100 mL with DI water). The combined solution 
was transferred to a 2.0 L volumetric flask making up to volume with DI water, before 
filtering through a 0.45 µm nylon filter. 
The acid solution was prepared by making 101.2 mL HNO3 up to 2.0 L with DI water and 
filtering through a 0.45 µm nylon filter. 
PST concentrations in sample extracts were quantified against a four-point calibration for 
each toxin and were expressed in µmol/kg. Total saxitoxin equivalents were calculated for 
each sample as an estimation of total toxicity using the guidance described in the AOAC 
official method [75]. 
The concentration range of the standards used during these studies are contained in Table 2-3. 
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Table 2-3: Concentration range of standards used for OMA AOAC 2011.02 analysis. 
Toxin Concentration Range (µmol/L) 
STX 0.019 → 0.195 
dcSTX 0.032 → 0.390 
GTX2 0.029 → 0.503 
GTX3 0.011 → 0.191 
GTX5 0.104 → 0.262 
dcGTX2 0.061 → 1.713 
dcGTX3 0.014 → 0.386 
C1 0.031 → 2.706 
C2 0.009 → 0.831 
NEO 0.052 → 0.291 
GTX1 0.142 → 0.733 
GTX4 0.046 → 0.239 
 
2.3.3 AOAC OFFICIAL METHOD 959.08 
The method involves the acidic aqueous extraction of shellfish tissue in 0.1M HCl. Aliquots 
(1 mL) were injected intraperitoneally into male albino CD1 strain mice in triplicate and 
toxicity (µgSTXdiHCl-eq/kg) was calculated from median death times using Sommer’s 
tables [76]. The method was standardised using an STX certified reference standard obtained 
from the Institute of Marine Biosciences, National Research Council Canada (IMB, NRCC, 
Halifax, Nova Scotia, Canada). 
 
2.4 MOISTURE CONTENT DETERMINATION 
2.4.1 ROTARY VACUUM METHOD 
Empty 50 mL PP centrifuge tubes were weighed using a 4-place balance before adding a 1.0 
± 0.1 g tissue sample into the pre-weighed tube, noting the weight of the tube and tissue 
combined. The tubes were then placed into a rotary drier (Jouan, Saint Herblain, France), 
dried under vacuum for 950 min on #4 heat setting. After completion of the run, the weights 
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of the dried centrifuge tubes were taken and the moisture content determined by the loss 
through drying as follows: 
% Moisture Content = (
𝑳𝒐𝒔𝒔 𝒕𝒉𝒓𝒐𝒖𝒈𝒉 𝒅𝒓𝒚𝒊𝒏𝒈
𝑨𝒍𝒊𝒒𝒖𝒐𝒕 𝒘𝒆𝒊𝒈𝒉𝒕
) 𝒙𝟏𝟎𝟎 
 
2.4.2 KARL FISCHER TITRATION (KFT) 
Volumetric KFT measurements were carried out using an Aquamax KF Volumetric (GR 
Scientific, Bedford, UK) on some of the freeze dried materials described in Chapter 5. The 
method was standardised using a Fluka hydranal water standard (Sigma Aldrich, Steinheim, 
Germany) with a certified water content of 10.02 mg/g ± 0.03 mg/g. The solid matrix samples 
were directly added to the vessel after standardisation with Hi-Dry KF Methanol (Sigma 
Aldrich, Steinheim, Germany) and titrated with a Romia one-component pyridine free KF 
reagent VC5 (Sigma Aldrich, Steinheim, Germany). The solvent was changed after each 
triplicate measurement. 
 
2.5 QUASIMEME 
All materials were prepared by the author and designed to test participants over a range of 
concentration levels and different complexities in toxin profile composition. The materials 
used were naturally contaminated with a range of PSTs and prepared following in-house 
procedures to ensure homogeneity. Stabilisation of the toxins and matrices was achieved 
using a combination of heat treatment and the addition of antibiotics and an antioxidant [113] 
with short-term stability and homogeneity studies performed on all materials before 
distribution to participants. 
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Table 2-4: Materials used in QUASIMEME rounds 2009-2014 with assigned codes, predominant toxins present and 
matrices. 
Tissue Rounds Used Year Codes Used Predominant Toxins Present Matrix 
A 
57 2009 QST075BT 
dcSTX, STX, GTX5 Mytilus galloprovincialis 
61 2010 QST093BT 
69 2012 QST132BT 
2014-1 2014 Sample 1 
B 
57 2009 QST076BT 
dcSTX, GTX2,3, GTX1,4, STX, 
GTX5 & C1,2 
Mytilus edulis & Mytilus 
galloprovincialis 
61 2010 QST095BT 
69 2012 QST133BT 
C 
61 2010 QST094BT 
dcGTX2,3, dcSTX & dcNEO Spisula solida 
65 2011 QST111BT 
69 2012 QST134BT 
2014-1 2014 Sample 2 
D 
65 2011 QST113BT 
GTX2,3 & STX Mytilus edulis 72 2013 QST152BT 
2014-1 2014 Sample 3 
E 
65 2011 QST114BT 
GTX2,3, STX & dcSTX Mytilus edulis 
72 2013 QST154BT 
F 69 2012 QST135BT GTX2,3, STX, GTX1,4 & NEO Crassostrea gigas 
G 72 2013 QST155BT 
GTX2,3, STX, GTX1,4 & 
dcSTX 
Mytilus edulis 
H 2014-1 2014 Sample 4 
GTX2,3, STX, GTX1,4 & 
dcSTX 
Crassostrea gigas 
 
A total of six materials were used over the six exercises 2009-2014, with Tissues A & C 
being used in four rounds (R) apiece, Tissues B & D being used in three rounds, Tissue E 
used in two rounds and Tissues F, G & H used in one round only. Table 2-4 lists each of the 
materials used over the 6 year period. 
No standardised method protocol was provided by QUASIMEME, apart from requesting 
TEFs to be used in total toxicity calculations, so participants were allowed to use either the 
analytical method routinely employed at their laboratories or any other method applicable to 
PST testing. In 2009 (R57) and 2010 (R61), the TEFs included in the protocol for use by 
participants in calculating total toxicity were those determined by Oshima et al. [17], while in 
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subsequent rounds 2011 (R65), 2012 (R69), 2013 (R72) and 2014 (R2014-1) TEFs 
recommended by the EFSA [6] were prescribed in the protocol (see Table 1-1). 
Data submitted by participants depended on which method was employed at their laboratory, 
with all submitting a total toxicity result such that all methods could be assessed together 
(Table 2-5). Participants using either the preCOX, PCOX or LC-MS/MS methods of analysis, 
where individual analogue concentrations can be determined, could additionally submit these 
results, such that a data assessment and therefore z-scores could be calculated in addition to 
the total toxicity results. This allowed participants receiving less than satisfactory z-scores to 
pinpoint potential causes if they related to the determination of a particular analogue. 
Table 2-5: Breakdown of methods used by participants in each of the rounds 2009-2014. 
Year Round 
Methods Used 
Total Number of 
Participants preCOX PCOX MBA ELISA LC-MS/MS 
2009 57 8 2 4 - - 14 
2010 61 9 5 2 - - 16 
2011 65 8 5 4 2 - 19 
2012 69 9 5 2 - - 16 
2013 72 13 6 2 - 1 22 
2014 2014-1 13 5 2 - 3 23 
 
 
2.6 ICELANDIC SAMPLING 
2.6.1 PHYTOPLANKTON SAMPLING 
Samples were taken from two sites in Iceland: Eyjafjordur on the north coast and 
Breidafjordur on the west coast (Figure 3-1). There were two sampling sites in Breidafjordur: 
Flatey in the north of the fjord and Stykkisholmur in the south and one location in 
Eyjafjordur, Hrisey Island, located in the middle of the fjord. Phytoplankton sampling was 
carried out weekly from spring to autumn 2009. Toxic species were screened by net sampling 
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using a 20 µm mesh. The net was hauled from a depth of 5 metres to the surface several 
times. All samples were fixed in hexamine buffered formalin and examined under a 
microscope. If toxic species were detected in these net samples then 50 mL water samples 
were allowed to settle in a sediment chamber for 24 hours according to the Utermöhl method 
[114] and examined in an inverted microscope where toxic species were identified and 
counted [115]. Phytoplankton sampling, identification and counting was carried out by Dr. 
Karl Gunnarsson and his team at the Icelandic Research Institute who supplied results 
described in Chapter 3 (Table 3-2). 
 
2.6.2 SHELLFISH SAMPLES  
Samples were collected from two sites: Eyjafjordur (Hrisey Isalnd) on the north coast and 
Breidafjordur (Stykkisholmur) on the west coast between June and August 2009. Mussels at 
both harvesting locations are grown in mesh sleeves attached to suspended long lines. 
Samples were stored in their shells at <-20°C until frozen samples were dispatched in one 
batch to the Marine Institute on ice. 
The samples were thawed and prepared by dissecting and removing the whole flesh from the 
shell, removing byssus threads and any fragments of shell before being homogenised using a 
Waring™ blender (Hartford, CT, USA). Aliquots of the homogenised tissues were then 
extracted and analysed, with the bulk tissues stored in PP containers frozen at -20°C.
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Chapter 3  
FIRST REPORT AND CHARACTERISATION OF PSP TOXINS FROM 
ICELAND 
 
 
This chapter details work described by Burrell et al. 2013. 
S. Burrell, T. Gunnarsson, K. Gunnarsson, D. Clarke, & A.D. Turner, (2013). First detection 
of paralytic shellfish poisoning (PSP) toxins in Icelandic mussels (Mytilus edulis): Links to 
causative phytoplankton species. J. Food Con. 31: 295-301 
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3.1 BACKGROUND AND AIMS 
The marine sector is hugely important to the Icelandic economy. In 2009 alone marine 
products accounted for 42% of Iceland’s total export value with the industry employing 
approximately 7300 people, representing nearly 4% of the overall Icelandic workforce [116]. 
Shellfish have been harvested commercially in Iceland over the last 40 years with Icelandic 
scallop (Clamys islandica) and ocean quahog (Artica islandica) being the main species 
harvested. Mussel farming is relatively new however, with investigations into its feasibility 
being carried out in 1973 and later in 1985-87 [117]. Since these initial investigations blue 
mussels (Mytilus edulis) have been grown experimentally around the coast of Iceland with 
harvesting figures contained in Table 3-1. 
Table 3-1: Quantities of blue mussel harvested from Icelandic waters since 2009 (Results provided by the Icelandic Food 
and Veterinary Authority). 
Year Harvest Figures (tonnes) 
2009 12 
2010 32 
2011 94 
2012 63 
2013 163 
2014 48 
 
With nearly 5000km of coastline, the Icelandic aquaculture industry has huge growth 
potential, making the implementation of an effective biotoxin monitoring program a necessity 
if the European and world shellfish markets are to be exploited.  
HABs are a variable yet worldwide phenomenon and can pose severe economic risks 
especially to fledgling shellfish markets such as Iceland’s. For human protection and as a 
statutory requirement, Iceland is obliged to conduct routine analysis of shellfish for regulated 
shellfish toxins from these harvesting sites. Due to the lack of biotoxin testing facilities in 
Iceland, shellfish samples have been transported to Ireland for biotoxin testing over the last 
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decade. Since 2005 toxic species of phytoplankton have been monitored in three fjords 
around the coast of Iceland, Eyjafjordur on the central north coast, Breidafjordur on the 
northwest coast and Hvalfjordur on the southwest coast (Figure 3-1) [115]. Phytoplankton 
sampling is carried out weekly from spring to autumn and closure of these sites for harvesting 
shellfish is recommended when cell numbers exceed 500 cells/L of Alexandrium spp. 
 
Figure 3-1: Map of Iceland showing shellfish production sites Hvalfjordur, Breidafjordur and Eyjafjordur. 
 
In order to prepare the RMs for the studies described in this thesis, it was necessary to source 
relatively large quantities of shellfish tissues containing high levels of PSTs. The lack of 
facilities at the MI for conducting shellfish feeding experiments coupled to the fact that PSP 
toxins rarely rise above the EU regulatory limit in Irish samples necessitated sourcing these 
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toxins outside of Ireland. Shortly after commencing the research for this thesis in 2009, 
routine PSP testing by MBA confirmed very high PST levels never seen before in Icelandic 
samples.  
The research contained in this chapter therefore, had two main aims. Firstly to collect and 
characterise M. edulis samples from fjords commercially producing this species and present 
the data as a first time report of PST profiles in Icelandic waters. Secondly to obtain and 
characterise large quantities of naturally contaminated shellfish tissues for the development 
work described in later chapters.  
Data is presented from the analysis of whole flesh M. edulis samples collected from two of 
these fjords Breidafjordur located on the west coast and Eyjafjordur on the north coast during 
a bloom of Alexandrium spp. in 2009. Samples were analysed for PSP toxicity by MBA with 
additional confirmatory analysis carried out by LC-FLD to determine toxin profiles and total 
saxitoxin equivalents.  
During this period a request was submitted to the Icelandic Food and Veterinary Authority by 
the author to harvest M. edulis samples in order to build-up stocks of contaminated shellfish 
at the MI. Consequently approximately 30 kg of shellfish meat in the shell was harvested and 
sent to the author under frozen conditions. 
The contamination of blue mussels with PSTs in Iceland in 2009 represents a new and unique 
geographical location for the occurrence of these toxins, and one which may potentially result 
in a serious impact upon the livelihood of Icelandic shellfish producers and exporters. 
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3.2 RESULTS 
3.2.1 TOXIC PHYTOPLANKTON SPECIES 
Results obtained from the Icelandic phytoplankton monitoring program have shown variable 
levels of toxic species present since 2005.  
 
3.2.1.1 BREIDAFJORDUR 
Between the years 2005-2007, in Breidafjordur (Flatey), no Alexandrium spp. were found in 
any samples taken. In 2008 cell numbers exceeded 500 cells/L only once in late May of that 
year [115] but in June and July 2009 however, cell numbers of over 3500 cells/L were 
recorded at this site (data not shown).  
Alexandrium spp. from the other sampling location in Breidafjordur, Stykkisholmur, have 
been found infrequently and in very low numbers in the years 2005-2008. In 2009 however 
high densities of cells were found, starting in late June and persisting until the middle of July, 
peaking at over 16,000 cells/L (Table 3-2). 
 
3.2.1.2 EYJAFJORDUR 
At Hrisey Island in Eyjafjordur, Alexandrium spp. have been observed each year from 2005 – 
2008 with cell densities >6000cells/L found in 2005 (data not shown). In 2009 Alexandrium 
spp. peaked twice, firstly at over 8,000 cells/L in June and secondly at over 10,000 cells/L in 
July (Table 3-2).The Alexandrium populations detected in phytoplankton samples from both 
fjords were mainly composed of A. tamarense with small numbers of A. ostenfeldii being 
found in samples with very high cell counts overall. 
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Table 3-2: Phytoplankton cell counts taken during May to September 2009 from Eyjafjordur and Breidafjordur, Iceland. 
Sample 
Sampling 
Date 
Cell Counts (Alexandrium spp.) cells/L 
  
Eyjafjordur Breidafjordur 
1 25/05/2009 0 - 
2 02/06/2009 0 - 
3 08/06/2009 620 - 
4 14/06/2009 1,000 - 
5 15/06/2009 - 260 
6 18/06/2009 1,300 - 
7 21/06/2009 1,520 - 
8 25/06/2009 2,200 - 
9 26/06/2009 - 4,208 
10 28/06/2009 8,750 - 
11 30/06/2009 - 16,680 
12 09/07/2009 360 6,500 
13 13/07/2009 1,540 - 
14 17/07/2009 - 1,880 
15 20/07/2009 2,160 - 
16 23/07/2009 10,920 - 
17 28/07/2009 6,400 - 
18 31/07/2009 - 160 
19 05/08/2009 80 - 
20 08/08/2009 20 - 
21 10/08/2009 - 0 
22 12/08/2009 120 - 
23 18/08/2009 40 - 
24 23/08/2009 60 - 
25 26/08/2009 - 0 
26 31/08/2009 20 - 
27 06/09/2009 0 - 
28 13/09/2009 0 - 
 
 
3.2.2 MBA AND LC-FLD TOXICITY DATA 
3.2.2.1 BREIDAFJORDUR 
The MBA and LC-FLD toxicity data from Breidafjordur is presented in Table 3-3. The first 
mussel sample was collected on the 30/06/09 when toxicity was already over three times the 
regulatory limit. The toxicity rose to over 4 times this limit by the second sample taken on the 
Chapter 3 
 
 
63 
 
10/07/09 before dropping over the next 4 weeks to levels below this regulatory action level. 
The highest total toxicity result was observed in sample 2, with an MBA result of over 4500 
µgSTXdiHCl-eq/kg. 
Table 3-3: MBA and preCOX LC-FLD data of mussel (M.edulis) samples harvested from Breidafjordur, Iceland. 
Sample 
Sampling 
Date 
Concentration (µmol/kg) Total Toxicity µgSTXdiHCl-eq./kg 
GTX-2,3 STX GTX-1,4 HPLC-FLD MBA 
1 30/06/2009 6.06 2.25 1.24 2652 3800 
2 10/07/2009 6.6 3.18 1.39 3175 4694 
3 16/07/2009 2.55 1.44 0.47 1280 1141 
4 01/08/2009 0.41 0.24 n.d 181 <LOQ 
5 13/08/2009 0.13 0.12 n.d 74 <LOQ 
6 26/08/2009 0.07 0.1 n.d 53 <LOQ 
n.d. Toxin not detected 
LOQ for MBA 280 µgSTXdiHCl-eq./kg 
 
3.2.2.2 EYJAFJORDUR 
The MBA and LC-FLD toxicity data generated from the analysis of the Eyjafjordur mussel 
samples collected during 2009 is presented in Table 3-4. Toxicity was found to be below but 
close to the regulatory action limit of 800µgSTXdiHCl-eq/kg in early June, seen in sample 1, 
but was found to rise quickly to nearly 10 times the limit in sample 2 within the subsequent 
two weeks.  
Table 3-4: MBA and preCOX LC-FLD data of mussel (M.edulis) samples harvested from Eyjafjordur, Iceland. 
Sample 
Sampling 
Date 
Concentration (µmol/kg) Total Toxicity µgSTXdiHCl-eq./kg 
GTX-2,3 STX GTX-1,4 HPLC-FLD MBA 
1 08/06/2009 0.02 1.44 n.d 540 720 
2 21/06/2009 9.05 6.18 3.39 5583 7460 
3 28/06/2009 12.4 9.97 5.6 8564 8510 
4 08/08/2009 2.63 0.86 0.48 1086 1050 
5 23/08/2009 0.45 0.7 n.d 361 550 
6 31/08/2009 0.28 0.54 n.d 264 440 
n.d. Toxin not detected 
LOQ for MBA 280 µgSTXdiHCl-eq./kg 
 
This emphasises the speed with which these toxins can accumulate in shellfish tissue during 
toxic phytoplankton blooms and the importance of conducting regular routine flesh 
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monitoring. Toxicity levels remained high for a further 6-8 weeks and did not drop below 
regulatory limits until the end of August, sample 5. The highest total toxicity result was 
observed in sample 3, with results by LC-FLD and MBA of over 8500µgSTXdiHCl-eq/kg.  
 
Figure 3-2: preCOX LC-FLD separation of PSP toxins present in an Icelandic sample from Breidafjordur in 2009 a) after 
SPE-C18 cleanup and peroxide oxidation and b) after SPE-ion exchange cleanup and periodate oxidation of fraction 2. 
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Chromatograms taken after a) peroxide and b) periodate oxidation of a sample from 
Breidafjordur are presented in Figure 3-2. These showed the clear presence of STX, GTX2,3 
and GTX1,4 toxins. Results from both fjords showed the absence of any chromatographic 
peaks which may relate either to other PSP toxins or metabolic products. Analysis of 
unoxidised extracts of the samples revealed no interfering matrix co-extractives (data not 
shown) which may have interfered with the qualitative identification of the PSP toxins and 
subsequently compromised toxin quantitation. 
 
3.3 DISCUSSION 
Conditions within both fjords during the sampling periods were favourable for phytoplankton 
growth as confirmed through the data presented in Table 3-2, where cell counts of 
Alexandrium spp. reached record levels in both Eyjafjordur and Breidafjordur. 
The exact causes of the high cell numbers observed is unknown and could be due to a number 
of factors. Temperature and salinity increases along the west and north coasts have been 
observed over the last decade due to a stronger inflow of Atlantic waters into these grounds 
[115]. It is unclear from results obtained to date whether these trends are related in any way 
to the effects of climate change or, as is more probable, relate to natural cyclic variations such 
as oscillations to the North Atlantic subpolar gyre [118,119]. Warmer more saline subtropical 
waters can spread north and westwards when this gyre weakens, as it controls the flow 
trajectory of the North Atlantic Current. A weakening of this gyre has been observed over the 
last decade which could explain the temperature and salinity increases observed by 
Gudfinnsson et al. [115]. 
A comparison of the results obtained from both the algal cell counts and the toxicity tests are 
illustrated in Figure 3-3. A clear correlation is evident between the high cell counts recorded 
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and flesh samples containing higher concentrations of PSTs. Notably, the data from 
Breidafjordur indicates a time delay between the highest concentrations of algae and toxin 
levels recorded in the flesh.  
 
Figure 3-3: Comparison of Alexandrium Cell Counts in the water (cells/L) and total sample toxicity of the harvested mussels 
(µg STX di-HCl eq./kg) returned by both LC-FLD and MBA in a) Eyjafjordur and b) Breidafjordur. 
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There is also a clear relationship between the reduction of algal cells and the total toxicity 
determined in the flesh samples. Unfortunately, an absence of flesh samples collected from 
Eyjafjordur in July 2009 prevents an actual comparison between the toxicity of the flesh and 
the Alexandrium cell count during the second algal bloom at this location. 
 
3.3.1 TOXIN PROFILE DETERMINATION  
The preCOX LC-FLD method [41] has been proven as a valuable tool in the qualitative and 
quantitative determination of PSP toxins in shellfish [120]. The epimeric pairs (e.g. GTX2 
and GTX3, GTX1 and GTX4, C1 and C2 and dcGTX2 and dcGTX3) are not separated 
analytically using this LC-FLD method and are therefore presented as a combined sum using 
the higher toxicity factor of the two co-eluted epimers to calculate total toxicity. Through 
analysis using this method the toxin profile was determined and found to be similar in both 
fjords with samples predominated by the carbamate toxins GTX2,3. STX was the next most 
abundant toxin present with GTX1,4 observed in half the samples analysed (Figure 3-4). 
The toxin profiles determined in these samples are similar to those found in other areas where 
Alexandrium spp. predominates such as the UK [121] where the toxins GTX2,3 and STX  
predominate with lower levels of GTX1,4, NEO and GTX5 also being found, or in Ireland 
where GTX2,3 has been found to predominate [122] with lower relative concentrations  of 
STX and GTX1,4 being determined (MI internal NMP data). 
Interestingly, there is no indication of the presence of any of the N-sulfocarbamoyl toxins 
such as C1,2, which have been found to occur in mussels containing PSP toxins in some UK 
waters since 2008 [121] and which are associated with a number of different strains of 
Alexandrium spp. The Norwegian PSP toxin profile typically observed is slightly different to 
that observed in Iceland, being predominated by GTX1,4, with both NEO and STX being 
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found at lower relative concentrations [123]. The differences between profiles in the region 
and Iceland’s is mainly the absence of the toxins NEO and C1,2 from samples analysed. 
 
 
Figure 3-4: Percentage PST profiles determined by LC-FLD (in terms of µmol/Kg) from mussel samples collected from a) 
Eyjafjordur and b) Breidafjordur. 
 
Profiles of A. tamarense mainly consist of the N-sulfocarbamoyl toxins, C1,2 and the high 
potency carbamate toxins GTX1-4, NEO and STX [124,125]. Profiles of A. ostenfeldii can 
contain the spirolides as well as the PSTs GTX6, C1,2 and GTX2,3 [126,127] The absence of 
the N-sulfocarbamoyl toxins C1,2 from mussel samples taken from both harvesting areas, if 
 
Eyjafjordur
0%
20%
40%
60%
80%
100%
120%
8/6/09 21/6/09 28/6/09 8/8/09 23/8/09 31/8/09
P
e
rc
e
n
ta
g
e
 t
o
x
in
 p
ro
fi
le
 (
in
 t
e
rm
s 
o
f 
u
m
o
l/
k
g
) GTX-2,3
STX
GTX-1,4
Breidafjordur
0%
10%
20%
30%
40%
50%
60%
70%
8/6/09 21/6/09 28/6/09 8/8/09 23/8/09 31/8/09
P
e
rc
e
n
ta
g
e
 t
o
x
in
 p
ro
fi
le
 (
in
 t
e
rm
s 
o
f 
u
m
o
l/
k
g
) GTX-2,3
STX
GTX-1,4
Chapter 3 
 
 
69 
 
not relating to the toxin profile in the source algae, could instead be due to the metabolic 
conversion of these toxins in shellfish to GTX2,3 via desulfonation and epimerization [128]. 
This hypothesis could explain the high concentrations of GTX2,3 found in samples as 
evidenced in Figure 3-4. The percentage toxin profile presented in this figure shows 
similarities between both fjords with GTX2,3 being the predominant toxins present in early 
samples taken in June and early August, although a discrepancy is noted in the data set with 
STX being the predominant toxin found in the Eyjafjordur sample from the 08/06/09. The 
ratio of GTX2,3 to STX changes by late August with STX becoming the predominant toxin 
present. Again this could relate either to changes in the toxin ratios present within the algal 
food source or alternatively relate to the potential toxin transformation of GTX2,3 to STX via 
desulfonation [129].  However it is noted that these in vitro experiments by Fast et al. were 
only carried out on clam tissues. 
It is interesting to note that although the Alexandrium cell counts found in Breidafjordur 
(Figure 3-3) were considerably higher than those found in Eyjafjordur, the same ratio was not 
evident in the toxicity results of the mussel samples. The total PSP toxicity found in mussels 
from Eyjafjordur was nearly twice that found in mussels from Breidafjordur. This may relate 
to slower uptake of PSTs by mussels found in Breidafjordur compared to Eyjafjordur or a 
greater composition of non-toxin producing Alexandrium species present in Breidafjordur. 
The absence of GTX1,4 in samples taken in early June and late August from Eyjafjordur and 
early August onwards from Breidafjordur is likely due to the low overall toxicity of these 
samples and the lower relative sensitivity of the N-hydroxylated toxins to their non-
hydroxylated counterparts when analysed using OMA AOAC 2005.06 [120]. 
It is imperative therefore to have adequate knowledge of specific toxin profiles for the 
analysis and risk management of this group of potent neurotoxins due to the range of relative 
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toxicities exhibited by the various analogues. These results highlight the presence in Iceland 
of some of the most toxic PSP toxins as well as levels of toxicity which may provide a 
serious risk to the human consumer. 
 
3.3.2 CHEMICAL AND BIOLOGICAL METHOD ANALYSIS 
Toxicity results returned by both the reference MBA method and the preCOX LC-FLD 
method appear to correlate reasonably well for these samples (Figure 3-3), as observed 
previously in this species for mussels sampled from within UK waters [120]. Overall the 
MBA method gave slightly higher values compared to the preCOX LC-FLD as evidenced in 
Table 3-3 and Table 3-4, although a variability in this ratio is noted.  
It is also clear from the results generated from samples 4-6 from Breidafjordur (Table 3-3), 
that the preCOX LC-FLD method provides useful data on the toxicity of samples containing 
levels of PSTs lower than the MBAs limit of quantitation. This again shows the usefulness of 
the preCOX LC-FLD method for the early warning of toxicity, especially important given the 
rapid increases in PSP toxin levels observed in these areas (Table 3-4). These results 
therefore clearly demonstrate the importance of a regular effective toxicity monitoring 
regime, without which there would be a clear potential risk to human consumers to toxic 
bloom events.  
The level of observed time delay between the peaks in phytoplankton cell presence found in 
the water and the maximum levels of toxicity found in shellfish (Figure 3-3) is also of 
interest. At Breidafjordur, the peak in toxicity appears approximately two weeks after the 
measured maximum of Alexandrium cells. This observation is consistent with those observed 
previously from water and flesh samples collected in the St. Lawrence region, Canada [130] 
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or from Busta Voe Lee North, Scotland [131] where time delays of over 7 days have been 
found. 
 
3.4 CONCLUSIONS 
These novel findings represent the first report of PSP toxins in shellfish from Iceland and 
furthermore indicate the potential increase in the presence of the toxins and causative 
phytoplankton over the past few years. It is difficult to ascertain however, if this increase is 
due to the application of phytoplankton monitoring in Icelandic waters or truly represents an 
increase in the incidence of these toxic dinoflagellates. With the increasing economic 
importance placed upon the shellfish industry in Iceland, this highlights the importance of 
continued monitoring of both shellfish toxicity and their causative organisms. A full and 
thorough risk assessment can then be produced, for the occurrence of PSP in Icelandic waters 
so as to provide the necessary information to ensure an appropriate biotoxin monitoring 
programme is continued. Ongoing work will continue with the analysis of both water and 
flesh samples from both current and developing shellfish harvesting beds and over time build 
up more data on the timing and intensity of the algal blooms and the subsequent shellfish 
toxin accumulation. Further data will allow the ongoing assessment of the presence and 
variability of PSP toxicity and toxin profiles, ultimately providing an essential resource to 
ensure the continued development of the Icelandic shellfish production program. 
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Chapter 4  
STABILISATION TECHNIQUES 
 
4.1 BACKGROUND AND AIMS 
As discussed in Chapter 1, homogeneity and stability are two of the most important 
parameters to consider in the preparation of RMs. In order for a material to be considered fit 
for purpose, the biological matrix and the PSTs themselves must be stable during 
transportation and throughout the materials use as well as ensuring uniformity across the 
entire production lot. Previous studies have proven the role of bacteria present in the 
digestive glands of shellfish in the biotransformation of PSTs [132], a process which may 
result in unstable PST concentration over time. Techniques investigated in this chapter, aimed 
at reducing or eliminating the bacterial effects, lowering the rates of toxin degradation, 
epimerization and biotransformations, should improve PST and matrix stability for RM 
production. Although the processing and dispensing procedures for all materials prepared in 
this study were not carried out aseptically, reducing or eliminating bacteria present in the 
source tissues, through the techniques investigated, significantly improves the stability of 
biological matrix RMs [52]. 
The stabilisation procedures investigated in this chapter include the effects of preserving 
additives, specifically antibiotics and an antioxidant spiked into tissue during preparation, 
thermal treatment of source tissues and the novel application of HPP. The use of preserving 
additives and the application of a thermal treatment step to sterilise source tissues has 
previously been shown to improve the stability of certain phycotoxins [54,60] but, along with 
HPP have not been investigated for the production of PST RMs. Due to the intended use of 
some of the materials prepared in this chapter, specifically in Quasimeme PT schemes where 
participants may use MBA, it was also necessary to determine if the preserving additives 
Chapter 4 
 
 
73 
 
would have any adverse effects on the animal assay, specifically inducing PSP like symptoms 
which could affect method interpretation. 
The study was broken down into distinct sections which investigated the following: 
 Spiking tissues with an antioxidant (ethoxyquin) 
 Spiking tissues with antibiotics (ampicillin, erythromycin and oxytetracycline) 
 Combined use of the preserving additives described above 
 Thermal treatment 
 Combined thermal treatment and spiking with the preserving additives described 
above 
 HPP 
 Untreated control materials 
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4.2 PRESERVING ADDITIVES 
This section of the study investigated the separate use of an antioxidant, ethoxyquin and three 
antibiotics, ampicillin, erythromycin and oxytetracycline and their effects on biological 
matrix stability and the PSTs present (Figure 4-1). These preserving additives have 
previously been shown to improve the stability of domoic acid and AZA3 however they 
provided no additional stability improvements for the other toxins covered in that study, 
AZA1, -2, OA or DTX2 [54,60]. To the author’s knowledge this is the first time these 
preserving additives have been investigated and compared directly to untreated control 
materials for their stabilisation effects on PSTs. 
 
4.2.1 MATERIALS AND METHODS 
4.2.1.1 SOURCE TISSUES 
The Canadian, Norwegian, Spanish, Icelandic and blank toxin free Irish tissues as listed in 
Table 2-1 were used to prepare the RMs used in this section of the study. The tissues were 
naturally contaminated with GTX2,3, STX, GTX1,4, NEO and dcSTX and were diluted with 
a blank toxin free mussel tissue due to the high levels of PSTs present in the contaminated 
tissues. It was necessary to combine different source tissues in order to gain a more 
comprehensive toxin profile than a single tissue alone would provide, therefore the PST 
NEO, although present in sufficient quantities in the source tissue, was diluted to levels 
below the limit of detection (<LOD) of the preCOX and PCOX LC-FLD methods of analysis. 
For this reason stability and homogeneity of this toxin was not investigated. 
An initial bulk tissue (>2.0 kg), containing the quantities detailed in Table 4-1 was prepared 
and subdivided into four separate lots, sealed in PP containers and stored at -20°C until 
further use. The four lots were then used to investigate the separate use of three antibiotics 
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combined (Tissue 1), an antioxidant (Tissue 2), and an untreated control material (Tissue 3). 
The fourth lot was prepared for use in freeze drying experiments as described in Chapter 5, 
Section 5.5. 
 
Figure 4-1: Chemical structures of the four additives used to stabilise the PSTs. 
a) Ethoxyquin
b) Ampicillin
c) Erythromycin
d) Oxytetracycline
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The bulk tissue was prepared by combining the proportions of tissues detailed in Table 4-1 in 
a 5 L Waring™ goblet. To ensure a good degree of homogeneity of the initial bulk tissue, in-
house RM procedures (Standard Operating Procedure (SOP) No. BCT-058) were followed 
which have previously been shown to produce sufficiently homogeneous RMs [54]. This 
specifically involved homogenising the tissues on medium power for 5.0 min, scrapping 
down the insides of the goblet intermittently to ensure thorough mixing.  
Table 4-1: Quantities of source wet frozen tissues used to prepare the bulk homogenate for the additives and freeze drying 
studies. 
Country Species Quantity (kg) 
Canada Mytilus edulis 0.01 
Norway Mytilus edulis 0.18 
Iceland Mytilus edulis 0.38 
Spain Mytilus galloprovancialis 0.95 
Ireland Mytilus edulis 0.63 
 
Aliquots were taken for MC determination (n=3) using the rotary vacuum method and 
analysis by preCOX LC-FLD (n=1) as described in the materials and methods sections 2.4.1 
and 2.3.1 respectively, to give approximate PST concentrations in the bulk tissue. The bulk 
homogenate was immediately subdivided into 3 x ~0.5 kg (Tissues 1-3) and 1 x ~0.7 kg 
(freeze drying experiment in Chapter 5) sub-samples by pouring the required amount of 
tissue into PP containers, sealing with lids and parafilm before storing at -20°C until required 
for use. The PST levels and MC results from this bulk homogenate are presented in Table 
4-2. 
Table 4-2: Toxin profile, concentrations and moisture content of bulk tissue used to prepare Tissues 1-3. 
Material 
Concentration (µmol / kg) Total Toxicity                  
(µg STX 
diHCl-eq / kg) 
%
Moisture 
Content 
dcSTX GTX2,3 GTX5 STX GTX1,4 neoSTX 
Bulk 
homogenate  
0.65 3.5 0.05 1.99 1.9 0.71 2737 80.6 
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4.2.1.2 ADDITIVES MATERIAL PREPARATION 
Both the antibiotics (Tissue 1) and antioxidant (Tissue 2) spiked materials were prepared 
similarly as follows. The frozen bulk homogenate described in section 4.2.1.1 was removed 
from the freezer and allowed to defrost overnight in a fridge at +4°C. The preserving 
additives were prepared by dissolving in ethanol (1% w/w) and adding to the tissue 
homogenates to give 0.02% w/w as described previously by McCarron et al., for domoic acid 
in shellfish [60]. For the antibiotics spike, 0.12 ± 0.01 g each of ampicillin, oxytetracycline 
and erythromycin were weighed into a 50 mL PP centrifuge tube using a calibrated 3-place 
balance. 6.0 ± 0.1 g ethanol was added to the centrifuge tube, capped and vortex mixed 
(Vortex Genie-2, Scientific Industries, NY, USA) for 5.0 min. The antioxidant spike was 
prepared in the same way, weighing 0.12 ± 0.01 g ethoxyquin into a 50 mL PP centrifuge 
tube with 6.0 ± 0.1 g ethanol and vortex mixing for 5.0 min. 
The defrosted tissues were further mixed by hand using a spatula before transferring 464 ± 1 
g into a Waring™ goblet. The additives/ethanol solution was then spiked into the tissue, 
washing out the centrifuge tube with a small volume of DI water before manually mixing 
with a spatula. The antibiotics/ethanol solution was spiked into tissue A and the 
antioxidant/ethanol solution spiked into tissue B. The final weights of both tissue A and B 
were made up to 600 ± 1 g with DI water in order to obtain a final tissue with a MC of ~85% 
to better reflect that found in a natural mussel matrix. 
The tissues were homogenised using a Waring™ blender on medium power for 5.0 min, 
scrapping down the vessel walls intermittently to ensure thorough homogenisation. The 
tissues were transferred to PP beakers and further homogenised using a Polytron™ mixer for 
30.0 min using a coarse head attachment and for 20.0 min using a fine head attachment. The 
Polytron™ homogenisation steps were carried out with the PP beaker placed in an ice-bath to 
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prevent localised heating through friction of the apparatus during homogenisation which 
could result in evaporation and an altered final MC. 
The materials were dispensed as 5.3 ± 0.1 g aliquots using a calibrated peristaltic pump 
(Bernant, IL, USA) into 5  mL PP vials (Teklab Ltd., Durham, UK) to ensure minimum 
retrieval amounts of 5.0 g, sufficient for preCOX method extraction. The tubes were 
hermetically sealed with aluminium lids under a stream of argon using a manual heat sealer 
(MK 1, Seal-it-Systems, Lancashire, UK), before being fitted with wadded (polyethylene 
disc) screw caps. A total of 110 aliquots of Tissue 1 and Tissue 2 were dispensed providing a 
sufficient quantity for short (n=45) and long-term (n=45) stability studies as well as 
homogeneity (n=14) and MC (n=3) determinations. All materials were stored at -80°C until 
required. 
 
4.2.1.3 UNTREATED CONTROL MATERIAL PREPARATION 
The untreated control material (Tissue 3) was prepared by defrosting the bulk homogenate 
described in section 4.2.1.1 overnight in a fridge at +4°C. The defrosted tissue was manually 
mixed using a spatula before transferring 464 ± 1 g into a Waring™ goblet. The final weight 
of the tissue was made up to 600 ± 1 g with DI water in order to obtain a final tissue with a 
MC of ~85% to better reflect that found in a natural mussel matrix. 
The tissue was homogenised using a Waring™ blender on medium power for 5.0 min, 
scrapping down the vessel walls intermittently to ensure thorough homogenisation. The tissue 
was transferred to a PP beaker and further homogenised using a Polytron™ mixer for 30.0 
min using a coarse head attachment and for 20.0 min using a fine head attachment. The 
Polytron™ homogenisation steps were carried out with the PP beaker placed in an ice-bath. 
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The material was dispensed as described in section 4.2.1.2 above. A total of 110 aliquots of 
Tissue 3 were dispensed providing a sufficient quantity for short (n=45) and long-term 
(n=45) stability studies as well as homogeneity (n=14) and MC (n=3) determinations. All 
materials were stored at -80°C until required. 
 
4.2.1.4 STUDIES AND ANALYSIS 
The between-bottle homogeneity of the materials prepared in sections 4.2.1.2 and 4.2.1.3 
above were assessed through the intra-batch analysis of 14 (3n
1/3
) aliquots selected through 
stratified random sampling of the entire fill series. This involved the division of the 
population into smaller groups known as strata, from which simple random sampling or 
systematic sampling is applied to each stratum. 
All materials were stability tested over a short term (ca. 32 day) and long term (ca. 12 month) 
period following a reverse isochronous experimental design [55] to negate day-to-day 
instrumental variations. The short term study was conducted with triplicate samples 
consisting of five time points (0, 3, 8, 16 and 32 days for Tissue 1; 0, 4, 8, 17 and 32 days for 
Tissue 2 and 0, 4, 6, 17 and 31 days for Tissue 3) and three temperature conditions (-20°C, 
+4°C and +40°C). The time points used in the study of each material were slightly different 
to each other as it was necessary to alter the time models slightly to ensure analysis was 
completed within the required time frame. The long term study was conducted with triplicate 
samples consisting of five time points (0, 3, 6, 9 and 12 month) and three temperature 
conditions (-20°C, +4°C and +20°C). The reference temperature used in both studies was -
80°C. A total of 9 aliquots were stored at this temperature for the duration of the study before 
being removed and extracted with the other stability study samples. In the case of all the 
stability studies aliquots of tissue (n=3), were removed from -80°C storage on the prescribed 
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day and transferred to the storage conditions being investigated. Table 4-3 is an example of a 
stability study data table and can be used to describe the process. On the first day of the study 
(Day 30, 12/06/11) 9 aliquots of tissue were removed from the -80°C freezer, transferring 3 
tissue aliquots into each of -20°C, +4°C and +40°C storage conditions and recording the 
aliquot numbers of each in the table below.  Two weeks later on the 26/06/11 another 9 tissue 
aliquots were removed from -80°C storage and placed in each of the three storage 
temperatures being investigated, recording their aliquot numbers in the same table below. 
This process was repeated on the 04/07/11 and the 08/07/11. 
Table 4-3: Table used to input data for a short-term stability study. 
  
Time point & Date 
 
  30 16 8 4 0 
 
Sample 
12/06/11 
Sunday 
26/06/11 
Sunday 
04/07/11 
Monday 
08/07/11 
Friday 
12/07/11 
Tuesday 
-20°C 
#1           
#2 
 
  
 
    
#3           
+4°C 
#1           
#2 
 
  
 
    
#3           
+40°C 
#1           
#2 
 
  
 
    
#3           
 
 
On the final day of the study, 12/07/11 the 9 remaining tissue aliquots were removed from -
80°C storage and their aliquot numbers recorded in the column labelled 0 in Table 4-3. At the 
same time all the other tissues were removed from the -20°C, +4°C and +40°C storage 
conditions, allowing them to equilibrate to room temperature before being extracted and 
analysed by preCOX LC-FLD closely following OMA AOAC 2005.06 [41] as detailed in 
section 2.3.1. PCOX LC-FLD [75] analysis was additionally performed on all samples to 
specifically investigate the extent of epimerisation, if any, of GTX2,3 in each material. The 
epimerisation of GTX1,4 was not determined as the concentration of these toxins in each 
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tissue was below the limit of quantification (<LOQ) of the PCOX LC-FLD method. GTX2 
and GTX3 are good indicator toxins however for rates of epimerization in tissues as 
evidenced from previous studies [133–135]. For PCOX LC-FLD analysis, the crude acetic 
acid extracts prepared according to section 2.3.1 were deproteinated and analysed following 
AOAC 2011.02 as described in section 2.3.2 [75]. 
PST concentrations in sample extracts were quantified against a 4 - 5-point calibration for 
each toxin and are expressed as µmol/kg with total saxitoxin equivalents calculated as an 
estimation of total toxicity. 
The MC of each of the Tissues 1-3 was determined using the rotary vacuum method as 
described in the materials and methods section 2.4.1. Aliquots (n=3) were selected from the 
beginning, middle and end of the fill series in order to determine if any evaporation had taken 
place during dispensing. 
The organoleptic properties of each of the tissues was also assessed, specifically the odour of 
the tissues stored at the elevated temperature conditions was noted during extraction of the 
stability study samples. 
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4.2.2 RESULTS AND DISCUSSION 
 
4.2.2.1 HOMOGENEITY AND MOISTURE CONTENT 
All the materials prepared in this section of the study were suitably homogenous for all the 
PSTs detected, as evidenced through the coefficient of variances contained in Table 4-4. 
A target %CV of below 8% for each analyte including total toxicity was set. This value is 
below expected levels of variability associated with intra-batch repeatability, determined 
through in-house validation of the preCOX LC-FLD method. The intra-batch repeatability of 
the preCOX LC-FLD method was determined to be >9% for all toxins determined during 
validation studies. The homogeneity techniques employed were therefore sufficient and the 
materials suitable for the study. 
Table 4-4: Homogeneity results for the antibiotic spiked (Tissue 1), antioxidant spiked (Tissue 2) and untreated control 
(Tissue 3) materials showing mean toxin concentrations determined by preCOX LC-FLD (n=14). 
  
Material 
dcSTX GTX2,3 GTX5 STX GTX1,4 Total Toxicity 
  µg STX diHCl-eq. / kg 
Average 
Tissue 1 205.4 606.0 2.7 705.8 490.5 2010 
Tissue 2 214.5 830.3 1.9 690.1 366.4 2103 
Tissue 3 194.0 641.8 2.1 545.8 304.1 1688 
Stdev 
Tissue 1 15.2 35.7 0.1 46.3 29.9 152.8 
Tissue 2 7.9 54.7 0.1 17.6 26.6 75.7 
Tissue 3 9.0 44.5 0.1 19.2 14.1 84.0 
%CV 
Tissue 1 7.4 5.9 3.0 6.6 6.1 7.3 
Tissue 2 3.7 6.6 3.9 2.6 7.3 3.5 
Tissue 3 4.7 6.9 5.9 3.5 4.7 5.0 
 
Each of the three materials were prepared from a pooled homogenate and adjusted to the 
same target value for moisture content of 85%. Despite this fact, a statistical difference in 
total toxicity means (P < 0.05; one-way analysis of variance [ANOVA]) was evident between 
the three tissues which can be seen from the data contained in Table 4-4. The cause or causes 
of these differences remain unclear and may be attributed to day-to-day instrument variations 
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as the homogeneity determinations were carried out on separate days. Despite the statistical 
differences between the means, the processing techniques employed to make the materials 
were suitable to prepare sufficiently homogenous materials for use in these studies. 
 
Figure 4-2: visual comparison of total toxicity homogeneity results for Tissues 1-3 (n=14). 
 
The moisture content of each of the Tissues 1-3 gave reproducible results for the three 
materials and is slightly higher than the desired value of 85% (Table 4-5). The coefficient of 
variances for each Tissue 1-3 was low which indicates that evaporation during dispensing 
was minimal. Each tissue took approximately 1 ½ hours to dispense in total so evaporation 
during this short timeframe was not expected, particularly given the precautions that were put 
in place such as the use of an ice bath to cool the tissue during dispensing. RMs prepared at 
the MI for use in the NMP where >1000 aliquots are generally dispensed can take up to 5-6 
hours to complete. Moisture content determinations of these large batches of RMs give 
coefficients of variance similar to those found in Table 4-5 (data not shown) which indicate 
the steps taken to minimise evaporation are sufficient even for dispensing large numbers of 
aliquots. The critical number of aliquots dispensed after which evaporation does present a 
problem is unknown but is >1000 if precautions are put in place. 
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Table 4-5: Moisture content of Tissues1-3 determined by the rotary vacuum method (n=5). 
Material 
Moisture 
Content 
%CV 
Tissue 1 86.0 0.05 
Tissue 2 85.9 0.23 
Tissue 3 85.6 0.07 
 
4.2.2.2 SHORT-TERM STABILITY 
PRECOX LC-FLD 
Figure 4-3 a-e represents the short-term stability results for the three materials at three 
different storage temperatures, -20°C, +4°C and +40°C, determined through preCOX LC-
FLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 and STX were generated and 
results were normalised to the average of replicate analysis (n=9) of samples stored at the 
reference temperature of -80°C for the duration of the study. The limits of stability from 
Figure 4-3 were generated from two times the standard deviation of the -80°C replicate 
analyses.  
Overall toxin stability was excellent in each of the Tissues 1-3 when stored at -20°C and 
additionally for Tissues 1 and 2 when stored at +4°C for the duration of the short-term study. 
Tissue 3 exhibited a slight increase in GTX2,3 concentration after 17 days at +40°C and after 
31 days at +4°C which showed the improvement additives spiking specifically had on the 
stability of these toxins. However the stability of the other toxins at +40°C differed between 
each stabilisation technique and also the control material. 
The stability of all the PSTs were improved in Tissue 2 compared to Tissue 3 when stored at 
+40°C which highlights the benefits of using an antioxidant in RM preparation for PSTs. The 
use of the antibiotics in Tissue 1 showed varying levels of stability for the PSTs with 
improvements made to GTX2,3 and GTX1,4 stability at +40°C compared to Tissue 3.  
Chapter 4 
 
 
85 
 
 
Figure 4-3: Short-term stability graphs for the PSTs present in Tissues 1, 2 and 3 determined by preCOX LC-FLD. Results 
are normalised to the time zero reference temperature of -80°C (error bars represent ± 2 s.d.). 
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Interestingly Tissue 1 appears to show instability issues for dcSTX and STX which are more 
pronounced than those observed in either Tissue 2 or 3 materials stored at +40°C, the exact 
causes of which remain unclear. Similar levels of instability were observed for GTX5 in all 
tissues when stored at +40°C which showed neither stability enhancement nor deterioration 
through the use of preserving additives for this toxin. 
An increase in GTX2,3 concentration was observed in the antioxidant material after 32 days 
storage at +40°C and in the control material after 17 and 31 days storage at +40°C and +4°C 
respectively. The cause of this increase is unknown but could be due to biotransformations 
taking place in the tissue [132]. 
The use of the antioxidant ethoxyquin improved the stability of the PSTs overall compared to 
the control which proves its inclusion for PST RM production to be beneficial. The use of the 
antibiotics however gave different results with their inclusion improving the stability of 
GTX1,4 compared to the control. The stability of the other PSTs investigated was apparently 
worsened, albeit only at the higher temperature of +40°C; similar levels of stability were 
evident at the lower temperatures studied for all three tissues. 
 
PCOX LC-FLD 
Further analysis was conducted on the short-term stability study extracts for each of the 
stabilisation techniques by PCOX LC-FLD and results are presented in Figure 4-4 a-b. The 
PCOX LC-FLD method was used specifically to determine the rate of epimerization of 
GTX2 and GTX3, if any, in the materials prepared by each technique compared to those 
found in the untreated control. Limits of stability and normalised results were calculated as 
per the preCOX LC-FLD analysis above. 
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No epimerization or degradation was observed in any materials when stored at -20°C for the 
duration of the study with results falling within the limits of stability set. Tissue 1 showed 
some slight signs of epimerization at +4°C after 32 days storage. At +40°C epimerization of 
GTX2,3 in Tissue 1 was evident after 3 days storage which highlights the speed this reaction 
can occur when samples are stored at an elevated temperature.   
Tissue 2, while similarly stable at -20°C as in the case of Tissue 1, showed slightly more 
instability issues at the higher temperatures investigated. Epimerization was evident after 4 
days storage at +40°C and after 17 days storage at +4°C in the Tissue 2 samples. 
The untreated control, Tissue 3 showed the epimerization of GTX2,3 at temperatures above -
20°C. This was evident after 4 days storage at +40°C and after 17 days storage at +4°C. 
Further instability issues of GTX3 were evident in the Tissue 3 samples, not seen in either of 
the other tissues. The total reduction of GTX3 in Tissue 3 at +40°C as seen in Figure 4-4 a 
could not be attributed solely to epimerization as the increase in GTX2 concentration (Figure 
4-4 b) does not occur to the same level. GTX3 concentration in Tissue 3 therefore reduces by 
~50% most likely through a combination of epimerization to GTX2 and some degradation of 
the toxin itself. The reduction of GTX3 in Tissues 1 and 2 however is only ~20-25% and is 
accompanied by an increase in GTX2 levels of the same magnitude ~20-25%, which 
indicates epimerization is the predominant reaction taking place and very little if any toxin 
degradation is occurring in these tissues. Although spiking with additives does not 
significantly reduce epimerization rates compared to untreated materials, inclusion of 
antibiotics or an antioxidant does improve the stability of GTX3 by approximately 25% 
which highlights their advantage in RM preparation, particularly for PCOX LC-FLD analysis 
where individual epimers can be quantified. 
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Figure 4-4: Stability graphs for the PST epimers GTX2,3 determined by PCOX LC-FLD for the short-term data (a-b) and 
the long-term data (c-d) Results are normalised to the time zero reference temperature of -80°C (error bars represent ± 2 
s.d.). 
 
The results from both the preCOX and PCOX analysis of the short-term stability samples 
provide useful information on the conditions required for transportation of materials 
stabilised using both techniques. Although transportation of matrix RMs ideally should be 
made under frozen conditions, results indicate materials would also be stable at +4°C for up 
to 32 days if spiked with antibiotics and up to 17 days if spiked with the antioxidant, 
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ethoxyquin. These findings indicate that if adverse conditions were experienced during 
transportation, PSTs would remain stable up to temperatures of +4°C for over two weeks. 
 
4.2.2.3 LONG-TERM STABILITY 
PRECOX LC-FLD 
Figure 4-5 a-e represents the long-term stability results for the three materials at three 
different storage temperatures, -20°C, +4°C and +20°C, determined through preCOX LC-
FLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 and STX were generated and 
results were normalised to the average of replicate analysis (n=9) of samples stored at the 
reference temperature of -80°C for the duration of the study. The limits of stability from 
Figure 4-5 were generated from two times the standard deviation of the -80°C replicate 
analyses. 
All three Tissues 1-3 exhibited excellent stability for all the PSTs throughout the duration of 
the yearlong study when stored at -20°C. Differing levels of stability were exhibited under 
the other storage conditions however.  
At the elevated storage temperatures of +4°C and +20°C the use of preserving additives in 
Tissues 1 and 2 did not significantly improve PST stability compared to Tissue 3. GTX5 
showed the greatest differences in stability across the three materials with Tissues 2 and 3 
exhibiting apparent increases in toxin concentration at +20°C (Tissues 2 and 3) and +4°C 
(Tissue 3), the causes of which are unclear. Tissue 1 showed no increase in GTX5 
concentration at this storage condition, in fact this tissue showed no signs of degradation until 
after 9 months of the study at +20°C and remained stable at +4°C over the course of the 12 
months. 
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Figure 4-5: Long-term stability graphs for the PSTs present in Tissues 1, 2 and 3 determined by preCOX LC-FLD. Results 
are normalised to the time zero reference temperature of -80°C (error bars represent ± 2 s.d.). 
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As in the case of the short-term stability studies, but significantly more pronounced, were 
increases in GTX2,3 concentrations observed at both +20°C and +4°C storage. Similar 
increased GTX2,3 concentrations were observed in all three tissues at +4°C but Tissue 2 
exhibited a greater increase at +40°C compared to either Tissues 1 or 3 which exhibited 
increases of a similar level. 
The results prove that whilst some benefits were obtained following additive pre-treatment, 
long-term storage conditions for the materials stabilised with either antibiotics or the 
antioxidant should still be at -20°C or below. 
 
PCOX LC-FLD 
Further analysis was conducted by PCOX LC-FLD on the long-term stability study extracts 
of each of the materials and results are presented in Figure 4-4 c-d. Limits of stability and 
normalised results were calculated as per the preCOX LC-FLD analysis above. Data for the 
toxins GTX1 and GTX4 were not generated as the concentration of these toxins in each 
material was <LOD of the PCOX LC-FLD method. 
No epimerization or degradation was observed in any materials when stored at -20°C for the 
duration of the study with results falling within the limits of stability set. Tissue 1 showed no 
visual evidence of epimerization at +4°C, although a low amount was observed after 32 days 
in the short-term study (Figure 4-4 a-b). GTX2 in Tissue 1 remained stable throughout the 
yearlong study at +4°C while GTX3 showed signs of degradation after 6 months storage with 
~20% of this toxin degraded by the end of the study, which suggests a more selective 
degradation of the β-epimer occurs. At +20°C epimerization of GTX2,3 in Tissue 1 was 
evident after 3 months storage.   
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Tissue 2 while similarly stable at -20°C as in the case of Tissues 1 and 3 showed 
epimerization of GTX2,3 after 12 months storage at +4°C and after 3 months at +20°C. 
Epimerization was also observed to take place in Tissue 3 control materials but the process 
occurred earlier than either Tissue 1 or 2 at +4°C. At this temperature epimerization was 
evident in Tissue 3 material after 6 months storage compared to 12 months in the case of 
Tissue 2 and no epimerization was observed in Tissue 1. At +20°C epimerization was 
observed to take place after 3 months storage which was similar to both Tissues 1 and 2, 
showing no clear advantage the preserving additives provided. 
The long-term stability study samples as determined by PCOX LC-FLD show no significant 
improvement in reducing epimerization rates through the inclusion of preserving additives. 
The rates of epimerization of all three tissues were similar at +20°C; however the use of 
antibiotics in Tissue 1 did lower epimerization rates in samples stored at +4°C (Figure 4-4 c-
d). 
Epimerization of these toxins followed predicted patterns with the β-epimer GTX3 being 
epimerized into the more stable α-form GTX2 [136], which was evident from both the short 
and long-term stability data generated through the PCOX LC-FLD analysis. 
 
CHROMATOGRAPHIC AND MATRIX STABILITY 
Another important factor to consider when choosing an RM preparation technique is ensuring 
good chromatographic stability is achieved. Figure 4-6 a-h displays chromatograms generated 
by preCOX LC-FLD for Tissues 1-3 by both peroxide and periodate oxidation after 12 
months storage at +20°C. Chromatograms of Tissue 3 stored at -80°C for 12 months are also 
shown in this figure as a visual comparison.  
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The chromatograms generated following peroxide oxidation (Figure 4-6 a-c) for Tissues 1-3 
show some differences in chromatographic peaks inferring either differing levels of toxin 
stability and/or the generation of naturally-flourescent matrix co-extractives over time. 
Chromatograms of Tissues 1 and 2 materials showing no formation of additional 
chromatographic peaks through the inclusion of either of the preserving additives compared 
to the control material stored at -80°C. Tissue 3 in comparison did show the additional 
formation of chromatographic peaks between 5.0 – 6.5 mins which could affect accurate 
quantitation of the C-toxins as their retention times are similar, although these toxins were 
not present in these tissues.  
The periodate oxidised extracts used to quantify the N-hydroxylated toxins GTX1,4 are 
contained in Figure 4-6 e-h. Good chromatographic stability was observed in all tissues up to 
a retention time of ~9.0 mins which would not interfere with accurate quantitation of 
GTX1,4. A large matrix peak, not present in the control material stored at -80°C was evident 
in all three tissues at a retention time of ~9.2 mins however which indicates some matrix 
instability. The presence of this additional peak would not affect accurate quantitation of 
GTX1,4 however. 
The retention time differences observed between the peroxide and periodate oxidised samples 
is due to both sets of analysis been carried out on different days. Retention time checks were 
carried out each day however, through comparison to standards. 
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Figure 4-6: PreCOX LC-FLD chromatograms following peroxide (5a-d) and periodate (5e-h) oxidation of Tissues 1, 2, 3 
and a control material stored for 12 months. 
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The organoleptic properties of each of the materials prepared are another indicator of the 
advantages using preserving additives have, particularly on matrix stability. Specifically the 
odour of the untreated control materials stored at +4°C and +40°C was significantly worse 
than either Tissue 1 or 2 materials stored at the same temperatures. The malodour indicated a 
high degree of rancidity of the mussel matrix in Tissue 3 which was reduced in the other two 
tissues. 
 
4.2.3 CONCLUSIONS 
All the materials used in this study were found to be homogeneous for the PSTs present as 
evidenced through the coefficients of variation determined for toxin concentrations quantified 
in selected tissue samples. This highlights the applicability of the in-house RM 
homogenisation techniques in preparing suitable materials for the study, as proven in 
previous studies at the MI [54]. 
The use of preserving additives improved the stability of the PSTs investigated in this section 
of the study which was particularly evident in the short-term samples at the higher 
temperature storage condition of +40°C. The use of the antibiotics (Tissue 1) improved the 
stability of the toxins GTX2,3 and GTX1,4 and the antioxidant (Tissue 2) improved the 
stability of dcSTX and STX when compared to the untreated control (Tissue 3) in the short-
term. Both Tissues 1 and 2 showed excellent stability at +4°C for all the toxins investigated, 
whereas Tissue 3 showed some instability issues for GTX2,3 under this storage condition. 
The results indicate that the use of either an antioxidant or antibiotics in stabilising PSTs 
depends on the toxin profile present. Their combined use however may provide better overall 
stability for a range of PSTs. These short-term stability observations have particular 
importance in determining transportation conditions required for shipment of materials and in 
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the case of either Tissue 1 or 2, this could be carried out at temperatures of up to +4°C for as 
long as 32 days without adverse effects to toxin stability. 
The long-term stability studies did not definitively prove the benefits of using preserving 
additives in RM preparation. Some minor improvements were observed in the case of 
GTX1,4 using either the antibiotics or the antioxidant but none were significant. Long-term 
storage of biological RMs should be at temperatures of -20°C or below. 
Tissues 1 and 2 showed good chromatographic stability in peroxide oxidised samples with no 
formation of additional peaks evidenced in the chromatograms. Conversely Tissue 3 showed 
the formation of extra chromatographic peaks although these would not necessarily affect 
accurate quantitation of any of the PSTs investigated in this study but which could affect 
quantitation of the toxins C1,2 if they were present. This highlights another advantage of 
using preserving additives in RM preparation to not only improve toxin stability but to 
improve matrix and therefore chromatographic stability. 
The results of these experiments indicate the applicability of using preserving additives in 
LRM and ILRM preparation but not for CRM production. The antibiotics and antioxidant 
spikes improve short-term stability, important for example in delivery of PT materials but the 
long-term stability of these materials was not significantly improved enough to warrant 
feasibility studies being undertaken for CRM production.  
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4.3 PRESERVING ADDITIVES AND THERMAL TREATMENT 
This section of Chapter 4 investigates the combined use of an antioxidant, ethoxyquin and 
three antibiotics, ampicillin, erythromycin and oxytetracycline which were separately 
evaluated in section 4.2. This section also evaluates the effects thermal treatment through 
autoclaving had on matrix stability and the PSTs present. The two stabilisation techniques 
were, as in the case of the section 4.2 materials, investigated in parallel with an untreated 
control material. 
Short and long-term stability experiments as well as homogeneity determinations were 
conducted on materials prepared by both techniques in comparison with an untreated control 
using two LC-FLD methods. 
 
This section of Chapter 4 details work described in Burrell et al. 2015 [113]. 
Stephen Burrell, Valentin Clion, Virginie Auroy, Barry Foley & Andrew D. Turner, 2015. 
Heat treatment and the use of additives to improve the stability of paralytic shellfish 
poisoning toxins in shellfish tissue reference materials for internal quality control and 
proficiency testing, Toxicon. 99:80–88. 
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4.3.1 MATERIALS AND METHODS 
 
4.3.1.1 SOURCE TISSUES 
The Icelandic, Spanish and blank toxin free Irish tissues from Table 2-1 were used to prepare 
the RM used in this section of the study. The tissues were naturally contaminated with 
GTX2,3, STX, GTX1,4, and dcSTX and were diluted with a blank toxin free mussel tissue 
due to the high levels of PSTs present in the other tissues.  
A bulk tissue (>4.0 kg) was prepared for use in this section of Chapter 4 and subdivided into 
four separate lots, sealed in PP containers and stored at -20°C until further use. The bulk 
tissue was prepared by combining the proportions of tissues detailed in Table 4-6 into a 5 L 
Waring™ goblet. The bulk tissue was homogenised as described in section 4.2.1.1. 
Table 4-6: Quantities of source tissues used to prepare bulk homogenate for additives, thermal treatment and freeze drying 
studies. 
Country Species Tissue Quantity (kg) 
Iceland Mytilus edulis WF 1.26 
Norway Mytilus edulis WF 1.00 
Spain Mytilus galloprovancialis WF 1.00 
Ireland Mytilus edulis WF 0.74 
 
Aliquots were taken for MC determination (n=3) using the rotary vacuum method and 
analysis by preCOX LC-FLD (n=1) as described in the materials and methods section 2.4.1 
and 2.3.1 respectively, to give approximate PST concentrations in the bulk tissue. The bulk 
homogenate was immediately subdivided into 3 x ~0.8 kg (Tissues A-C) and 1 x ~0.8 kg 
(freeze drying in Chapter 5, section 5.4) aliquots by pouring the required amount of tissue 
into PP containers, sealing with lids and parafilm before storing at -20°C until required for 
use. The PST levels and MC results from this bulk homogenate are presented in Table 4-7. 
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Table 4-7: Toxin profile, concentrations and moisture content of bulk tissue used to prepare Tissues A-C and a freeze dried 
material in chapter 5. 
Material 
Concentration (µmol / kg) Total Toxicity                  
(µg STX diHCl-eq / kg) 
% 
Moisture 
Content dcSTX GTX-2,3 GTX-5 STX GTX-1,4 
Bulk 
homogenate  
0.65 0.94 0.06 0.62 0.22 685 81.6 
 
 
4.3.1.2 ADDITIVES AND THERMAL TREATMENT MATERIAL PREPARATION 
Both the additives spiked (Tissue A) and thermally treated (Tissue B) materials were 
prepared similarly as follows. The frozen bulk homogenate described in section 4.3.1.1 above 
were removed from the freezer and allowed to defrost overnight in a fridge at +4°C. The 
preserving additives were prepared at a concentration of 0.02% w/w by dissolving in ethanol 
(1% w/w). For the additives spike, 0.18 ± 0.01 g each of ampicillin, oxytetracycline, 
erythromycin and ethoxyquin were weighed into a 50 mL PP centrifuge tube using a 
calibrated 3-place balance. 9.0 ± 0.1 g ethanol was added to the centrifuge tube, capped and 
vortex mixed for 5.0 min. 
For Tissue A the defrosted tissues were manually mixed using a spatula before transferring 
734 ± 1 g into a Waring™ goblet. The additives/ethanol solution was then spiked into the 
tissue, washing out the centrifuge tube with a small volume of DI water before manually 
mixing with a spatula. The final weight of the tissue was made up to 900 ± 1 g with DI water 
in order to obtain a final tissue with a MC of ~85%. 
For Tissue B the defrosted tissues were manually mixed using a spatula before being 
transferred to a 3L PP beaker and autoclaved (Systec VE-100, Focus Scientific Solutions, 
Meath, Ireland) at 121°C for 15.0 ± 0.1 min. The tissues were allowed to cool to room 
temperature before being transferred, including any liquid to a Waring™ goblet and 
homogenised on medium power for 5.0 ± 0.1 min. Aliquots (n=3) were taken for MC 
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determination which was determined to be ~82%. 670 ± 1 g of the tissue was gravimetrically 
transferred into a Waring™ goblet. The final weight of the tissue was made up to 800 ± 1 g 
with DI water in order to obtain a final tissue with a MC of ~85%. 
The final homogenisation steps of Tissue A and B using both Waring™ and Polytron™ 
blenders, including the dispensing of both was carried out as described in section 4.2.1.2. A 
total of 150 aliquots of Tissue A and 120 aliquots of Tissue B were dispensed providing a 
sufficient quantity for short (n=45) and long-term (n=45) stability studies as well as 
homogeneity (n=16) and MC (n=3) determinations. All materials were stored at -80°C until 
further use. 
 
4.3.1.3 UNTREATED CONTROL MATERIAL PREPARATION 
The untreated control material (Tissue C) was prepared by defrosting the bulk homogenate 
described in section 4.2.1.1 above overnight in a fridge at +4°C. The defrosted tissue was 
manually mixed using a spatula before transferring 734 ± 1 g into a Waring™ goblet. The 
final weight of the tissue was made up to 900 ± 1 g with DI water in order to obtain a final 
tissue with a MC of ~85%. 
Tissue C was homogenised and dispensed as described in section 4.2.1.3. A total of 150 
aliquots of Tissue C were dispensed providing a sufficient quantity for short (n=45) and long-
term (n=45) stability studies as well as homogeneity (n=16) and MC (n=3) determinations. 
All materials were stored at -80°C until required. 
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4.3.1.4 STUDIES AND ANALYSIS 
The between-bottle homogeneity of the materials prepared in sections 4.3.1.2 and 4.3.1.3 
above was assessed through the intra-batch analysis of 16 aliquots (3n
1/3
) selected through 
stratified random sampling of the entire fill series. 
All materials were stability tested over a short term (ca. 30 day) and long term (ca. 12 month) 
period following a reverse isochronous experimental design [55]. The short term study was 
conducted with triplicate samples consisting of five time points (0, 4, 6, 16 and 30 day for 
Tissue A, 0, 4, 8, 15 and 28 days for Tissue B and 0, 4, 8, 15 and 32 days for Tissue C) and 
three temperature conditions (-20°C, +4°C and +40°C). The time points used in the study of 
each material were again slightly different as it was necessary to alter the time models 
slightly to ensure analysis was completed within the required time frame. The long term 
study was conducted with triplicate samples consisting of five time points (0, 3, 6, 9 and 12 
month) and three temperature conditions (-20°C, +4°C and +20°C). The reference 
temperature used in both studies was -80°C. The stability studies were set up and carried out 
as described in section 4.2.1.4. 
At the end time point all samples were removed from storage, allowed to equilibrate to room 
temperature before being extracted and analysed by preCOX LC-FLD closely following 
OMA AOAC 2005.06 [41] as detailed in section 2.3.1. PCOX LC-FLD [75] analysis was 
additionally performed on all samples to specifically investigate the extent of epimerisation, 
if any, of GTX2,3 in each material. For PCOX LC-FLD analysis, the crude acetic acid 
extracts prepared according to section 2.3.1 were deproteinated and analysed following 
AOAC 2011.02 [75]. 
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PST concentrations in sample extracts were quantified against a 4 - 5-point calibration for 
each toxin and are expressed in µmol/kg with total saxitoxin equivalents calculated as an 
estimation of total toxicity. 
The MC of each of the Tissues A-C was determined using the rotary vacuum method as 
described in the materials and methods section 2.4.1, selecting aliquots from the beginning, 
middle and end of the fill series. 
 
4.3.2 RESULTS AND DISCUSSION 
 
4.3.2.1 HOMOGENEITY 
 
Figure 4-7: Homogeneity results for the additives spiked (Tissue A), heat treated (Tissue B) and untreated control (Tissue C) 
materials showing mean toxin concentrations (± 1 s.d) determined by preCOX LC-FLD (n=16). 
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Figure 4-7 illustrates the homogeneity results for the three tissues, showing mean PST 
concentrations and standard deviations (sd) associated with the triplicate analysis. This allows 
for a visual representation of the effects each treatment had on the toxin content, specifically 
if any toxin degradation occurred during the processing steps. The homogeneity results for 
the individual analogues and total toxicity from the three materials showed a statistical 
difference (P < 0.05; one-way analysis of variance [ANOVA]) between the three means, 
showing there were some effects on toxin concentrations following treated sample 
preparation. The quantity of toxin degraded during the preparation of materials and the 
acceptability of these losses depends on the needs of the RM producer and whether the 
improvements to toxin stability these techniques provide outweigh the toxin losses incurred 
through each processing technique. This was particularly important in the case of the heat 
treated materials, which showed the relative thermal stability of the toxins during exposure to 
high temperatures, even though a 15% reduction in total toxicity was determined, compared 
to the control. The toxin profiles in each tissue remained consistent, as evidenced from Figure 
4-7, which showed no visual evidence for the degradation or biotransformation of toxins 
through any of the stability techniques. 
The homogeneity results for each material were acceptable with percentage relative standard 
deviations (RSD%; n=16) of <8 % for total toxicity (mean = 5.0 %) and individual analogues 
(mean = 4.9 %), which were within expected levels of variability associated with intra-batch 
repeatability as determined through previous validation studies [120]. 
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4.3.2.2 SHORT-TERM STABILITY 
PRECOX LC-FLD 
Figure 4-8 a-e represents the short-term stability results for the three materials at three 
different storage temperatures, -20°C, +4°C and +40°C, determined through preCOX LC-
FLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 and STX were generated and 
results were normalised to the average of replicate analysis (n=9) of samples stored at the 
reference temperature of -80°C for the duration of the study. The limits of stability from 
Figure 4-8 were generated from two times the standard deviation of the -80°C replicate 
analyses.  
Overall toxin stability was excellent in each of the materials, including the untreated tissues 
when stored at -20°C or +4°C for the duration of the short-term study. The stability of the 
toxins at +40°C differed between each stabilisation technique and the control materials with 
the thermally treated tissues in particular showing significant stability improvements for all 
toxins present when compared to the untreated materials. From these results, heat treatment 
proved the most effective technique investigated with dcSTX, GTX1,4, GTX2,3 and STX 
showing excellent stability, even at the highest temperature of +40°C in addition to the two 
other temperature conditions investigated. Mean concentrations of the N-sulfocarbamoyl 
toxin GTX5 were however found to fall well below the standard deviation limits which may 
indicate some stability issues relating to this toxin. The level of degradation of GTX5 
(ca.50%),  in the +40°C materials was very similar for the two stabilisation techniques as well 
as the untreated materials however which showed neither an improvement nor deterioration 
in GTX5 stability through the use of either technique compared to the control. 
Chapter 4 
 
 
105 
 
 
Figure 4-8: Short-term stability graphs for the PSTs present in Tissues A, B and C determined by preCOX LC-FLD. Results 
are normalised to the time zero reference temperature of -80°C (error bars represent ± 2 s.d.). 
 
Similar stability issues for dcSTX, GTX1,4, GTX5 and STX were evident in both the 
additives spiked and control materials at +40°C indicating that no clear advantage is provided 
in the additive treated tissues in the case of short-term toxin stability. Spiking tissues with 
these additives did however significantly improve the stability of GTX2,3 with no stability 
issues evident from Figure 4-8 c under any of the temperature conditions studied. Conversely 
stability issues could be observed for these toxins after 4 days in the control materials stored 
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at +40°C where an apparent increase in concentration could be observed which culminated in 
an approximate 40% increase by the end of the study. 
The preCOX analysis of these samples therefore clearly indicated that thermally treating 
materials provides a significant stability improvement to all the toxins investigated, except 
GTX5, compared to both the additives spiked and control materials. The inclusion of 
additives such as those used in this study only appear to improve the stability of the toxins 
GTX2,3 in the short-term compared to the control with no significant improvement made in 
stabilising the other toxins present, although no deterioration was evident either. 
Previous studies carried out by Smith et al., proved the role of bacteria, present in the 
digestive glands of shellfish species, in the biotransformation of PSTs [132]. They concluded 
that, in the presence of bacterial isolates taken from mussel digestive glands, GTX1,4 
reductively transformed with concomitant production of GTX2,3. A decrease in GTX1,4 
concentration under the +40°C storage condition was observed in both the additives and 
control materials, which  culminated in a total decrease of approximately 40% (additives) and 
80% (control) by the end of the study. The increase in GTX2,3 concentration observed in 
Tissue C is therefore most probably due to the reductive transformation of GTX-1,4 present 
in the tissue. This transformation is thought to take place by the reductive elimination of the 
C-11 hydroxysulfate (OHSO3) and N-1 hydroxyl (OH) moiety (Figure 1-3) by bacteria as 
previously described by Kotaki et al, 1985 [137]. This reaction was observed to take place 
when these toxins were present with Vibrio and Pseudomonas spp. of bacteria present in blue 
mussels. 
Further evidence for this hypothesis can be found in the fact that the slight increase in GTX-
2,3 levels and the decrease in GTX-1,4 concentration observed in the additives material was 
significantly less than that observed in the control. If the changes in toxin concentration are 
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indeed due to bacterially induced biotransformations, then the inclusion of additives would 
limit the role these bacteria have in toxin transformation, through lowering the cell counts in 
the tissue, resulting in the smaller changes observed in the additives material. 
Thermally treating the material also provided excellent stability with dcSTX, STX and GTX-
2,3 stable under all storage conditions for the duration of the study. GTX-5 showed some 
degradation under the elevated storage condition however. This technique, while maintaining 
the same level of stability for dcSTX and STX, improves the stability of the toxins GTX-2,3 
when compared to the control material.  
 
PCOX LC-FLD 
Further analysis was conducted on the short-term stability study extracts for each of the 
techniques by PCOX LC-FLD and results are presented in Figure 4-9 a-b. The PCOX LC-
FLD method was used specifically to determine the rate of epimerization of GTX2 and 
GTX3, if any, in the materials prepared by each technique compared to those found in the 
controls. Limits of stability and normalised results were calculated as per the preCOX 
analysis above. 
No epimerization or degradation was observed in any materials when stored at -20°C for the 
duration of the study with results falling within the limits of stability set. The materials spiked 
with additives also showed no evidence for epimerization of GTX2 and GTX3 at +4°C, 
although some slight degradation of GTX3 was observed after day 30 of the study under this 
temperature condition, with GTX2 remaining stable throughout. However epimerization of 
these toxins was observed in the additives spiked samples stored at +40°C which was evident 
after day 4 of the study. 
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Figure 4-9: Stability graphs for the PST epimers GTX2,3 determined by PCOX LC-FLD for the short-term data (3a-b) and 
the long-term data (3c-d) Results are normalised to the time zero reference temperature of -80°C (error bars represent ± 2 
s.d.). 
 
No epimerization was observed in materials stabilised through thermal treatment under any of 
the temperature storage conditions, -20°C, +4°C or +40°C which showed stability 
improvements over both the additives and untreated materials. GTX2 remained stable 
throughout the study under all temperature conditions but there was some degradation of the 
toxin GTX3 evidenced after 15 days at +4°C and after 4 days at +40°C. 
The control material while stable at -20°C showed signs of epimerization under the other two 
storage conditions investigated. This was evident after 32 days of the study in samples stored 
at +4°C and after 4 days in samples stored at +40°C. The rates of epimerization were greater 
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in the control materials compared to either the thermally treated or additives spiked materials 
which was particularly apparent under the +40°C storage condition. This highlights the 
significant improvements these techniques make to toxin stability and epimerization rates 
compared to the control materials in the short-term. 
The results from both the preCOX and PCOX analysis provide useful information on the 
conditions required for transportation of materials stabilised using both techniques. Although 
transportation of matrix RMs ideally should be made under frozen conditions, results indicate 
materials would also be stable at +4°C for up to 15 days which would be indicative of any 
adverse conditions potentially experienced during transit which is particularly important for 
producers of RMs or PT providers. 
 
4.3.2.3 LONG-TERM STABILITY 
 
PRECOX LC-FLD 
Figure 4-10 a-e represents the long-term stability results for the three materials at three 
different storage temperatures, -20°C, +4°C and +20°C, determined through preCOX LC-
FLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 and STX were generated and 
results were normalised to the average of replicate analysis (n=9) of samples stored at the 
reference temperature of -80°C for the duration of the study. The limits of stability from 
Figure 4-10 were generated from two times the standard deviation of the -80°C replicate 
analyses. 
All three tissues exhibited excellent stability for all the toxins throughout the duration of the 
yearlong study when stored at -20°C. Differing levels of stability were exhibited under the 
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other storage conditions however with both the heat treated and additives spiked materials 
showing significant improvements to toxin stability compared to the control materials.  
Heat treating the tissues provided better stability for the non N-hydroxylated toxins; dcSTX, 
GTX2,3 and STX including the N-sulfocarbamoyl toxin GTX5, compared to both the 
additives spiked and control materials. In comparison, the N-hydroxylated toxins GTX1,4 
exhibited better stability in the additives-spiked materials compared to the control and 
thermally treated tissues.  
Excellent stability was evident in the heat treated materials stored at +4°C in addition to the -
20°C results. The toxins dcSTX and STX also showed excellent stability when stored at 
+20°C throughout the study, although some slight degradation of GTX5 was evidenced after 
9 months at this higher temperature. GTX1,4 showed signs of degradation after 3 months at 
+20°C with these toxins totally degraded by month 9 in the heat treated materials, while an 
increase in GTX2,3 concentration was observed in samples after 6 months storage at this 
temperature. 
The inclusion of combined additives to the tissues significantly improved the stability of the 
toxins compared to the control materials. This was particularly evident for the toxins GTX1,4 
which showed no signs of degradation or increases in toxin content throughout the study 
under any of the storage conditions used even though these toxins were present at relatively 
low concentrations in the tissues. Some slight degradation of dcSTX, GTX5 and STX was 
evident after 12 months, 9 months and 9 months respectively when stored at +20°C, with 
these toxins exhibiting no stability issues under the +4°C storage condition with results 
falling between the limits of stability set. An increase in GTX2,3 concentration was observed 
in the additives spiked samples after 3 months under both the +4°C and +20°C storage 
temperatures. 
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Figure 4-10: Long-term stability graphs for the PSTs present in Tissues A, B and C determined by preCOX LC-FLD. Results 
are normalised to the time zero reference temperature of -80°C (error bars represent ± 2 s.d.). 
 
Stability issues were evident for all the toxins studied in the control materials most notably 
with GTX1,4 and GTX2,3 becoming completely degraded after 3 months storage at +20°C 
and GTX5 showing significant degradation (>50%) after 9 months storage at the same 
temperature. At +4°C GTX1,4 showed some signs of degradation after 6 months storage, 
conversely an increase in GTX2,3 concentration was observed after 3 months storage at the 
same temperature. GTX5 showed no stability issues at this temperature. An increase in STX 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
0 50 100 150 200 250 300 350
C
o
n
ce
n
tr
at
io
n
 (
n
o
rm
al
is
e
d
 t
o
 t
im
e
 z
e
ro
)
Time (days)
c) GTX2,3
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
0 50 100 150 200 250 300 350
C
o
n
ce
n
tr
at
io
n
 (
n
o
rm
al
is
e
d
 t
o
 t
im
e
 z
e
ro
)
Time (days)
a) dcSTX
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
0 50 100 150 200 250 300 350
C
o
n
ce
n
tr
at
io
n
 (
n
o
rm
al
is
e
d
 t
o
 t
im
e
 z
e
ro
)
Time (days)
b) GTX1,4
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
0 50 100 150 200 250 300 350
C
o
n
ce
n
tr
at
io
n
 (
n
o
rm
al
is
e
d
 t
o
 t
im
e
 z
e
ro
)
Time (days)
d) GTX5
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
0 50 100 150 200 250 300 350
C
o
n
ce
n
tr
at
io
n
 (
n
o
rm
al
is
e
d
 t
o
 t
im
e
 z
e
ro
)
Time (days)
e) STX
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
0 50 100 150 200 250 300 350
C
o
n
ce
n
tr
at
io
n
 (n
o
rm
al
is
e
d
 t
o
 t
im
e 
ze
ro
)
Time (days)
Additives -20°C
Additives +4°C
Additives +20°C
Untreated -20°C
Untreated +4°C
Untreated +20°C
Heat treated -20°C
Heat treated +4°C
Heat treated +20°C
± 2 x sd
Chapter 4 
 
 
112 
 
concentration was observed after 3 months storage at +20°C which was not evidenced in 
samples prepared by the two stabilisation techniques and this toxin was found to be stable at 
+4°C in the untreated materials. dcSTX showed some signs of degradation after 9 months 
storage at +20°C, although no dcSTX stability issues were observed in samples stored at the 
other two temperatures. These results highlight the benefits of both stabilisation techniques 
and specifically the level of stability provided to each toxin while emphasizing the significant 
improvement each procedure makes in comparison to the untreated materials. 
 
PCOX LC-FLD 
Further analysis was conducted by PCOX LC-FLD on the long-term stability study extracts 
of each of the materials and results are presented in Figure 4-9 c-d. Limits of stability and 
normalised results were calculated as per the preCOX analysis. Data for the toxins GTX1 and 
GTX4 were not generated as the concentration of these toxins in each material was <LOD of 
the PCOX LC-FLD method. 
No epimerization or degradation was observed in any materials when stored at -20°C for the 
duration of the long-term study with results falling within the limits of stability set. As in the 
case of the short-term study, no epimerization was observed in the heat treated materials 
under any temperature condition, with the only stability issue evident in these materials being 
a slight degradation of GTX3 observed after 3 months at +4°C. 
Epimerization was observed in the additives spiked materials under both the +4°C and +20°C 
storage temperatures after 3 months of the study, although this was a significant improvement 
compared to the control materials where epimerization of the toxins was evident in the +4°C 
samples but the GTX2,3 content was completely degraded by month 3 at +20°C. 
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The thermal treatment of materials again proved to be the most effective in minimising or 
eliminating the amount of epimerization of GTX2,3 with the additives spiked materials also 
significantly reducing these rates compared to the control tissues. 
Epimerization of these toxins followed predicted patterns with the β-epimer GTX3 being 
epimerized into the more stable α-form GTX2 [136] which was evident from both the short 
and long-term stability data generated through the PCOX LC-FLD analysis. 
 
CHROMATOGRAPHIC STABILITY 
The chromatographic stability of each of the preparation techniques were compared through 
visual comparison. Figure 4-11 a-h displays chromatograms generated by preCOX LC-FLD 
for the three materials by both peroxide and periodate oxidation after 12 months storage at 
different temperatures. Chromatograms of the control material stored at -80°C for 12 months 
are also shown in this figure as a visual comparison. The chromatograms generated through 
peroxide oxidation (Figure 4-11 a-c) show differing levels of stability, with the control 
material showing the total degradation of the toxins GTX2,3 and the formation of an 
additional fluorescent peak close to that of GTX2,3 in the additives material (Tissue A). 
Good chromatographic stability was observed in the heat treated materials (Tissue B) with no 
visual evidence for the formation of additional chromatographic peaks by this processing 
technique after peroxide oxidation when compared to the control material stored at -80°C. 
The retention time differences observed in Figure 4-11 are due to the analysis of the tissues 
being carried out on separate days using different HPLC columns. Retention time QC checks 
through comparison to standards was however carried out each day. 
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Figure 4-11: PreCOX LC-FLD chromatograms following peroxide (5a-d) and periodate (5e-h) oxidation of Tissues A, B, C 
and a temperature control material stored for 12 months. 
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The periodate oxidised extracts used to quantify the N-hydroxylated toxins GTX1,4 are 
illustrated in Figure 4-11 e-h. In the case of the control and heat treated materials, 
chromatograms from the +4°C storage condition are shown while a chromatogram for an 
additives spiked material stored at +20°C for 12 months is shown. This is due to the fact that 
the total GTX1,4 content in the heat treated and control materials was degraded under the 
+20°C storage condition. Good chromatographic stability was observed in the samples shown 
(Figure 4-11 e-h) with no visual evidence for the additional formation of chromatographic 
peaks from any of the processing techniques after periodate oxidation. 
 
4.3.3 CONCLUSIONS 
The techniques investigated in this study were found to significantly improve the stability of 
PSP toxins in M. edulis tissue matrices. The application of a heat treatment step or the 
inclusion of additives during material processing provided a more stable matrix that was less 
prone to degradation when compared to an untreated control material. As with previous 
studies showing the role of bacteria in biotransformations of PSTs [132], techniques such as 
those investigated in this study, aimed at reducing or eliminating the bacterial effects will 
lower the rates of toxin degradation, epimerization or biotransformations. Although the 
material processing and dispensing steps are not carried out aseptically, reducing or 
eliminating bacteria present in the source tissues through these techniques significantly 
improves the stability of matrix RMs [52]. 
As evidenced in both the short and long-term stability studies, frozen sample storage 
improved toxin stability for all three tissues. Of particular interest however is stability under 
elevated temperature conditions, which are used to mimic adverse transportation conditions. 
This is particularly important for RM producers and PT providers to know, as well as 
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ascertaining ideal long-term storage parameters. Under higher temperature storage 
conditions, both stabilisation procedures significantly improved toxin stability compared to 
the untreated control materials, although both techniques varied in the extent to which they 
enhanced stability. Specifically, the thermal treatment provided better stability for the non-N-
hydroxylated toxins GTX2,3, GTX5, STX and dcSTX while the additives spiked materials 
provided better stability for the N-hydroxylated toxins GTX1,4. 
This observation was particularly evident from the long-term study where the total GTX1,4 
content in the thermally treated materials were completely degraded by month 9 with these 
toxins remaining stable throughout the study in the additives spiked material (Figure 4-10 b). 
The stability of STX and dcSTX in the thermally treated materials was significantly 
improved compared to the additives spiked with both toxins remaining stable throughout the 
12 months under all temperature conditions, whereas some degradation was observed at 
+20°C in the additives spiked material. Thermally treating the material also eliminated the 
epimerization of GTX2,3 in contrast to both the additives spiked and control materials, 
although the inclusion of additives significantly improved the stability and lowered the 
epimerization rates compared to the control materials. 
Overall both material preparation techniques proved effective in stabilising both the tissue 
matrix and the PSP toxins present as compared to the control material. Each technique 
provided a greater degree of stability for certain toxins which indicate that combining the two 
techniques for preparing RMs would result in a well stabilised material for both the non-N-
hydroxylated and N-hydroxylated toxins. A combined technique of thermally treating the 
source tissues prior to spiking with additives is described in the following section 4.4. 
These techniques also provide a cost effective means of improving PSP toxin stability and 
prove the applicability of these materials for a range of different uses including method 
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development and validation as well as use in the general QC of routine monitoring methods 
and PT schemes as detailed in the following section.  
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4.4 COMBINED TECHNIQUES, QUALITY CONTROL AND QUASIMEME 
This section of Chapter 4 presents data generated from a RM prepared by combining the 
techniques described in section 4.3, specifically thermally treating the source tissues prior to 
spiking with preserving additives. This optimised preparation technique is detailed and data is 
presented from its use over a two year period in the Irish NMP (internal MI code LRM-09-
02) and in a development exercise as part of a proficiency testing scheme operated by 
QUASIMEME since 2011 (PT code Tissue B in Chapter 6).  
This material’s use in QUASIMEME PT schemes is detailed more thoroughly in Chapter 6 
but is highlighted here because a separate issue became apparent during the planning stages 
of the PT development exercise. This relates to methods used by some participants in 
QUASIMEME exercises, specifically the use of the MBA and the potential effects which the 
preserving additives/ethanol solution may have had on this assay. Although in this study each 
additive is spiked into tissues at levels well below their individual LD50 values no data exists 
in literature on their combined effects, if any. PST free M. edulis tissues as determined by 
both LC-FLD and MBA were spiked with these additives at various levels, extracted 
following the MBA protocol [40] and injected into mice to observe if there were any effects, 
particularly PSP-like symptoms which could be misinterpreted. The extraction procedure as 
described in the materials and methods section 2.3.3 for the MBA was scaled down to 
incorporate the smaller aliquot size of 5 grams which was used for QUASIMEME samples. 
This aliquot size was chosen due to the large amount of tissue which would have been 
required to make samples for MBA at the prescribed quantity described in the official method 
[40]. 
Short-term stability as well as homogeneity were determined experimentally on materials 
prepared by the optimised preparation technique. Long-term stability was not assessed in this 
Chapter 4 
 
 
119 
 
material due to its primary use in PT schemes and internal QC/QA where stability during 
transportation is more of a requirement and which can be adequately determined through 
short-term stability studies. 
 
4.4.1 MATERIALS AND METHODS 
 
4.4.1.1 SOURCE TISSUES 
The Spanish and UK (Busta Voe) tissues from Table 2-1 were used to prepare the RM used 
in this section of the study. The tissues were naturally contaminated with the carbamates 
GTX2,3 and STX, the decarbamoyl toxin dcSTX as well as the N-sulfocarbamoyl toxins 
C1,2 and GTX5. 
The quantities detailed in Table 4-8 were combined in a 5 L Waring™ goblet. The bulk 
tissues were homogenised as described in section 4.2.1.1.  
Table 4-8: Quantities of source wet frozen tissues used to prepare RM with combined techniques of spiking preserving 
additives with initial thermal pre-treatment.. 
Country Species Quantity (kg) 
UK (Busta Voe) Mytilus edulis 1.4 
Spain Mytilus galloprovancialis 1.4 
 
Aliquots were taken for MC determination (n=3) using the rotary vacuum method and 
analysis by preCOX LC-FLD (n=1) as described in the materials and methods section 2.4.1 
and 2.3.1 respectively, to give approximate PST concentrations which are detailed in Table 
4-9. 
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Table 4-9: Concentrations for combined source tissues used to prepare RM. 
Material 
Concentration (µmol / kg) Total Toxicity                  
(µg STX diHCl-eq / kg) 
dcSTX GTX2,3 GTX5 STX C1,2 GTX1,4 
Bulk 
homogenate  
1.45 2.12 0.13 2.36 - 2.9 2975 
 
 
4.4.1.2 MATERIAL PREPARATION 
The preserving additives solution was prepared at a concentration of 0.02% w/w by 
dissolving in ethanol (1% w/w). For the additives spike, 0.6 ± 0.01 g each of ampicillin, 
oxytetracycline, erythromycin and ethoxyquin were weighed into a 50 mL PP centrifuge tube 
using a calibrated 3-place balance. 30 ± 0.1 g ethanol were added to the centrifuge tube, 
capped and vortex mixed for 5.0 min. 
The tissues were autoclaved in 2 x 3L PP beakers at 121°C for 15.0 min. Subsequently the 
tissues were allowed to cool to room temperature before being transferred, including any 
liquid, into a Waring™ goblet and homogenised on medium power for 5.0 min. Aliquots 
(n=3) were taken for MC determination which was determined to be 76.9% with a %RSD of 
0.31%. 2215 ± 1 g of the tissue were gravimetrically transferred into a Waring™ goblet. The 
additives /ethanol solution was spiked into the tissue washing out the centrifuge tube with a 
small volume of DI water before manually mixing with a spatula. The final weight of the 
tissue was made up to 3000 ± 1 g with DI water in order to obtain a final tissue with a MC of 
~83%. 
The final homogenisation and dispensing steps followed were as described in section 4.2.1.2. 
A total of 582 aliquots were dispensed which provided sufficient quantities for short-term 
stability studies, homogeneity determinations as well as its intended use as a QC material for 
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the Irish NMP and as a material in the first PSP development exercise organised by 
QUASIMEME. All materials were stored at -80°C until further use. 
 
4.4.1.3 MBA MATERIALS 
An M. edulis tissue was sourced from an Irish NMP sample originating from Carlingford 
Lough, Co. Louth, Ireland and shown to be free from all EU regulated marine biotoxins by 
fully accredited MI methods preCOX LC-FLD and MBA for PSP toxins, LC-MS/MS for the 
lipophilic toxins and LC-UV for domoic and epi-domoic acid (MI Irish National 
Accreditation Board No. 130T). The tissue was homogenised in a 3 L Waring™ goblet 
before being subdivided into four separate lots. Three tissues were prepared with additive 
spikes at 0.01, 0.02 and 0.05% w/w by dissolving antibiotic and antioxidant chemicals in 
ethanol at a volume of 1% of the total tissue weight. 
The 0.01% (100 mg/kg) solution was prepared by weighing 0.012 ± 0.001 g each of 
ethoxyquin, ampicillin, erythromycin and oxytetracycline into a 50 mL PP centrifuge tube 
with 1.20 ± 0.01 g ethanol. This solution was vortex mixed (Vortex Genie-2, Scientific 
Industries, NY, USA) for 5.0 min before being spiked into 120 ± 1 g of the M.edulis tissue 
described above in a 1 L Waring™ goblet, stirred with a spatula and homogenised on 
medium power for 5.0 min. 
The 0.02% and 0.05% additives solutions were prepared identically as above spiking 0.024 ± 
0.001g and 0.060 ± 0.001 g of each additive respectively into 1.2 ± 0.1 g ethanol in a PP 
centrifuge tube. Each additive solution was spiked separately into 120 ± 1 g M.edulis tissue 
described above in a 1 L Waring™ goblet, stirred with a spatula and homogenised on 
medium power for 5.0 min. The fourth tissue remained untreated and contained no additives 
or ethanol spike. 
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4.4.1.4 STUDIES AND ANALYSIS 
The between-bottle homogeneity of the material was assessed through the intra-batch 
analysis of 10 aliquots selected through stratified random sampling of the entire fill series. 
The number of aliquots chosen for homogeneity determination was based on the 
recommendations of ISO for PT materials [71].  
The material was stability tested over the short term following a reverse isochronous 
experimental design [55] as conducted previously for other tissues. The short term study was 
conducted with triplicate samples consisting of five time points (0, 2, 8, 16 and 30 day) and 
three temperature conditions (-20°C, +4°C and +40°C). The reference temperature used was -
80°C. The stability studies were carried out as described in section 4.2.1.4. 
At the end time point all samples were removed from storage, allowed to equilibrate to room 
temperature before being extracted and analysed by preCOX LC-FLD closely following 
OMA AOAC 2005.06 [41] as detailed in section 2.3.1. PCOX LC-FLD analysis was not 
performed on this RM due to its primary use as an internal QC/QA material for the preCOX 
LC-FLD method routinely used at the MI for PST analysis. 
PST concentrations in sample extracts were quantified against a 5-point calibration for each 
toxin and are expressed in µmol/kg with total saxitoxin equivalents calculated as an 
estimation of total toxicity as described in section 2.3.1. 
The MC was determined using the rotary vacuum method as described in the materials and 
methods section 2.4.1, selecting aliquots from the beginning, middle and end of the fill series.  
For the additives spiking MBA experiments, each material was extracted according to the 
AOAC official method 959.08 [40] using a scaled down procedure to incorporate the 5.0 g 
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aliquot size. Aliquots (1mL) were injected intraperitoneally into male albino CD1 strain mice 
in triplicate. 
 
4.4.2 RESULTS AND DISCUSSION 
 
4.4.2.1 ADDITIVES SPIKING MBA EXPERIMENTS 
Mice were observed for 60 min after intraperitoneal injection with the extracted additives 
materials. No PSP-like or other symptoms were observed during this time which could be 
misinterpreted as a PSP positive sample. The additives should therefore have no adverse 
effect on PSP determination using the MBA. 
 
4.4.2.2 HOMOGENEITY AND MOISTURE CONTENT 
As evidenced from Table 4-10 the homogeneity of the PST-positive material was sufficient 
and was suitable for its intended purposes as a QC/QA and PT material. The target %CV of 
8% was achieved for each analyte so again below expected levels of intra-batch repeatability. 
The homogeneity of the toxins C1,2 were not determined due to the lack of a CRM 
calibration standard available at the time, although homogeneity of the other toxins should be 
indicative of overall homogeneity in this tissue. 
Table 4-10: Homogeneity results for LRM-09-02 (n=25) 
 
Concentration (µmol / kg) Total Toxicity                  
(µg STX diHCl-eq / 
kg) 
% 
Moisture 
Content dcSTX GTX2,3 GTX5 STX C1,2 GTX1,4 
Average 0.77 1.44 0.12 0.40 - 0.34 888 84.8 
Stdev 0.03 0.08 0.01 0.02 - 6.6 47 0.2 
%CV 3.8 5.6 6.3 4.7 - 5.2 4.7 0.7 
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4.4.2.3 SHORT-TERM STABILITY 
Figure 4-12 a-e represents the short-term stability results for the material prepared using the 
combined techniques at three different storage temperatures, -20°C, +4°C and +40°C, 
determined following preCOX LC-FLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 
and STX were generated and results were normalised to the average of replicate analysis 
(n=9) of samples stored at the reference temperature of -80°C for the duration of the study. 
As with previous experiments the limits of stability illustrated in Figure 4-12 were generated 
from two times the standard deviation of the -80°C replicate analyses.  
Overall toxin stability was excellent in the materials stored at -20°C and +4°C for the 
duration of the short-term study. The stability of the toxins at +40°C differed however with 
GTX2,3 being the only toxins stable at this elevated storage temperature. Degradation was 
evident after 8 days in the case of dcSTX and after 16 days in the case of the toxins GTX1,4, 
GTX5 and STX. GTX5 showed the most signs of degradation with ~80% of this toxins total 
content in the tissue destroyed by the end of the study compared to ~60% of dcSTX and 40% 
of GTX1,4 and STX. 
The results from the short-term stability studies provide useful information on the conditions 
required for transportation which was particularly important for this materials use in a PT 
scheme. Although transportation of matrix RMs ideally should be made under frozen 
conditions, results indicate materials would also be stable at +4°C for up to 30 days and at 
+40°C for as long as 8 days. This would mimic any adverse conditions potentially 
experienced during transit to participants, particularly to countries where delivery is 
logistically difficult. 
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Figure 4-12: Short-term stability graphs for LRM-09-02. 
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4.4.2.4 INTERNAL QC AND PT SCHEMES 
Total toxicity data generated through the use of this RM is presented in the Shewhart chart in 
Figure 4-13. This RM was used over a two year period from January 2011 to December 2012 
as part of the Irish NMP for marine biotoxins and the data was generated using the preCOX 
LC-FLD method AOAC2005.06 [41]. This data was used to estimate the long-term method 
reproducibility as an RSD of 8.7%, which was used to calculate an expanded uncertainty of 
measurement (U) of ~17% at a concentration level just above the EU regulatory limit of 
800µg STX diHCl eq./kg based on a coverage factor of 2. The data generated through this 
materials use and in validation and optimisation experiments was instrumental in the MI 
ceasing its use of the MBA and moving to PSP analysis by preCOX LC-FLD which was 
accredited by the Irish National Accreditation Board (INAB) in 2010 (130T). 
The within lab reproducibility, expressed as an RSD of 8.7% (Total Toxicity) correlates well 
with data generated through previous validation studies [120,138,139]. In a single laboratory 
validation carried out on mussel tissues and reported by Turner et al., [120] long-term method 
reproducibility (> 2 months) was estimated through repeat analysis of an internal LRM. The 
RSD (%) was determined to be between 11-69% for the individual analogues with total 
toxicity giving a result of 17%. The low RSD (%) value determined at the MI is indicative of 
both long-term method reproducibility as well as the long-term stability of the LRM being 
used. 
The use of such materials for internal QC can give valuable information on trends or drifts 
associated with the method. Figure 4-13 also demonstrates the within-laboratory 
reproducibility of this method which has been fully in-house validated. Changes to the system 
made over the two year period this material was in use had no noticeable effects on the 
overall performance of the method and therefore this RM use. Such changes included new 
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personnel being trained on and incorporated into running the method, analytical column and 
guard cartridge replacements, changes in suppliers of chemicals and consumables such as 
solid phase extraction cartridges, preparation of new standards on a monthly basis and the 
general and annual maintenance carried out on the instrument. The use of this RM in the Irish 
NMP also demonstrates the long-term stability of the material using a classical stability 
model. 
 
Figure 4-13: Shewhart chart representing total toxicity data collected over a two year period at the Marine Institute in the 
analysis of PSP toxins by preCOX LC-FLD (AOAC2005.06) as part of the Irish NMP. 
 
The same RM has been used in three PSP development exercises of the QUASIMEME PT 
scheme over a four year period. These exercises gave further evidence for long-term stability 
and reproducibility, evidenced through consistent assigned values of 977, 950 and 986 µg 
STX diHCl eq./kg determined by participants and the associated between laboratory RSD 
values of 15, 16 and 13% respectively determined from participants receiving satisfactory z-
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scores. The assigned values were determined from participants using a range of different 
methods based on preCOX and PCOX LC-FLD and MBA which demonstrates the 
applicability of these materials for a range of different methods. This PT data is further 
discussed in chapter 6. 
A material prepared using one of these techniques was used in another PT scheme operated 
by VEREFIN in 2013. This PT scheme was organised to assess the performance of 
designated EU laboratories in analysing STX due to its inclusion on the schedule I list of UN 
chemical weapons. The details of these PT schemes are not discussed in this thesis but are 
described in Harju et al. 2015a and 2015b [140,141]. 
 
4.4.3 CONCLUSIONS 
From the results contained in this section the combined techniques of thermally treating the 
source tissues prior to spiking with additives produced a stable RM for the toxins studied. 
The results were indicative of both short-term stability under transportation conditions and 
the long-term stability of the material as evidenced through consistent assigned values in the 
case of the proficiency testing scheme and a low relative standard deviation of 10.5% for total 
toxicity data generated over 24 months as part of the Irish NMP. 
Materials prepared by these techniques were used successfully for a number of different 
purposes including method development, optimisation and validation studies, as a QC tool in 
the Irish NMP for PSP toxins and as PT materials used by QUASIMEME and VEREFIN. 
The relatively simple techniques described in this chapter so far produce materials 
sufficiently stable and homogenous for the toxins studied. 
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4.5 HIGH PRESSURE PROCESSING 
The research described in this section of Chapter 4 details work described in Turner et al. 
2014 [135]. 
Andrew D. Turner, Andy L. Powell and Stephen Burrell. 2014. Novel application of High 
Pressure Processing for the production of shellfish toxin matrix reference materials. Toxicon. 
90:1-14 
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FLD. The control material was prepared by Dr. Turner at CEFAS, including all toxin 
analysis, and results were provided to the author for comparison purposes. 
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High Hydrostatic Pressure Processing (HHP) or High Pressure Processing (HPP) is a 
pasteurisation technique which has been employed for over a hundred years as a non-thermal 
method of preserving and sterilising food [69]. The process has been applied to high water 
content foodstuffs including seafood [142] and, owing to the minimal impact the process has 
on the physical and nutritional characteristics of the product coupled to its sterilising 
properties, is of  interest to RM producers. The pressure is evenly distributed throughout the 
foodstuff by using water as the transmission medium. Pressures typically in the range of 
150MPa to 600 MPa are applied to the product for 1 – 15 min. [70]. Application of HPP in 
the area of shellfish safety has garnered significant interest, particularly for bivalve molluscs 
such as oysters. This species, typically eaten raw may have significant microbial activity 
owing to the filter feeding activities of the animal, with HPP removing total viable counts as 
well as specific microbiological contaminants including Escherichia coli, Vibrio and 
norovirus [70,143–146].  
The novel application of HPP was therefore investigated for the removal of biological 
activity from homogenised oyster tissues, specifically in producing stable and homogeneous 
matrix reference materials. The effects of various HPP parameters  on biological activity and 
PSP toxin concentrations was assessed. 
Short and long-term stability experiments as well as homogeneity determinations were 
conducted on materials prepared by both techniques in comparison with an untreated control 
using two LC-FLD methods which enabled the quantitation of individual PSP toxins and 
toxin epimeric pairs. The within-batch repeatability of the process was assessed through the 
treatment of replicate samples under different processing conditions and the between-batch 
repeatability examined through the treatment of a second larger volume of tissue also 
subsequently subjected to analysis to assess material homogeneity and stability. 
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4.5.1 MATERIALS AND METHODS 
 
4.5.1.1 INITIAL STUDIES (CARRIED OUT BY THE COLLABORATOR AT CEFAS AND AFBI) 
CONTAMINATED OYSTER PREPARATION 
Pacific oysters (Crassostrea gigas) fed mass cultured toxic Alexandrium algae as described 
previously [147], were used to produce two batches of PSP positive material. 350L of an 
Alexandrium fundyense culture (strain CCMP 1719) was produced using a 12 tubular bag 
photobioreactor set to a 14:10 hour light:dark cycle at 17°C. The culture was subsequently 
fed to the Pacific oysters over a 5 day period using aerated re-circulating tanks set to 17°C. 
The oysters were removed from the tank after this period, shucked, homogenised and placed 
in polythene bags and stored at -20°C until further use. The first batch was diluted with PSP-
free Pacific oyster tissue to reduce the total PSP levels to close to the regulatory action limit. 
The second batch remained undiluted. 
 
HIGH PRESSURE PROCESSING 
Following homogenisation, 700 g of the oyster tissue was divided into six sub-samples, with 
each further sub-divided into three sub-samples. These triplicate sub-samples were labelled 
and bagged together. In order to successfully transmit pressure through the material, it was 
necessary to suitably package the tissues to ensure the integrity of the seal was maintained. 
This involved further sealing the tissues in separate vacuum-pack bags which were placed 
into additional polythene bags, grouping replicates together. Samples were then sent to the 
Food Microbiology Branch of Agri-Food and Bioscience Institute (AFBI) of Northern Ireland 
together with travel control materials which were to remain unprocessed during the 
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procedure. The packaged samples were allowed to equilibrate to room temperature before the 
processing conditions detailed in Table 4-11 were applied. 
Table 4-11: Experimental conditions used for HPP treatment of oyster tissues (batch 1 and 2). 
Sample Pressure (bar) Temperature (°C) Time (min) 
HPP1 2000 5 5 
HPP2 3500 5 5 
HPP3 7000 5 5 
HPP4 2000 35 5 
HPP5 3500 35 5 
HPP6 7000 35 5 
 
A processing error resulted in samples being treated for 1.0 min only, with the remaining 4.0 
min treatment applied the next day. Six months after this initial treatment, a second batch of 
materials, in singe 300 g samples was subjected to HPP using the same processing conditions 
but administered in single 5 min treatments. After both treatments, samples were shipped 
back to CEFAS under temperature controlled conditions alongside the untreated travel 
controls. On receipt at CEFAS, samples were opened and processed immediately.  
 
BACTERIAL LEVEL TESTING 
Pouches containing the HPP-treated as well as the untreated control samples were opened and 
tested for microbial activity using a total viable count (TVC) method. Each tissue sample was 
tested by taking duplicate 100µL aliquots of serial log10 dilutions spread onto the surface of 
plate count agar (Oxoid CM0325) plates, with dilutions performed using 0.1% peptone water 
depending on the microbial activity of the sample. Plates were incubated at 25 ± 1°C for a 
total of 7 days before being visually assessed, with plates yielding up to 300 colony forming 
units (CFU)/plate recorded for each dilution test. The mean of each duplicate pair was used 
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and results were expressed as CFU/g LRM. The nominal limit of detection of the TVC 
method was 5CFU/g. 
 
TOXIN ANALYSIS 
Aliquots of the HPP treated tissues as well as the untreated travel controls were removed 
from their packaging and allowed to equilibrate to room temperature. After thorough mixing 
aliquots were taken for toxin analysis with the remaining material stored at -20°C for future 
stability testing. 
Sample extraction, SPE cleanup and oxidation was carried out at CEFAS flowing OMA 
AOAC 2005.06 [41]. LC-FLD analysis was performed using an Agilent (Stockport, UK) 
1200 LC-FLD system with a Gemini C18 reversed-phase column (150 mm x 4.6 mm, 5 μm; 
Phenomenex, Manchester, UK) (set to 35 °C). Mobile phases and LC gradient conditions 
used were those described previously [147]. 
Samples were extracted and analysed at the MI by preCOX LC-FLD closely following OMA 
AOAC 2005.06 [41] as detailed in section 2.3.1. PCOX LC-FLD [75] analysis conducted at 
the MI was additionally performed on all samples to specifically investigate the extent of 
epimerisation. For PCOX LC-FLD analysis, the crude acetic acid extracts prepared according 
to section 2.3.1 were deproteinated and analysed following AOAC 2011.02 [75]. 
Toxin concentrations were quantified against 5-6-point calibration standards with both 
individual PST concentrations and total saxitoxin equivalents determined. For the 
homogeneity and stability experiments, the extraction was scaled down to enable the testing 
of a suitable number of aliquots, specifically performing extractions on 2.0 g tissue and 
diluting to a total of 5.0  mL prior to C18 clean-up. 
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STUDY DESIGN 
The first batch of HPP-treated tissues, including untreated travel controls were analysed for 
PSP toxin concentration as well as being assessed for biological activity. Triplicate samples 
from each of the processing conditions HPP1-6 were analysed to determine the within batch 
variability of each condition as well as determining optimum HPP parameters. The second 
batch of HPP treated materials was assessed as these materials were subjected to a single 5 
min HPP treatment while also generating a sufficient volume of tissue for stability testing. 
Extracted tissues were analysed by LC-FLD in triplicate with samples spread evenly 
throughout the instrumental sequence. Selected HPP-treated tissues were re-homogenised and 
assessed for homogeneity and stability as described below. 
 
4.5.1.2 ANALYSIS AND STUDY DESIGN (CARRIED OUT BY THE AUTHOR AT THE MI) 
HOMOGENEITY 
The selected HPP-treated bulk tissues were combined, mixed thoroughly before weighing 2.0 
g aliquots into pre-labelled plastic vials and hermetically sealed with foil caps under a stream 
of nitrogen. Aliquots were stored at -20°C until required for analysis. The homogeneity of the 
HPP-treated oyster tissue was assessed through the intra-batch analysis of samples selected 
through stratified random sampling. Ten aliquots were selected, extracted and analysed 
according to section 2.3.1. 
 
STABILITY STUDIES 
All materials were stability tested over a short term (ca. 14 day) and long term (ca. 6 month) 
period following a reverse isochronous experimental design [55]. The short term study was 
conducted with triplicate samples consisting of five time points (0, 2, 5, 10 and 14 day) and 
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four temperature conditions (-20°C, +4°C, +20°C and +40°C). The long term study was 
conducted with triplicate samples consisting of five time points (0, 1, 2, 4 and 6 month) and 
three temperature conditions (-20°C, +4°C and +20°C). The reference temperature used in 
both studies was -80°C. In the case of all the stability studies; aliquots (n=3) were removed 
from -80°C storage on the prescribed day and transferred to the storage conditions being 
investigated. 
At the end time point in both studies samples were removed from the various storage 
conditions, allowed to equilibrate to room temperature before being extracted and analysed 
by preCOX LC-FLD closely following OMA AOAC 2005.06 [41] as detailed in section 
2.3.1. PCOX LC-FLD [75] analysis was additionally performed on all samples to investigate 
the extent of epimerisation, if any. For PCOX LC-FLD analysis, the crude acetic acid extracts 
prepared according to section 2.3.1 were deproteinated and analysed following AOAC 
2011.02 [75]. 
PST concentrations in sample extracts were quantified against a 4 - 5-point calibration for 
each toxin and are expressed in µmol/kg with total saxitoxin equivalents calculated as an 
estimation of total toxicity. 
The stability studies for the untreated oyster tissue were carried out at a different time and 
using a different model to the HPP described above so the time points graphically represented 
in both the short and long-term studies differ slightly (Figure 4-16 & Figure 4-18). 
 
 
 
 
Chapter 4 
 
 
136 
 
4.5.2 RESULTS 
 
PROCESSING CONDITIONS 
The processing conditions recorded during the HPP treatment of the batch 1 and 2 materials 
are detailed in Table 4-12. The pressures recorded during the HPP treatment were all within 
1% of the set values. Adiabatic heating during the process could not be avoided so the 
processing temperatures recorded during the treatment are different to the set values. 
Table 4-12: Actual HPP conditions recorded during the two processing batches. 
 Batch 1 Batch 2 
Sample 
Maximum 
temperature  
Minimum 
pressure (bar) 
Maximum 
pressure 
(bar) 
Maximum 
temperature  
Minimum 
pressure (bar) 
Maximum 
pressure 
(bar) 
HPP1 15°C 1998 2020 15°C 1998 2017 
HPP2 18°C 3999 4030 17°C 3996 4019 
HPP3 21°C 5989 6023 22°C 5961 6023 
HPP4 42°C 1997 2019 39°C 1988 2011 
HPP5 45°C 3977 4027 45°C 3977 4019 
HPP6 50°C 5959 6021 49°C 5961 6029 
 
BIOLOGICAL ACTIVITY 
The TVC testing results of both HPP treated batches of oyster tissue and the untreated travel 
controls are contained in Table 4-13. The data clearly demonstrates the advantages HPP has 
on removing biological activity with each treatment HPP 1-6 significantly reducing microbial 
activity compared to the travel controls, although the lower values in replicate C, batch 1 
were noted. The most intensive treatment HPP 6 provided the greatest success in terms of 
microbial removal. 
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Table 4-13: Results from duplicate microbial testing of HPP-treated Pacific oyster tissues plus travel controls from two 
batches of processing, after incubation for 7 days at 25°C (units CFU/g; LOD = 5 CFU/g). 
  Batch 1   Batch 2 
Sample Replicate A Replicate B Replicate C       
HPP 1 <LOD 20 20 <LOD 40 40 
 
<LOD <LOD 
HPP 2 <LOD 20 10 <LOD 20 50 
 
300 <LOD 
HPP 3 <LOD 30 50 20 30 <LOD 
 
200 <LOD 
HPP 4 10 40 20 <LOD 70 <LOD 
 
800 <LOD 
HPP 5 20 <LOD <LOD 30 40 <LOD 
 
1100 300 
HPP 6 <LOD 20 <LOD <LOD <LOD <LOD 
 
<LOD <LOD 
Travel 160000 120000 340000 160000 10000 10000   6000000 6000000 
 
 
4.5.2.1 PRECOX LC-FLD 
 
BATCH 1 
Mean toxin concentrations including total toxicity for each of the HPP treatments and 
untreated control materials are detailed in Table 4-14. Toxin concentrations were found to be 
similar in each of the HPP treatments including the travel controls, apart from HPP 1 where a 
lower concentration of GTX1,4 was determined which resulted in a lower STX-eq/kg value 
(Figure 4-14). 
Table 4-14: Results from PreCOX LC-FLD analysis of HPP-treated tissues (batch 1) and travel controls, showing toxin 
concentrations and total saxitoxin in STX di-HCl eq/kg (± 1 s.d; n=3). 
 
HPP1 HPP2 HPP3 HPP4 HPP5  HPP6 Controls 
GTX1,4 83 ± 7 102 ± 7 102 ± 6 109 ± 7 103 ± 5 103 ± 5 100 ± 7 
NEO 46 ± 4 55 ± 4 55 ± 3 58 ± 3 54 ± 2 56 ± 3 58 ± 7 
C1,2 3.7 ± 0.4 4.6 ± 0.3 4.4 ± 0.3 3.9 ± 0.2 4.2 ± 0.4 4.5 ± 0.7 4.2 ± 0.4 
GTX2,3 5.8 ± 0.7 6.8 ± 0.6  6.6 ± 1 6.1 ± 0.6 7.2 ± 0.8 6.9 ± 0.8 7.3 ± 0.8 
STX 4.4 ± 0.5 5.2 ± 0.3 5.0 ± 0.4 5.2 ± 0.3 5.4 ± 0.2 5.1 ± 0.2 5.2 ± 0.3 
Total 143 ± 12 174 ± 11 173 ± 10 182 ± 10 174 ± 7 175 ± 7 175 ± 15 
 
The percentage relative standard deviations (%RSD) as seen in Table 4-14 were below those 
expected for within-batch repeatability determined for this method during validation studies 
[120,148]. There was a statistical difference found in the HPP 1 (GTX1,4, NEO, GTX2,3 and 
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total STX-eq.) and HPP 4 materials (GTX2,3 only) using two-tailed t-tests using pooled 
standard deviations (two samples assuming equal variance). Two-tailed t-tests showed no 
statistical difference between the means of the other materials however. 
Chromatograms of selected HPP treated and travel controls after periodate and peroxide 
oxidation are illustrated in Figure 4-15. They show no visual evidence for the generation of 
additional chromatographic peaks in comparison to the control materials which may relate to 
the formation of degradation or other naturally fluorescent products. 
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Figure 4-14: Results from PreCOX LC-FLD analysis of HPP-treated oyster tissues and travel controls showing mean toxin concentrations ± 1 s.d. (n=3). 
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Figure 4-15: Chromatograms obtained from the PreCox LC-FLD analysis following periodate and peroxide oxidation of 
travel controls and HPP-treated oyster tissues. 
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BATCH 2 
Mean toxin concentrations including total toxicity for each of the HPP treatments (batch 2) 
and untreated control materials are detailed in Table 4-15 where tissues were HPP treated for 
a single 5 min step. Although STX-eq values between HPP 1-6 and the travel controls were 
similar, some differences between individual toxin concentrations were noted across the 
various treatments. The HPP 1-3 samples processed at the lower temperature of 5°C showed 
no visual differences in toxin concentrations compared to the travel controls. Conversely the 
HPP 4-6 samples processed at the higher temperature of 35°C showed some evidence for a 
reduction of GTX2,3 and STX concentrations and an increase in GTX1,4 and NEO 
concentrations, compared to the travel controls. A statistical difference was found for the 
lower GTX2,3 and STX concentrations but not the GTX1,4 or NEO increases after a two-
tailed t-test. 
Table 4-15: Results from PreCOX LC-FLD analysis of HPP-treated tissues (batch 2) and travel controls, showing toxin 
concentrations and total saxitoxin in STX di-HCl eq/kg (± 1 s.d; n=3). 
 
HPP1 HPP2 HPP3 HPP4 HPP5  HPP6 Controls 
GTX1,4 284 ± 61 282 ± 86 269 ± 3 357 ± 37 329 ± 70 317 ± 8 296 ± 34 
NEO 197 ± 35 187 ± 50 206 ± 31 231 ± 23 227 ± 57 217 ± 26 194 ± 27 
C1,2 20 ± 1.4 21 ± 0.7 20 ± 1.7 20 ± 0.6 18 ± 0.3 19 ± 1.0 21 ± 0.3 
GTX2,3 45 ± 6 45 ± 3 40 ± 3 36 ± 1 33 ± 0.7 35 ± 2 51 ± 4 
STX 62 ± 8 63 ± 7 51 ± 3 46 ± 1 43 ± 1 43 ± 1 65 ± 4 
Total 609 ± 110 600 ± 125 587 ± 41 692 ± 61 651 ± 128 632 ± 37 628 ± 70 
 
BULK SAMPLE TESTING 
Bulk materials were prepared for homogeneity and stability testing from HPP 5 and HPP 6, 
batch 2 materials only, which were treated at 6000 bar and 50°C for 5 min. 
 
4.5.2.2 HOMOGENEITY 
From the coefficients of variances contained in Table 4-16, all materials were suitably 
homogeneous for all the PSP toxins present. A target %CV of below 8% for each analyte, 
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including total toxicity was set which is below expected levels of variability associated with 
intra-batch repeatability, determined through in-house validation of the LC-FLD method at 
the MI. The homogeneity techniques employed were sufficient and the materials were 
suitable for the analytical study. 
Table 4-16: Mean concentrations (STX di-HCl eq/kg), standard deviations (sd) and percentage relative standard deviations 
(%RSD) of toxins in HPP-treated tissues as determined by PreCOX LC-FLD (n=10). 
 
GTX-2,3 STX C-1,2 GTX-1,4 NEO Total 
Mean 77 55 34 307 486 960 
sd 5 1 2 9 26 35 
%RSD 6.2 2.5 4.5 2.9 5.3 3.6 
 
 
4.5.2.3 SHORT-TERM STABILITY 
 
PRECOX LC-FLD 
Figure 4-16 displays the stability results generated by preCOX LC-FLD analysis over 14 
days for the HPP oyster tissue, and 16 days for the untreated controls, at four different 
temperature conditions. Data were generated for all toxins present in the materials as well as 
total toxicity (Figure 4-16a-f)  and results were normalised to the average of replicate 
analyses of samples stored at -80°C for the duration of the study (time zero). Limits of 
stability were generated from two times the standard deviation of the -80°C time zero 
average. 
Similar stability between the HPP treated and control materials was observed at storage 
temperatures of -20°C and +4°C for the duration of the 14 and 16 day studies respectively. 
Significant improvements could be observed between both materials at the higher 
temperatures studies however, particularly for the toxins C1,2, GTX2,3 and NEO. 
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Figure 4-16: Stability charts of PSTs and total saxitoxin equivalents in HPP and untreated tissues over 14 days (HPP) and 
16 days (untreated) storage respectively, following preCOX LC-FLD analysis. Concentrations are normalised to time zero 
(error bars represent ± 2 sd). 
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Excellent stability was exhibited for all toxins stored at +20°C in the HPP materials with 
GTX2,3 also found to be stable at +40°C for the duration of the study. Some signs of 
degradation of the other toxins were observed under the +40°C storage temperature but not to 
the extent as that observed in the untreated controls. In the case of NEO ~70% of this toxin 
was degraded by the end of the study in the untreated control compared to ~25% in the HPP 
materials. An apparent increase in GTX2,3 concentration was observed in the untreated 
controls at +20°C and +40°C after 8 and 4 days respectively. No stability issues were noted 
for these toxins in the HPP treated materials however. 
 
PCOX LC-FLD 
PCOX LC-FLD analysis was conducted on the HPP tissues stored under all four storage 
conditions (-20°C, +4°C, +20°C and +40°C) and results are presented in Figure 4-17. The 
same analysis was conducted on the untreated tissues, with only three storage conditions (-
20°C, +4°C and +22°C) studied however. The stability results of the PSP epimers C1,2, 
GTX1,4 and GTX2,3 in both tissues are presented in Figure 4-17a-f with limits of stability 
and normalised results calculated as per the preCOX analysis above. 
Excellent stability was observed in both the HPP and untreated tissues at -20°C for all the 
epimers over the course of the short-term study. In addition GTX1,4 were found to be stable 
at +4°C in both tissues with no signs of epimerisation evident from Figure 4-17 c+d. 
Epimerisation was observed to take place in the untreated material at +22°C for these toxins, 
while some degradation of GTX4 was evident in the HPP tissue at +20°C and +40°C with 
GTX1 showing good stability under the same temperature conditions. 
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Figure 4-17: Stability charts of the PST epimers C1,2, GTX1,4 and GTX2,3 in HPP and untreated tissues over 14 days 
(HPP) and 19 days (untreated) storage respectively, following PCOX LC-FLD analysis. Concentrations are normalised to 
time zero (error bars represent ± 2 sd). 
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GTX2,3 showed good stability in both tissues when stored frozen at -20°C but epimerisation 
was observed to take place in tissues stored above this temperature. No epimerisation of C1,2 
was observed to take place at +4°C in either tissue but was evident in samples stored at the 
higher temperatures. The rate of epimerisation was far greater in the untreated tissues stored 
at +22°C in comparison to HPP samples stored at either +20°C or +40°C however, which 
demonstrates the significant improvements that this stability technique has over untreated 
samples. 
 
4.5.2.4 LONG-TERM STABILITY 
 
PRECOX LC-FLD 
Figure 4-18 shows the long-term stability results over 6 months duration for all toxins, 
including total toxicity in both the HPP and untreated oyster tissues generated by preCOX 
LC-FLD. Three temperature conditions were studied in both tissues with -20°C and +4°C 
common to both and the higher temperature conditions of +20°C and +40°C studied in the 
HPP and untreated tissues respectively. This was due to the stability studies of both tissues 
being carried out at different times and using a different model. Normalised concentrations 
and limits of stability were calculated as above. 
Excellent stability was exhibited throughout the 6 month study for all toxins stored at -20°C, 
however differing levels of stability were observed at the other temperature conditions. In 
addition to the -20°C results, HPP treated materials also exhibited excellent stability at +4°C 
with the exception of GTX1,4 where some degradation was observed after 2 months at this 
temperature. As in the case of the HPP materials, GTX1,4 stability issues were evident at 
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+4°C in the untreated controls but additionally stability problems were observed after 6 
months for GTX2,3. 
 
Figure 4-18: Stability charts of PSTs and total saxitoxin equivalents in HPP and untreated tissues over 6 months storage, 
following preCOX LC-FLD analysis. Concentrations are normalised to time zero (error bars represent ± 2 sd). 
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In the case of GTX1,4, some degradation was observed in the HPP material at both the +4°C 
and +20°C storage conditions after 2 months and 1 month respectively. The same level of 
degradation was observed in the untreated material at +4°C, but an increase in GTX1,4 
concentration was observed at +40°C, both evident after 3months. 
In materials stored at higher temperatures, C1,2 and STX stability issues were evident in the 
untreated controls with ~80% and 90% of the toxins degraded by the end of the study. These 
toxins were found to be stable in the HPP materials, although the different temperature 
conditions in both studies are noted. 
The total toxicity, expressed in STX equivalency, was found to be stable in the HPP material 
at -20°C and +4°C but some slight degradation was observed at +20°C, while the untreated 
material gave stable results under all temperature conditions over the 6 months. 
 
PCOX LC-FLD 
Long-term stability results of both HPP treated and control materials generated by PCOX 
LC-FLD analysis are presented in Figure 4-19. Temperature conditions of -20°C and +4°C 
were assessed in both tissues with an additional +20°C storage temperature studied in the 
HPP tissue only. The limits of stability and normalised results contained in Figure 4-19a-f 
were calculated as above. 
Excellent stability in both the HPP and untreated controls were exhibited over the 6 month 
study when stored frozen at -20°C, with no signs of epimerisation or toxin degradation 
observed. In addition the untreated material also showed excellent stability at +4°C for all 
three pairs of epimers studied. 
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Epimerisation of C1,2 and GTX2,3 was observed to take place in the HPP treated material, 
particularly at +20°C. GTX1 was found to be stable in both the HPP and untreated tissues 
under all storage conditions over the 6 month study. GTX4 showed signs of degradation after 
1 month at +20°C and after 6 months at +4°C in the HPP tissue while no degradation was 
observed in the untreated tissues for this toxin. 
 
Figure 4-19: Stability charts of the PST epimers C1,2, GTX1,4 and GTX2,3 in HPP and untreated tissues over 6 months 
storage, following PCOX LC-FLD analysis. Concentrations are normalised to time zero (error bars represent ± 2 sd). 
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4.5.3 DISCUSSION 
The treatment of Pacific oyster tissues by High Pressure Processing under different 
conditions was shown to successfully remove biological activity from the materials. Analysis 
by preCOX LC-FLD showed that HPP under these conditions showed no significant changes 
to toxin content compared to untreated controls. In addition there was no visual 
chromatographic differences between the HPP treated and control materials either. 
A reduction in GTX1,4 concentrations was noted in one set of samples (HPP 1, batch 1), the 
causes of which are unknown. The second batch of HPP treated materials, processed in a 
single 5 min step showed statistically different GTX2,3 and STX results in samples treated at 
higher temperatures compared to the untreated controls. This may have been caused by the 
single 5 min processing step, although it is not clear if these differences are repeatable or not. 
The stability of the PSP toxins was significantly improved in HPP treated materials both in 
the short and long-term compared to control samples where no pre-treatment was carried out. 
Figure 4-16 - Figure 4-19 which were generated by different analytical methods employed to 
investigate potential degradation, conversion or epimerisation issues associated with this 
stabilisation technique graphically present these findings. 
Under frozen storage conditions both the HPP and untreated materials showed excellent 
stability. At storage temperatures above freezing, toxins in HPP treated materials showed 
significant stability improvements over untreated particularly in the short-term. Figure 4-16a-
f clearly illustrates this with all toxins, in particular GTX2,3 and NEO stability considerably 
improved when compared to the controls. Transportation of HPP treated materials should be 
carried out under frozen conditions but stability results prove that even at temperatures as 
high as +4°C the toxins would be stable for up to 5 days. This has particular relevance for 
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RM producers or PT providers where the stability of the toxins during transportation is of 
critical importance. 
No toxin degradation was observed in the HPP tissue for any toxins in the short-term 14 day 
study up to temperatures of +20°C, while some toxins, namely GTX2,3 and STX were also 
stable at temperatures as high as +40°C. Conversely untreated materials showed stability 
issues at temperatures above +4°C, particularly GTX2,3 and NEO. Epimerisation of the 
toxins GTX2,3 observed in HPP tissue in the short-term stability study would require 
materials to be transported at temperatures below +4°C. 
The results generated through these studies clearly show the improvements HPP treatment 
gives to PSP toxin stability and highlight the advantages this processing technique gives. 
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4.6 OVERALL CONCLUSIONS 
The main aims of the research undertaken as part of these studies were to improve the 
understanding of the mechanisms of PST degradation, biotransformation, and epimerization 
taking place in various shellfish tissue matrices. The chapter has detailed various techniques 
investigated for their potential effects on reducing or eliminating these toxin instability 
issues, and through the findings, shortlist applicable methods for the production of RMs for 
various uses. As discussed in the introduction, RMs have multiple uses and the techniques 
investigated were evaluated for their potential feasibility in CRM, ILRM or simple LRM 
production. Each technique was evaluated not only for its influence on PST stability, which is 
of critical importance, but also for its accessibility and ease of use by laboratories. Investment 
in the equipment used in producing these RMs to both stabilise and ensure homogeneity can 
be substantial and therefore accessibility may be an issue for monitoring and research 
laboratories particularly those under fiscal constraints. This chapter presents techniques 
which are polar opposite in terms of equipment costs with HPP providing arguably the best 
stabilisation method investigated but also representing the costliest in terms of equipment 
required. Conversely simpler techniques such as the use of preserving additives or thermal 
treatment represent a cost effective means of producing high quality RMs. These techniques 
may not be feasible in CRM production owing to the superior stability offered by alternatives 
such as HPP or freeze drying (Chapter 5), but their use as internal LRMs and for use as PT 
materials has been adequately demonstrated. 
Table 4-17 lists the RMs prepared in this chapter and summarises the stability observations 
determined through the short and long-term studies. As expected no issues were observed in 
any of the tissues when stored at -20°C including the untreated control materials which shows 
degradation, epimerization and biotransformations of toxins are minimised under this storage 
condition. 
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Table 4-17: Summary of RMs prepared in Chapter 4 with short and long-term stability details. 
Material Matrix 
Stabilisation 
Technique 
Analyte 
Stability 
-20°C +4°C +20°C +40°C 
Degradation Epimerization Degradation Epimerization Degradation Epimerization Degradation Epimerization 
Tissue 1 Mussel 
Antibiotic 
Spike 
dcSTX 348 days n/a 348 days n/a 69 days n/a 8 days n/a 
GTX2,3 348 days 32 days 32 days 16 days 0 days 0 days 32 days 0 days 
GTX5 348 days n/a 348 days n/a 154 days n/a 3 days n/a 
STX 348 days n/a 348 days n/a 154 days n/a 3 days n/a 
GTX1,4 348 days n/a 69 days n/a 154 days n/a 8 days n/a 
Tissue 2 Mussel 
Antioxidant 
Spike 
dcSTX 351 days n/a 351 days n/a 224 days n/a 8 days n/a 
GTX2,3 351 days 32 days 32 days 8 days 0 days 0 days 17 days 0 days 
GTX5 351 days n/a 221 days n/a 73 days n/a 4 days n/a 
STX 351 days n/a 351 days n/a 351 days n/a 17 days n/a 
GTX1,4 351 days n/a 73 days n/a 158 days n/a 4 days n/a 
Tissue 3 Mussel 
Untreated 
Control 
dcSTX 354 days n/a 354 days n/a 221 days n/a 17 days n/a 
GTX2,3 354 days 32 days 17 days 6 days 0 days 0 days 6 days 0 days 
GTX5 354 days n/a 224 days n/a 73 days n/a 6 days n/a 
STX 354 days n/a 354 days n/a 354 days n/a 17 days n/a 
GTX1,4 354 days n/a 76 days n/a 76 days n/a 0 days n/a 
Tissue A Mussel Additives Spike 
dcSTX 364 days n/a 364 days n/a 168 days n/a 6 days n/a 
GTX2,3 364 days 364 days 30 days 16 days 0 days 0 days 30 days 0 days 
GTX5 364 days n/a 364 days n/a 91 days n/a 6 days n/a 
STX 364 days n/a 364 days n/a 168 days n/a 6 days n/a 
GTX1,4 364 days n/a 364 days n/a 364 days n/a 4 days n/a 
Tissue B Mussel 
Thermal 
Treatment 
dcSTX 364 days n/a 364 days n/a 175 days n/a 28 days n/a 
GTX2,3 364 days 364 days 364 days 364 days 91 days 364 days 28 days 0 days 
GTX5 364 days n/a 364 days n/a 175 days n/a 8 days n/a 
STX 364 days n/a 364 days n/a 364 days n/a 28 days n/a 
GTX1,4 364 days n/a 364 days n/a 0 days n/a 8 days n/a 
Tissue C Mussel 
Untreated 
Control 
dcSTX 364 days n/a 364 days n/a 183 days n/a 15 days n/a 
GTX2,3 364 days 364 days 32 days 0 days 0 days 0 days 0 days 0 days 
GTX5 364 days n/a 364 days n/a 77 days n/a 8 days n/a 
STX 364 days n/a 364 days n/a 0 days n/a 15 days n/a 
GTX1,4 364 days n/a 77 days n/a 0 days n/a 4 days n/a 
LRM-09-02 Mussel 
Additives Spike 
& Thermal 
Treatment 
dcSTX 30 days n/a 30 days n/a n/a n/a 2 days n/a 
GTX2,3 30 days n/a 30 days n/a n/a n/a 30 days n/a 
GTX5 30 days n/a 30 days n/a n/a n/a 8 days n/a 
STX 30 days n/a 30 days n/a n/a n/a 8 days n/a 
GTX1,4 30 days n/a 30 days n/a n/a n/a 8 days n/a 
HPP Tissue Oyster HPP 
GTX2,3 180 days 180 days 180 days 180 days 120 days 14 days 2 days 2 days 
STX 180 days n/a 180 days n/a 120 days n/a 14 days n/a 
GTX1,4 180 days 180 days 30 days 180 days 14 days 180 days 8 days 14 days 
C1,2 180 days 180 days 180 days 180 days 180 days 10 days 0 days 0 days 
NEO 180 days n/a 180 days n/a 30 days n/a 5 days n/a 
N.B. All time points listed in columns titled degradation indicate stability was observed up to and including that stated; after which degradation or instability issues were observed. 
Time points listed in columns titled epimerization indicate this was not observed to occur in materials up to and including this point; after which epimerization was observed. 
A time point of 0 indicates degradation or epimerization was observed to occur before the first time point in the study. 
n/a analysis not carried out. 
*degradation or epimerization observed before the first time point of 3 months.
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Thermally treating materials significantly improved toxin stability with tissues stabilised in 
this way showing no instability issues when stored at +4°C over a one year period in addition 
to the -20°C observations. This treatment was the only one observed to have no stability 
issues at +4°C. This treatment also eliminated or minimised epimerization of the toxins 
GTX2,3 over the same time period at -20°C, +4°C and +20°C. This relatively simple 
technique of autoclaving source tissues prior to being dispensed provides considerable 
benefits in RM preparation and could be used as a stabilisation pre-step to any of the other 
techniques investigated in combining these procedures. 
The use of antibiotics in RM preparation gave more stability to the PSTs when compared to 
the use of an antioxidant alone. This was particularly evident in the +20°C and +40°C 
samples where instability issues were observed earlier in Tissue B, apart from STX which 
was found to be more stable in this material. The stability enhancements observed in the 
antibiotics spiked material (Tissue 1) were also observed in the combined additives spiked 
material (Tissue A) which indicated these improvements have come mostly from the effects 
of antibiotics. The use of the antioxidant would still be recommended however because of the 
stability improvements this additive provides for STX compared to antibiotics. 
HPP also proved an excellent stabilisation technique significantly decreasing instability 
issues compared to untreated controls. Arguably this technique provided no significant 
stability improvements compared to the thermal treatment of tissues with the latter technique 
being substantially more cost effective. However, both studies were carried out in different 
matrices so a study of HPP treatment of M. edulis tissues would be required to definitively 
prove this conclusion. 
An interesting observation concerns the toxins GTX2,3 in the untreated control materials, 
Tissue 1 and Tissue C which can be seen in the long-term stability graphs in Figure 4-5 and 
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Figure 4-10. Figure 4-5 shows GTX2,3 increases at +40°C by the first time point after 3 
months storage and this increase remains relatively consistent over the yearlong study with 
no obvious degradation of these toxins. Conversely Figure 4-10 shows the complete 
degradation of GTX2,3 at the same temperature after 3 months storage. The source of 
GTX2,3 in both tissues is slightly different but the preparation techniques in both cases were 
identical so the source of the instability issues could come from the alternative tissues used in 
both or potential contamination during the process as steps are not carried out aseptically. 
Bacteria may have been introduced into the tissue during its preparation which has led to the 
instability issues observed or this issue could relate to different bacterial colonies being 
present in the source tissues. 
Another interesting observation relates to dcSTX and the instability issues observed in the 
antibiotics material (Tissue 1) compared to the untreated control (Tissue 3) where stability up 
to 221 days storage at +20°C was evident for this toxin. This deterioration in stability of 
dcSTX could be due to bacteria being introduced during the processing steps as these are not 
carried out aseptically; although spiking with antibiotics should minimise these effects.  
Microorganisms, such as bacteria present in the shellfish can spoil the tissue leading to the 
degradation of the material. Toxin biotransformations are also known to take place in tissues 
when certain bacteria are present [132], so any process aimed at reducing the numbers of 
these microorganisms, destroying them completely or stopping them from multiplying will 
aid in the stabilisation of the tissue. 
All the techniques investigated in these studies improved the stability of the PSP toxins 
overall. The applicability of each technique in preparing RMs depends on their final use 
however.  
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The relatively simple techniques of thermal pre-treatment or the inclusion of additives 
improves the stability of the material without adding significant costs. These techniques 
could be employed by most laboratories and would lead to a significant improvement in the 
standard of RMs being produced. Bacteria play a major role in the stability of both the matrix 
and the toxins themselves, as evidenced through the stability studies, and biotransformations 
have been observed to take place in these tissues.  
The techniques detailed in this chapter were used to prepare materials which have been used 
in PT schemes globally. Multiple materials were prepared by additives spiking with an initial 
heat treatment step and used in QUASIMEME PT schemes as detailed in Chapter 6. Another 
material, stabilised in the same way was prepared and used in a PT scheme organised by 
VERIFIN, one of eighteen laboratories globally which has been assigned “designated status” 
by the OPCW (Organisation for Prohibition of Chemical Weapons). This scheme was 
organised to assess EU MSs proficiency in determining PSTs, in particular STX which is a 
Schedule 1 substance under the CWC (Chemical Weapons Convention). 
Based on the information generated in this chapter, recommendations for the preparation of 
stable and homogeneous reference materials would be: 
 The homogenisation techniques employed in these studies, such as the use of 
Waring™ and Polytron™ blenders, were sufficient to prepare materials fit for 
purpose. 
 HPP was the most effective in stabilising PSTs in a Pacific oyster tissue matrix 
although access to the relevant equipment may be a limiting factor in using this 
technique for other purposes than CRM preparation. 
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 The thermal treatment of tissues significantly improves matrix and PST stability and 
presents a cheap and simple technique in preparing RMs. Furthermore thermal 
treatment could be carried out in combination with other stabilisation techniques. 
 Materials prepared through the combined use of preserving additives coupled with a 
thermal pre-treatment step significantly improve PST stability. Materials prepared in 
this way were shown to have a wide range of applications including PT, internal 
QC/QA or for validation studies. 
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Chapter 5  
FREEZE DRYING 
 
5.1 BACKGROUND AND AIMS 
The presence of water in biological matrices is an essential ingredient for microbial growth. 
The previous chapter dealt with stabilisation techniques in the preparation of wet tissue RMs 
where water was not removed but increased in most cases to alter the final MC of the 
material to reflect natural shellfish matrices. The biological matrix, unless stabilised through, 
for example one of the techniques investigated in the previous chapter is prone to bacterially 
induced degradation, biotransformations or epimerization as evidenced from the instability 
issues of untreated control materials. Removal of water from the matrix should therefore 
improve stability through alteration of the environment necessary for bacterial colonies to 
flourish.  
The techniques investigated in the previous chapter proved effective in stabilising PSTs in 
mussel and oyster tissue matrices but their feasibility in the production of CRMs was 
questionable mainly due to epimerization issues observed at storage conditions above 
freezing. An alternative technique of freeze drying was investigated in order to ascertain if 
stability, particularly epimerization rates, could be minimised or eliminated. Freeze drying 
was previously investigated in the preparation of RMs for PSTs [67,68,149] where 
homogeneity and stability were adequately demonstrated in mussel tissues. The stability 
experiments carried out in the study by van Egmond et al., in 1998 [149] was not assessed in 
comparison with wet tissue homogenates however, nor were the details provided on the 
freeze drying processes involved, parameters which are critically important in assuring 
homogeneity with consistent recoveries [150]. More recently this technique was used to 
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successfully prepare a candidate CRM for multiple phycotoxins [63–65], although this 
material did not contain PSTs.  
The aim of this chapter was to investigate this stabilisation technique by developing a freeze 
drying method using instrumentation at the MI, incorporating specialised processing and 
dispensing techniques, to ensure homogeneity and minimise water uptake by the hygroscopic 
material. Feasibility of producing an oyster CRM was assessed and a large scale RM was 
produced using the optimised freeze drying, processing and dispensing conditions. The 
ultimate aim was to prepare a candidate RM for certification. 
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5.2 FEASIBILITY STUDY 
The research described in this section of Chapter 5 appears as described in Turner et al. 2013 
[133]. 
Turner A, Lewis A, Hatfield R, Higman W, Burrell S (2013) A feasibility study into the 
production of a freeze-dried oyster reference material for paralytic shellfish poisoning toxins. 
Anal Bioanal Chem 405:8621–8632. 
 
ACKNOWLEDGEMENT OF COLLABORATION 
The work in this section was carried out in collaboration with Dr. Andrew Turner and his 
team at CEFAS. The RM was freeze dried, processed and dispensed by the author and 
collaborator at MI facilities. The finished product was shipped back to CEFAS facilities on 
ice and stability studies were set up and conducted by the collaborator at his facilities. Toxin 
analysis was carried out by the author and collaborator during a site visit by the author to 
CEFAS facilities. 
 
Figure 5-1: Site visit made by the author to CEFAS facilities during the freeze drying feasibility studies. 
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Here, the objective was to develop procedures using modern freeze-drying processes for the 
generation of a freeze dried shellfish tissue and to conduct experiments to assess the 
characteristics of the material in relation to its suitability as a candidate RM. Oyster tissue 
was selected as the matrix of preference for two main reasons. Firstly, there is a known issue 
in this species with the comparability of method performance between the MBA and non-
animal testing methods [77]. Availability of a suitable CRM in this matrix would provide a 
useful tool for ongoing method assessment purposes. Secondly, it was the authors 
understanding that a mussel reference material was to be made available by the NRCC in the 
near future, so concentrating on a different shellfish species was likely to be of greater 
interest. This section of work was a collaborative study involving CEFAS and the MI. 
Paralytic Shellfish Toxin (PST) contaminated oyster tissues generated following shellfish 
feeding experiments at CEFAS were shipped to the MI where a suitable freeze-drying 
process had been developed, optimised and applied. Preliminary materials were assessed at 
both laboratories before tailored tissue materials were shipped back to CEFAS for subsequent 
investigations to assess the RM characteristics, including the comparison of toxin profiles 
with the wet tissues and assessing the stability and homogeneity between tissue sub-samples. 
In particular the stability of the tissues was examined over both short term and long term 
storage and over a range of temperature conditions. The data generated was subsequently 
used to determine the feasibility in producing a freeze dried oyster tissue for PSP toxins with 
the future aim of producing a large volume of certified RM. The flow chart contained in 
Figure 5-2 details the steps involved in preparing the feasibility study materials. 
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Figure 5-2: Flow chart of process used to prepare freeze dried feasibility study tissues. 
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5.2.1 SOURCE TISSUE 
Pacific oyster (Crassostrea gigas) tissue contaminated with PSTs was prepared at CEFAS 
through mass culturing of toxic Alexandrium fundyense [147] and feeding experiments as 
described in section 4.5.1.1. Once complete, the oysters were shucked and homogenised as 
one batch of ~4 kg of whole flesh tissue. The bulk tissue was further sub-divided in two, half 
of which was used to prepare a wet tissue RM and the other half used to prepare the freeze 
dried RM. The wet tissue RM was prepared at CEFAS through the addition of DI water, to 
adjust the MC to ~85%, and adjustment to pH 4.0 to stabilise the toxins present in the tissue. 
The tissue was dispensed as 6.0 g aliquots into PP vials and hermetically sealed under a 
stream of nitrogen. Aliquots were stored at -20°C until further use. 
The MC of the sub-sample for freeze drying was determined gravimetrically following 
replicate baking steps at CEFAS before being adjusted to ~85% MC through the addition of 
DI water. The tissue was then frozen at -20°C before dispatch to the MI using temperature 
controlled transport containers. Upon receipt, the material was stored at -20°C until further 
use. 
 
5.2.2 FREEZE DRYING 
All equipment used to prepare the freeze dried materials were acid washed, rinsed thoroughly 
with DI water before being placed in a desiccator containing activated silica beads. The 
oyster tissue was removed from the freezer and allowed to defrost to room temperature 
overnight before being homogenised further through the use of Waring™ and Polytron™ 
blenders. The tissue was transferred into two stainless steel freeze drying trays, covered in 
tinfoil and frozen overnight at -20°C. 
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The trays were removed from the freezer and immediately transferred to the freeze dryer 
(VirTis, Virtual 50XL) which were then subjected to a 116 hour freeze drying programme. 
The freeze drying programme was similar to that described in Table 5-5, FD-1 but 20 hours 
longer in duration. The process involved increasing the temperature in the chamber over a 
116 hour period from -35°C to +20°C through a series of ramping steps. Simultaneously the 
pressure inside the chamber was reduced from atmospheric pressure to ~1 Pa. 
Upon completion of the programme the trays were removed from the chamber and the freeze 
dried cakes of oyster tissue were manually ground using a pestle to break up large 
conglomerates. The tissue was transferred to stainless steel bowls containing 25 x 20 mm 
steel balls, in ~100 g lots. The tissue was milled using a planetary ball mill (Retsch PM100) 
for 5.0 min at 400 rpm. The milled material was sieved through a 2mm sieve to remove large 
pieces of material, followed by a 125 µm sieve to remove any material with particle sizes 
>125 µm for 30 min. This was due to issues with the homogeneity of powder materials with 
particle sizes above 125µm. To minimise water uptake by the hygroscopic freeze dried 
material, the sieving unit was covered with a polyethylene sheet and a steam of low moisture 
content argon was constantly flushed over the unit [62]. The sieved material was manually 
mixed using a large spatula before dispensing 2 x 2.2 g aliquots into 5 mL amber glass 
ampoules, sealed under a vacuum of low moisture content argon. The remaining material was 
transferred to PP bags, vacuum heat sealed and stored at -20°C until further use. 
 
5.2.3 DISPENSING 
The optimum aliquot size to dispense these materials was determined through weighing 
variable masses (0.1, 0.2, 0.3, 0.5 and 1.0 g) of the 2.2 g aliquot, dispensed in the previous 
section, into 50 mL PP centrifuge tubes. The tissues were reconstituted to 5.0 g through the 
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addition of DI water and vortex mixing for 5.0 min. The five samples were then extracted and 
analysed according to OMA AOAC 2005.06 as described in section 2.3.1. 
The remaining freeze dried material was removed from the freezer and allowed to equilibrate 
to room temperature overnight. The vacuum sealed bag was opened and the freeze dried 
material transferred to a PP beaker. The material was mixed using a large spatula before 
being dispensed as ~0.53 g aliquots into pre-labelled 5 mL amber glass ampoules. The 
dispensing steps were carried out in a modified glove box purged with low moisture content 
argon which was kept at a low constant flow throughout the process. After dispensing, the 
aliquots were removed from the glove box and transferred to the freeze dryer where they 
were vacuum sealed under an atmosphere of low moisture content argon. 300 aliquots were 
dispensed and crimp capped before being stored at -20°C until further use. 
 
5.2.4 RECONSTITUTION, EXTRACTION AND TOXIN ANALYSIS 
The freeze dried material was re-constituted by weighing 0.50 ± 0.01g into 50 mL PP 
centrifuge tubes. 4.50 g of DI water was added, making a total sample mass of 5.0 ± 0.01g. 
Re-constituted freeze dried tissues were then extracted and analysed closely following OMA 
AOAC 2005.06 [41] as detailed in section 2.3.1. PCOX LC-FLD [75] analysis was 
additionally performed on all samples. Crude acetic acid extracts prepared according to 
section 2.3.1 were deproteinated and analysed following AOAC 2011.02 [75]. The 
instrumentation used in this study was the same as that described in section 4.5.1.1 (Toxin 
Analysis), with additional PCOX analysis performed at CEFAS using a standard Agilent 
1200 LC-FLD instrument including a quaternary LC pump module, two Agilent isocratic 
pumps and an external column oven containing the post-column reaction coil. 
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PST concentrations in sample extracts were quantified against a 6-point calibration for each 
toxin with PST concentrations and total saxitoxin equivalents determined. 
 
5.2.5 TOXIN PROFILE AND HOMOGENEITY STUDIES 
The toxin profiles of the untreated wet tissue RM and the freeze dried RM were compared by 
extracting aliquots (n=3) of each material. The freeze dried RM was initially re-constituted, 
as described above before both untreated and freeze dried aliquots were extracted and 
analysed following OMA AOAC 2005.06 as described in section 2.3.1. Analysis of both 
materials was performed in the same chromatographic sequence. 
The homogeneity of both the untreated and freeze dried materials was assessed through the 
intra-batch analysis of 14 aliquots. Tissues were re-constituted, extracted and analysed as 
described above. 
 
5.2.6 STABILITY STUDIES 
Short and long-term stability studies were conducted on both the untreated and freeze dried 
materials following a reverse-isochronous experimental design [55]. The short term study 
was conducted with triplicate samples consisting of five time points (0, 4, 10, 19 and 33 days) 
and four temperature conditions (-20°C, +4°C, +22°C and +40°C). The long term study was 
conducted with triplicate samples consisting of five time points (0, 3, 6, 9 and 12 month) and 
three temperature conditions (-20°C, +4°C and +40°C). The reference temperature used in 
both studies was -80°C. 
At the end time point all samples were removed from storage, allowed to equilibrate to room 
temperature before being re-constituted as described above, and extracted and analysed by 
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preCOX LC-FLD closely following OMA AOAC 2005.06 [41] as detailed in section 2.3.1. 
PCOX LC-FLD [75] analysis was additionally performed on all samples to specifically 
investigate the extent of epimerisation of GTX1,4, GTX2,3 and C1,2. For PCOX LC-FLD 
analysis, the crude acetic acid extracts prepared according to section 2.3.1 were deproteinated 
and analysed following AOAC 2011.02 [75]. 
 
5.2.7 RESULTS AND DISCUSSION 
 
5.2.7.1 CHARACTERISATION 
PreCOX LC-FLD analysis results from variable masses of re-constituted freeze dried 
material are contained in Table 5-1. Total saxitoxin equivalents values ranged from 140 – 
2060 µgSTXdiHCl-eq/kg for the powder masses of 0.1 – 1.0 g, although the N-hydroxylated 
PSTs were quantified directly from SPE C18 cleaned extracts so these values may be 
overestimated [151]. The signal to noise ratios of the main quantitation peaks are also 
summarised in Table 5-1.  
Table 5-1: PST concentrations (µg STX di-HCl eq/kg) determined by preCOX LC-FLD in freeze-dried oyster tissues 
following reconstitution to a total of 5.0g with variable masses (0.1 to 1.0g) of powder (signal to noise ratios of quantitation 
peaks shown in brackets). 
 Weight of freeze-dried powder 
 0.1g 0.2g 0.3g 0.5g 1.0g 
GTX1,4 71 (2.7) 117 (7.0) 333 (10) 493 (15) 1143 (21) 
NEO 34 (2.6) 112 (6.8) 180 (8.1) 254 (15) 614 (20) 
C1,2 4.8 (1.8) 13 (2.9) 18 (5.1) 26 (6.8) 56 (8.5) 
GTX2,3 18 (1.3) 30 (2.9) 48 (5.1) 70 (6.8) 139 (8.5) 
STX 12 (2.7) 31 (8.4) 35 (12) 55 (14) 107 (20) 
Total 140 302 613 898 2060 
 
The aliquot size of 0.50 g in Table 5-1 was chosen and the materials were dispensed at this 
mass. This aliquot size ensured that after re-constitution, extraction and analysis that the 
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material had a concentration close to the EU regulatory limit. This size was also chosen as at 
this level the least concentrated toxins in the material still produced a signal to noise of >5.0 
after preCOX LC-FLD. 
 
Figure 5-3: PreCOX and PCOX LC-FLD chromatograms of freeze-dried and unprocessed wet oyster tissue. 
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Figure 5-3 a-d contains chromatograms of both freeze dried and untreated wet oyster tissues 
after periodate and peroxide oxidation and analysis by preCOX LC-FLD. Chromatograms of 
both tissues were visually similar and showed the presence of the non-N-hydroxylated toxins 
C1,2, GTX2,3 and STX and the N-hydroxylated toxins GTX1,4 and NEO. There was 
evidence for the formation of additional chromatographic peaks which may have been caused 
by the freeze drying process. The PCOX LC-FLD chromatogram of the freeze dried tissue is 
contained Figure 5-3 e, which also shows no additional fluorescent peaks from the freeze 
drying process.  
 
Figure 5-4: Comparison of PST profiles in a) wet untreated and b) freeze-dried oyster tissues (error bars represent ± 1 s.d. 
of triplicate samples). 
 
Toxin profiles of both the untreated wet tissue RM and the freeze dried RM are contained in 
Figure 5-4 and are expressed as a percentage of total saxitoxin equivalents. The PST profiles 
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in both tissues had similar relative proportions, although a potential loss in concentration of 
NEO was noted but were still within repeatability limits. There was no visual evidence for 
any degradation or conversion of the PSTs through the freeze drying process. 
 
5.2.7.2 HOMOGENEITY 
Both the freeze dried and untreated wet tissue RMs were suitably homogenous for all the 
PSTs detected, as evidenced through the coefficient of variances contained in Table 5-2. 
A target %CV of below 8% for each analyte including total toxicity was set. This value is 
below expected levels of variability associated with intra-batch repeatability, determined 
through in-house validation of the preCOX LC-FLD method [148]. The homogeneity 
techniques employed were therefore sufficient and the materials suitable for the study. 
Table 5-2: Mean concentrations (µg STX di-HCl eq/kg), standard deviations (sd) and percentage relative standard 
deviations (%RSD) of toxins in reconstituted freeze-dried and untreated wet frozen oyster tissues as determined by preCOX 
LC-FLD (n=14). 
Sample 
 
GTX1,4 NEO C1,2 GTX2,3 STX Total 
 Mean 519 320 26 70 59 993 
Freeze-dried sd 32 17 2 5 3 48 
 %RSD 6.1% 5.3% 6.9% 7.8% 4.3% 4.9% 
 
 
Mean 718 770 17 34 48 1586 
Wet tissue sd 30 51 1 3 2 65 
 %RSD 4.1% 6.7% 6.1% 7.7% 3.4% 4.1% 
 
The data from both materials was similar and showed there were no major effects on the 
distribution of toxins in the freeze dried powder from sample processing, re-constitution or 
analysis. 
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5.2.7.3 SHORT-TERM STABILITY 
 
PRECOX LC-FLD 
Figure 5-5 a-j represents the short-term stability results for the untreated wet tissue RM and 
the freeze dried RM at four different storage temperatures, -20°C, +4°C, +22°C and +40°C, 
determined through preCOX LC-FLD analysis. Data for GTX1,4, GTX2,3, NEO, C1,2 and 
STX were generated and results were normalised to the average of replicate analysis (n=9) of 
samples stored at the reference temperature of -80°C for the duration of the study. The limits 
of stability from Figure 5-5 were generated from two times the standard deviation of the -
80°C replicate analyses.  
Overall toxin stability was excellent in both materials when stored at -20°C for the duration 
of the study with the freeze dried materials additionally showing excellent toxin stability at 
+4°C. The stability of the toxins at the higher temperatures studied showed variability 
however. Some degradation of GTX1,4 and NEO in the untreated RM was observed after 14 
days storage at +4°C, while the other toxins present in the material remained stable at this 
temperature. At the higher temperatures of +20°C and +40°C degradation of NEO, C1,2 and 
STX was evident after as little as 4 days of the study with ~80% of the total toxin content in 
the case of NEO degraded by day 33. Apparent increases in GTX1,4 and GTX2,3 
concentrations were evident in materials stored at these higher temperatures with ~30% and 
~60% increases respectively noted at +40°C (Figure 5-5 a-e). 
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Figure 5-5: PreCOX LC-FLD results showing short term stability of PST concentrations normalised to the -80°C reference 
samples in untreated wet frozen (3a-3e) and freeze-dried (3f-3j) oyster tissues over 1 month (error bars represent ±1 sd of 
triplicate samples). 
 
Conversely the freeze dried materials showed no evidence for the degradation or 
enhancement of any toxins when stored at -20°C or +4°C. At +20°C STX and NEO also 
showed excellent stability but there was evidence for the degradation of GTX1,4 after 9 days 
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and increases in C1,2 and GTX2,3 concentrations after 19 and 33 days respectively at this 
temperature. At +40°C STX also showed excellent stability during the study but degradation 
of GTX1,4 and NEO was evident after 9 and 4 days respectively. Under this temperature 
condition apparent increases in C1,2 and GTX2,3 concentrations after 4 days were noted. 
These results prove conclusively the significant stability enhancement freeze drying gives 
PSTs compared to untreated wet tissue RMs in the short-term. This has particular importance 
for transporting materials where temperatures could potentially rise above freezing. 
 
PCOX LC-FLD 
Further analysis was conducted on the short-term stability study extracts for both the 
untreated wet tissue RM and the freeze dried RM by PCOX LC-FLD and results are 
presented in Figure 5-6 a-l. Limits of stability and normalised results were calculated as per 
the preCOX LC-FLD analysis above. No PCOX LC-FLD stability data for the tissues stored 
at +40°C is presented due to instability issues in both wet and freeze-dried tissues stored at 
this temperature.  
Excellent stability was exhibited in both the untreated and freeze dried materials stored at -
20°C throughout the study with no evidence for epimerisation taking place under frozen 
conditions. In addition the freeze dried materials also showed no evidence for epimerisation 
of any of the three epimeric pairs at +4°C over the 33 day study. At the higher temperature 
storage condition of +20°C epimerisation was observed to take place in the freeze dried 
materials with increases in relative concentrations of GTX1, GTX2 and C1, coupled with 
decreases in GTX4, GTX3 and C2 respectively. 
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Conversely epimerisation was observed to take place at +4°C and +20°C in the untreated wet 
tissue RM. At +4°C GTX1,4 and GTX2,3 showed signs of epimerisation after 33 days but 
C1,2 remained stable at this storage condition. At +20°C epimerisation was clearly evident 
after 4 days of the study for all three epimeric pairs with an approximate 80% toxin 
conversion observed by the end of the study. 
These results again highlight the advantages freeze drying materials have on the stability of 
PSTs, particularly epimerisation which was significantly reduced. These results confirm the 
transport of freeze dried materials containing these toxins could be carried out at 
temperatures of up to +4°C. 
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Figure 5-6: PCOX LC-FLD results showing short term stability of PST concentrations normalised to the -80oC reference 
samples in untreated wet frozen (4a-4f) and freeze-dried (4g-4l) oyster tissues over a 1 month assessment period (error bars 
represent ±1 sd of triplicate samples). 
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5.2.7.4 LONG-TERM STABILITY 
 
PRECOX LC-FLD 
Figure 5-7 a-e represents the long-term stability results for both materials at two different 
storage temperatures, -20°C and +4°C, determined through preCOX LC-FLD analysis. 
Results were normalised and limits of stability set as described above. Data was not 
generated for materials stored at +40°C due to the instability of the toxins at this temperature. 
Overall excellent stability was observed in both materials when stored at -20°C throughout 
the 12 month study with freeze dried materials also showing excellent stability at +4°C with 
no signs of toxin degradation or enhancement during this period. The wet tissue RM did show 
stability issues however, with degradation of GTX1,4 noted by month 3 and increases in C1,2 
and GTX2,3 concentrations after 6 and 3 months respectively. 
This study highlights the long-term stability of PSTs in freeze dried materials with excellent 
stability observed under frozen or refrigerated storage conditions. The data confirms freeze 
drying materials to be advantageous in stabilising these toxins compared to untreated wet 
tissues. 
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Figure 5-7: PreCOX LC-FLD results showing normalised long term stability data of a) GTX1,4 b) NEO c) C1,2 d) GTX2,3 
e) STX in untreated wet frozen and freeze-dried oyster tissues held at -20oC and +4oC over 1 year (error bars represent sd 
of triplicate samples). 
 
PCOX LC-FLD 
Further analysis was conducted by PCOX LC-FLD on the long-term stability study extracts 
of both materials and results are presented in Figure 5-8 a-f. Limits of stability and 
normalised results were calculated as above. PCOX LC-FLD analysis was only conducted on 
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samples stored at -20°C and +4°C due to stability issues in materials stored above these 
temperatures. 
No epimerization or degradation was observed in the freeze dried materials stored at both -
20°C and +4°C, with any variability throughout the 12 months being within the limits 
specified by within-batch repeatability. 
 
 
Figure 5-8: PCOX LC-FLD results showing long term stability of PST concentrations normalised to the -80oC reference 
samples in untreated wet frozen and freeze-dried oyster tissues held at -20oC (6a-c) and +4oC (6d-f) over a 12 month 
assessment period (error bars represent ±1 sd of triplicate samples). 
 
The untreated wet tissue RMs showed signs of epimerisation and degradation at both these 
storage conditions however. Epimerisation of GTX4 to GTX1 was observed in these 
materials at both temperature conditions studied with signs of additional degradation of 
GTX4 in samples stored at +4°C (Figure 5-8 a+d). Epimerisation of GTX2,3 was also 
observed in the untreated tissues stored at +4°C which was evident after 9 months storage. 
An increase in GTX2 concentration was noted in frozen samples, although epimerisation is 
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not assumed as this increase did not coincide with any decreases in GTX3 concentration. No 
epimerisation of C1,2 was observed to take place in the wet tissue RM at either of the 
temperatures studied. 
Overall the long-term stability study gave further evidence for the improvements freeze 
drying provides in the production of RMs, with no epimerisation observed in frozen or 
refrigerated tissues over a 12 month period. 
 
5.2.7.5 USE AS CANDIDATE REFERENCE MATERIAL 
The work detailed in this section of the study has shown the feasibility in producing a freeze 
dried oyster tissue as a candidate RM for PSP toxins. The technique, including all associated 
processing steps, were sufficient to produce homogeneous materials with significant PST 
stability enhancements made when compared with untreated wet tissue RMs. The freeze 
dried tissues showed excellent short and long-term stability, the data of which can be used to 
determine optimum transportation and long-term storage conditions. 
The results confirm freeze drying as an excellent technique to prepare PST RMs with scope 
to produce a larger, production scale batch of materials that could be released as a 
commercial product. 
 
5.2.8 CONCLUSIONS 
Through feeding experiments of Pacific oysters, a naturally contaminated tissue was used to 
prepare a wet tissue and a freeze dried RM. Initial characterisation of the materials showed no 
visual evidence for changes to the toxin profile of the material from the freeze drying process. 
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Analysis of replicate aliquots of both the untreated and freeze dried materials showed the 
materials to be homogeneous, which proved the freeze drying processing techniques 
developed during these studies were sufficient. Short and long-term stability, determined 
using both the preCOX and PCOX methods proved conclusively the advantages this 
technique gives compared to untreated wet tissue RMs. The study provides good evidence for 
the applicability of the freeze drying process for the preparation of homogenous and stable 
PST reference materials, with excellent scope for producing CRMs. 
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5.3 OPTIMISATION STUDIES 
5.3.1 AIMS AND OBJECTIVES 
The feasibility study carried out in the previous section demonstrated the improved stability 
this technique provides for PSTs and also indicated that the facilities at the MI are suitable for 
producing high quality freeze dried RMs. This section focused on optimising the freeze 
drying programme including the processing and dispensing steps. 
Freeze drying programmes of 2, 3 and 4 days duration were compared and contrasted to 
observe the effects on PST content and MC. The hygroscopic nature of freeze dried materials 
coupled to the fact that these materials were not always kept under low moisture conditions 
for example during transfer to different apparatus led to a re-freeze drying study being 
examined. This process was investigated with tissues freeze dried, processed and dispensed 
before being re-freeze dried in their containers using a short time programme before sealing. 
The capacity of the freeze drier and processing techniques were also determined as this would 
be a factor in producing any large scale RMs using this method. The dispensing of the freeze 
dried materials was also optimised using a semi-automated powder dispenser (Zinsser-
Analytic, Berkshire, UK) purchased and used instead of manually dispensing each aliquot 
using a spatula and bench top balance, as was carried out in the feasibility study in the 
previous section. 
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5.3.2 SOURCE TISSUES 
The Spanish tissue from Table 2-1 was used to prepare the optimisation study material which 
contained, dcSTX, GTX5 and STX. An initial bulk tissue was prepared by transferring ~3.0 
kg of the Spanish tissue into a 5 L Waring™ goblet with 0.300 ± 0.001 L DI water to aid 
mixing. The tissue was homogenised on medium power for 5.0 min before aliquots were 
taken for MC determination (n=3) using the rotary vacuum method and analysis by preCOX 
LC-FLD (n=1) as described in the materials and methods section 2.4.1 and 2.3.1 respectively, 
to give approximate PST concentrations in the bulk tissue. The bulk homogenate was 
immediately subdivided into 5 aliquots by pouring ~ 0.6 kg of tissue into PP containers, 
sealing with lids and parafilm before storing at -20°C until required for use. The PST levels 
and MC results from this bulk homogenate are presented in Table 5-3. 
Table 5-3: Toxin profiles, concentrations and moisture content of bulk tissue used in freeze drying optimisation studies. 
Material 
Concentration (µmol / kg) Total Toxicity                  
(µg STX diHCl-eq / kg) 
% Moisture 
Content dcSTX GTX5 STX 
Bulk 
homogenate  
1.31 0.13 0.04 507 82.9 
 
5.3.3 FREEZE DRYING 
Table 5-4 gives details of the various freeze drying programs evaluated in the optimisation 
studies. As discussed previously five freeze drying optimisation experiments were conducted 
using various lengths of time, depth of tissue in each tray and one process where the material 
was re-freeze dried after being dispensed. 
Each experiment, FD-I - FD-V was conducted on separate days but each study followed 
similar processes. A container was removed from the freezer and allowed to defrost overnight 
at +4°C. 526.0 ± 0.1 g of each tissue was transferred to a 1 L Waring™ goblet, made up to 
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600.0 ± 0.1g with DI water to adjust the MC to ~85% and homogenised on medium power 
for 5.0 min. 
Table 5-4: Details of the five freeze drying conditions used in optimisation studies. 
Material 
FD Times 
(hours) 
Tissue depth 
on tray (mm) 
Secondary 
Freeze Drying 
FD-I 96 ~5 No 
FD-II 72 ~5 No 
FD-III 72 ~10 No 
FD-IV 72 ~10 Yes 
FD-V 48 ~10 No 
 
The tissue was then transferred to two freeze drying trays in the case of FD-I and FD-II 
experiments and transferred into one tray in the case of the FD-III, FD-IV and FD-V 
experiments. This was to ensure the depth of tissue in each tray was roughly as stated in 
Table 5-4. 
Table 5-5: Details of freeze drying programmes used to prepare materials contained in chapter 5. 
Process 
FD-
I 
FD-
II/III/IV 
FD-
V 
Secondary 
2nd Step Temperature 
(°C) 
Pressure 
(mbar) 
Hold/Ramp 
Time (h) 
Thermal 
Treatment 
0 0 0 0 20 1013 - 
2 1.5 1 1 -35 1013 R 
Primary Drying 
2.1 1.6 1.1 0.6 -35 1013 H 
5.7 4.3 2.8 1.4 -35 1.03 R 
7.7 5.8 3.8 1.9 -35 1.03 H 
8.7 6.5 4.3 2.2 -25 0.21 R 
28.7 21.5 14.3 7.2 -25 0.21 H 
29.7 22.3 14.8 7.4 -20 0.13 R 
48.7 36.5 24.3 12.2 -20 0.13 H 
49.7 37.3 24.8 12.4 -10 0.13 R 
56.7 42.5 28.3 14.2 -10 0.13 H 
57.7 43.3 28.8 14.4 0 0.13 R 
71.7 53.8 35.8 17.9 0 0.13 H 
Secondary Drying 
72.7 54.5 36.3 18.2 20 0.01 R 
74.7 56 37.3 18.7 20 0.01 H 
78.7 59 39.3 19.7 20 0.01 R 
94 70.5 47 23.5 20 0.01 H 
Secondary Set 
Point 
96 72 48 24 20 0.01 H 
Condenser 
-70°C 
Condition 
The trays were then placed into the freeze drier, the door was sealed and the pre-programmed 
freeze dry sequence as described in Table 5-5 was started. 
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5.3.4 MATERIAL PROCESSING AND DISPENSING 
 
Figure 5-9: Flow chart depicting steps in the preparation of the freeze dried materials contained in section 5.3. 
 
All equipment used to process and dispense the freeze dried material was first washed in a 
2% Decon-90™ solution followed by thorough rinsing in DI water. The equipment was then 
 
MATERIAL PLANNING AND 
SOURCE TISSUE SELECTION 
FREEZE DRYING 
MANUAL CRUSHING WITH 
PESTLE 
BALL MILLING 
SIEVING UNDER A STREAM 
OF LOW MOISTURE ARGON 
ALIQUOTS DISPENSED IN 
PRE-LABELLED VIALS USING 
SEMI-AUTOMATED UNIT 
TISSUE MANUALLY MIXED 
USING LARGE SPATULA. 
ALIQUOTS VACUUM SEALED 
UNDER ARGON AND CRIMP 
CAPPED 
STORAGE AT -20°C 
<125µm 
DISCARD 
>125µm 
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placed in an oven at +40°C for ~5.0 hours before being transferred to a large desiccator 
containing activated silica beads. These steps were carried out in order to reduce the potential 
for bacterial contamination as much as possible through the use of Decon-90™ and to keep 
the equipment sufficiently dry to process the hygroscopic freeze dried materials. 
The flowchart contained in Figure 5-9 illustrates the freeze drying process followed. Upon 
completion of the freeze drying programme, the vacuum was released and the door was 
opened. The tray was removed and the cake formed by the freeze dried material was 
manually ground to break up large conglomerates using a large mortar. Approximately 90.0 g 
freeze dried material remained after the process and in each case this was transferred equally 
to three grinding bowls containing 25 x 15 mm stainless steel balls. The lid was attached and 
the material was ground for 5.0 ± 0.1 min at 400 rpm using a planetary ball mill (Retsch PM 
100, Verder Group, The Netherlands).  
The material was transferred to a 125 µm sieve fitted with a base plate and attached to a 
motorised sieve shaker (Impact Test Equipment Ltd., U.K.). The sieve shaker was covered 
with a large plastic sheet and sealed with brown tape. A hose was inserted through an 
opening made at the top of the sheet and low moisture content argon was flushed over the 
sieve plates during the shaking sequence of 30.0 ± 0.1 min. A small hole was made at the 
bottom of the sheet to allow pressure release during this process.  
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Figure 5-10: Photo of modified glove box constructed to dispense the freeze dried materials described in this chapter 
showing the setup for dispensing the RMs. 
 
The base plate containing the material (~80.0 g) passed through the 125 µm sieve was 
transferred to a 100 mL PP beaker and placed immediately into the modified glove box 
constructed for dispensing the materials in this section. The glove box also contained all the 
dispensing equipment and the setup is illustrated in Figure 5-10. 
The glove box chamber was purged with low moisture content argon for ~5.0 min with the 
exhaust valve fully open. The argon flow rate was lowered before dispensing the freeze dried 
material as 0.76 g aliquots using a calibrated powder dispenser (Zinnsser Analytical, 
Germany) into 5 mL amber serum vials (Wheaton, USA). The freeze dried material was 
continually mixed with a spatula throughout the dispensing process. 
An antistatic fan was switched on throughout the dispensing process and an antistatic gun 
discharged periodically to prevent issues with dispensing powders and static. After being 
fully dispensed the FD-I – FD-IV vials were removed from the glove box, placed on a freeze 
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dry tray, and lyophilisation stoppers inserted half way. In the case of the FD-V materials 
lyophilisation stoppers were not initially inserted and the vials were placed back into the 
freeze drier and subjected to the 2
nd
 step freeze drying program as detailed in Table 5-5. Once 
this 2
nd
 freeze drying step was complete, lyophilisation stoppers were inserted halfway in the 
vials. 
All materials, FD-I – FD-V, were placed back into the freeze drier, the door was sealed and 
the vacuum applied, removing air from the chamber. A cylinder of low moisture content 
argon was attached to the exhaust vent of the freeze drier before releasing half the vacuum in 
the chamber to argon. The shelves were contracted, pushing the lyophilisation stoppers fully 
in and sealing the vials, before releasing the chamber to atmospheric pressure. This created a 
small vacuum inside each of the vials which held the lyophilisation stoppers in place. The 
vials were removed from the freeze drier, crimp capped before being stored at -80°C until 
further use. Only 50 aliquots of each material FD-I – FD-V were dispensed and any 
remaining freeze dried material discarded as this number was sufficient to carry out the 
studies contained in this section. 
Figure 5-11 illustrates the processes involved in dispensing the freeze dried materials. 
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Figure 5-11: Pictures showing the various steps in the freeze drying process, I) Virtis 50XL instrument, II) dispensing freeze 
dried materials inside modified glove box, III) dispensed materials in freeze drier with shelves contracted to push 
lyophilisation stoppers into place IV) sealed aliquots of freeze dried materials and V) various stages of materials being 
dispensed with empty containers (A) to sealed and crimp capped aliquots (F). 
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5.3.5 RECONSTITUTION, EXTRACTION AND TOXIN ANALYSIS 
A total of 10 aliquots was randomly selected from the entire fill series and all extracted on the 
same day. All materials FD – I -V were first reconstituted with DI water by weighing 0.75 ± 
0.01 g into a PP centrifuge tube and making the final weight up to 5.0 ± 0.1 g with DI water. 
The centrifuge tubes containing the tissue were then vortex mixed for 1.0 ± 0.1 min, 
sonicated for 1.0 ± 0.1 min followed by vortex mixing for 1.0 ± 0.1 min. The reconstituted 
tissue was then extracted according to OMA AOAC 2005.06 as detailed in Section 2.3.1. 
Toxin analysis was only carried out using preCOX LC-FLD as stability and specifically 
epimerization was not being assessed in this study. The moisture content of the freeze dried 
tissues was determined using a volumetric Karl Fischer method as described in Section 2.4.2. 
 
5.3.6 RESULTS AND DISCUSSION 
The homogeneity results are detailed in Table 5-6 and graphically represented in Figure 5-12 
to give a visual comparison. The FD-I and FD-II materials showed the least amount of toxin 
degradation from 3 and 4 day freeze drying when compared to the source tissue 
concentrations contained in Table 5-3.  
Table 5-6: Homogeneity results for freeze dried tissues prepared in optimisation studies (n=10). 
Material 
Concentration (µgSTX diHCleq/kg) 
dcSTX GTX-5 STX Total Toxicity 
Average Stdev %CV Average Stdev %CV Average Stdev %CV Average Stdev %CV 
FD-I 441 14 3.2 4.8 0.4 7.8 17 1 6.5 463 15 3.3 
FD-II 452 19 4.3 5.2 0.2 3.9 18 1 4.6 475 20 4.2 
FD-III 401 17 4.5 4.5 0.2 5.2 15 1 5.2 422 19 4.4 
FD-IV 372 13 3.6 4.3 0.2 3.7 15 1 4.7 392 14 3.6 
FD-V 391 16 4.3 4.9 0.3 5.2 16 1 3.5 412 17 4.2 
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The results suggest the use of longer, less aggressive freeze drying programmes of 96 or 72 
hours in duration coupled with tissue depths of ~50 mm are ideal for these materials. Under 
these conditions PST degradation from the freeze drying process is minimised, leaving total 
toxin content very similar to that found in the original source tissues. 
 
Figure 5-12: Graphical representation of homogeneity data generated for freeze drying optimisation studies using a 
logarithmic scale. 
 
There was a statistical difference (P < 0.05; one-way analysis of variance [ANOVA]) found 
between the means of the five materials which showed some effects on toxin concentration 
following each of the freeze drying treatments. FD-IV materials showed the greatest level of 
toxin degradation which was most likely caused by the re-freeze drying of these aliquots. The 
more aggressive freeze drying programme of 2 days (FD-V) demonstrated the benefits of 
using a longer programme as toxin instability was caused by the more rapid increases in 
temperature and pressure required for this programme. 
The moisture content of these tissues was assessed using a volumetric Karl Fischer method 
and the results are contained in Table 5-7. Moisture content of these freeze dried tissues is 
important to minimise the risk of bacterial growth and ideally this level should be below ~5% 
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[56]. The conditions investigated in this section gave varying results with 4 and 3 day freeze 
drying programmes producing MC levels acceptable for materials and close to the targeted 
value of 5%. Materials freeze dried only once and with a tissue depth of 100 mm (FD-III & 
FD-V) gave the highest MC determined which indicates that tissue depth in each tray should 
be below 10 mm and ideally ~5 mm in order to obtain a sufficiently low MC.  
Table 5-7: Moisture content of freeze dried tissues. 
Material Average Stdev %CV 
FD-I 5.5 0.3 6.1% 
FD-II 5.8 0.4 6.9% 
FD-III 7.2 0.4 5.7% 
FD-IV 2.7 0.1 4.2% 
FD-V 8.9 0.5 7.9% 
 
The FD-IV materials gave the lowest MC of any determined which although in theory this 
provides the most inhospitable conditions for microbial growth it also produces the most 
hygroscopic material which when opened would absorb water relatively quickly affecting 
toxin concentration and compromising efforts to accurately certify the material [62,63]. 
From these results the ideal conditions were determined to be either 3 or 4 day freeze drying 
programmes with ~ 5 mm tissue depth in each tray. The results indicate the freeze drying of 
tissues can be adequately carried out at the MI using in-house apparatus and the various 
processing steps are sufficient in dealing with hygroscopic materials. 
The optimised FD process used in this study is represented on the phase diagram of water 
graphically represented in Figure 5-13. The red trace corresponds to the freeze drying 
programme applied and shows the process of water sublimation from the tissue, passing 
straight from the solid to the gas phase.  
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Figure 5-13: Phase diagram of water showing optimised freeze drying program. 
 
Figure 5-14 below shows the variation of temperature and pressure applied during the FD 
process as a function of time and illustrates the conditions used in the 96 hour freeze drying 
programmes. 
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Figure 5-14: Graphical representation of temperature and pressure changes applied to the tissues during the 4-day 
optimised freeze drying process. 
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5.4 FREEZE DRYING USING OPTIMISED PROGRAM 
The previous section sought to optimise the conditions for freeze drying materials at the MI 
and also the processing conditions necessary to produce small and relatively large scale 
freeze dried materials. The optimised techniques show that the processing of hygroscopic 
materials using the equipment either constructed or purchased as part of these studies, to be 
suitable for producing freeze dried materials with the required MCs and sufficient 
homogeneity. 
Once the optimised conditions had been determined further studies were conducted to assess 
the stability of a range of PSTs in both short and long-term studies. 
 
5.4.1 SOURCE TISSUES 
The material used in this section was prepared as part of the additives study in chapter 4 as 
described in Section 4.3.1.1. The bulk homogenate was removed from the freezer and 
allowed to defrost overnight in a fridge at +4°C. The tissue was manually mixed with a 
spatula before transferring 734 ± 1 g into a Waring™ goblet. The final weight was made up 
to 900 ± 1 g with DI water to alter the final MC to ~85% as the freeze drying programme was 
optimised with tissues at this level. The slurry was poured into the freeze drying trays with a 
tissue depth of ~50 mm, and placed into a freezer overnight at -20°C. 
 
5.4.2 FREEZE DRYING AND MATERIAL PROCESSING 
The trays were removed from the freezer and placed into the freeze drier for the duration of 
the 96 hour programme as detailed in Table 5-5. Upon completion of the freeze drying 
programme the material was removed from the instrument and was processed and dispensed 
Chapter 5 
 
 
195 
 
as described in Section 5.3.4. Dispensed aliquots were placed into -80°C storage until further 
use. 130 aliquots of this material were dispensed which gave sufficient numbers for short and 
long-term stability studies as well as homogeneity determination. The remaining freeze dried 
material not dispensed was transferred to a vacuum bag, sealed and stored at -80°C. 
 
5.4.3 STABILITY AND HOMOGENEITY STUDIES 
The between-bottle homogeneity of the materials was assessed through the intra-batch 
analysis of 16 aliquots (3n
1/3
) selected through stratified random sampling of the entire fill 
series.  
The material was stability tested over a short term and long term period following a reverse 
isochronous experimental design [55] as in previous experiments. The short term study was 
conducted with triplicate samples consisting of five time points (0, 4, 7, 17 and 31 day) and 
three temperature conditions (-20°C, +4°C and +40°C). The long term study was conducted 
with triplicate samples consisting of five time points (0, 3, 6, 9 and 12 month) and three 
temperature conditions (-20°C, +4°C and +20°C). The reference temperature used in both 
studies was -80°C. In the case of all the stability studies; aliquots (n=3) were removed from -
80°C storage on the prescribed day and transferred to the storage conditions being 
investigated. 
At the end time point all samples were removed from storage, allowed to equilibrate to room 
temperature before removing the crimp seal and lyophilisation stopper. Immediately 0.75 ± 
0.01 g of each tissue was weighed out to minimise moisture uptake of the hygroscopic 
material. The tissues were reconstituted and extracted as described in Section 5.3.5. 
Analysis was carried out by preCOX LC-FLD closely following OMA AOAC 2005.06 [41] 
as detailed in Section 2.3.1. PCOX LC-FLD [75] analysis was additionally performed on all 
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samples to specifically investigate the extent of epimerisation, if any, of GTX2,3 in each 
material. For PCOX LC-FLD analysis, the crude acetic acid extracts prepared according to 
Section 2.3.1 were deproteinated and analysed following AOAC 2011.02 [75]. 
PST concentrations in sample extracts were quantified against a 4 - 5-point calibration for 
each toxin and are expressed in µmol/kg with total saxitoxin equivalents calculated as an 
estimation of total toxicity. 
The MC of these freeze dried tissues was not determined due to technical issues with the Karl 
Fischer apparatus which could not be rectified during the course of these studies. The 96 hour 
freeze drying programme, including material processing and dispensing techniques as 
detailed in Section 5.3 has previously demonstrated that materials can be produced with a MC 
of ~5% however. 
 
5.4.4 RESULTS AND DISCUSSION 
All the materials prepared in this section of the study were suitably homogenous for all the 
PSP toxins quantified, as evidenced through the coefficient of variances contained in Table 
5-8. The homogeneity techniques employed were therefore sufficient and the materials were 
suitable for the analytical study. 
Table 5-8: Homogeneity results for freeze dried material prepared using optimised 96 hour program (n=16). 
 
dcSTX GTX-2,3 GTX-5 STX 
Total 
Toxicity 
µg STX diHCl-eq. / kg 
Average 237.9 237.4 2.7 263.2 738.5 
Stdev 8.4 15.8 0.1 8.3 32 
%CV 3.5 6.7 4.4 3.2 4.3 
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5.4.4.1 SHORT-TERM STABILITY 
 
PRECOX LC-FLD 
Short-term stability graphs for dcSTX, STX, GTX-2,3, GTX1,4 and GTX-5 are presented in 
Figure 5-15. Results are normalised to the -80°C freezer mean on day zero and are presented 
with error bars of the standard deviation from the triplicate analyses. 
Excellent stability was demonstrated at -20°C and +4°C for all the toxins studied in this 
section with all data points falling within the limits of stability set. The PSTs dcSTX, STX, 
GTX1,4 and GTX5 also showed excellent stability when stored at +40°C in addition to the 
other conditions. Some slight instability issues were evident for GTX2,3 at this temperature 
condition with a slight increase in concentration observed after 17 days storage. This GTX2,3 
increase was not as pronounced as that observed in the control materials (Figure 4-8) which 
highlights the stability improvements this technique provides. 
The results provide evidence that the toxins would be stable during transportation, even at 
elevated temperatures of up to +40°C for 17 days. This has particular relevance for PT 
providers or suppliers of RMs where stability during transportation to participants or 
customers is critical. 
As discussed in the previous chapter, the role of bacteria could explain the slight increases in 
GTX2,3 concentration observed in freeze dried samples stored at +40°C through 
biotransformations [132]. GTX2,3 increases were also observed in the untreated control 
(Tissue C) materials as evidenced in Section 4.3.2.2.  
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Figure 5-15: Short-term stability graphs by preCOX LC-FLD for freeze dried material using optimised method. 
 
As evidenced from the short-term stability results above, freeze drying provides the best 
stability for both PSTs and the matrix itself compared to the other two techniques 
investigated or the untreated control (Figure 4-8) where stability issues at +40°C were 
evident. 
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PCOX LC-FLD 
Further analysis was conducted by PCOX LC-FLD on the short-term stability study extracts 
of each of the materials and results are presented in Figure 5-16 a-b. Limits of stability and 
normalised results were calculated as per the preCOX analysis above. Data for the toxins 
GTX1 and GTX4 were not generated as the concentration of these toxins in each material 
was <LOD of the PCOX LC-FLD method. 
No epimerization or degradation was observed in any materials when stored at -20°C or +4°C 
for the duration of the study with results falling within the limits of stability set. However 
epimerization was observed in materials stored at +40°C which became evident after 4 days 
of the study. As such, it would seem that tissue samples stabilised by freeze-drying only, 
would still need to be sent under temperature control conditions, if the end user required 
quantitation of individual epimers. These results were similar to those observed for Tissue A 
in Section 4.3.2.2 (where additives were used to stabilise the matrix) which shows no 
significant improvement freeze drying makes to epimerization rates in the short-term 
compared to additives spiking. Freeze drying does, however, improve stability compared to 
the untreated control (Tissue C, Section 4.3.2.2) where epimerization was also observed at 
+4°C in addition to the +40°C samples. 
Interestingly the thermally treated material (Tissue B) in Section 4.3.2.2 did not show any 
epimerization of GTX2 and GTX3 under any of the temperature conditions studied. GTX2 
remained stable throughout the study and GTX3 showed some slight degradation but 
epimerization of these toxins was not evidenced. This demonstrated the improvement that 
thermally treating materials has on epimerization rates and suggests this step could be 
performed in tandem with any other stabilisation technique being undertaken to combine the 
advantages of these various techniques. 
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Epimerization of these toxins followed predicted patterns with the β-epimer GTX3 being 
epimerized into the more stable α-form GTX2 [136] which was evident from both the short 
and long-term stability data generated through the PCOX LC-FLD analysis. 
 
 
Figure 5-16: Short and long-term stability data by PCOX LC-FLD for freeze dried material using the optimised method. 
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5.4.4.2 LONG-TERM STABILITY 
 
PRECOX LC-FLD 
Figure 5-17 a-e represents the long-term stability results for the freeze dried material at three 
different storage temperatures, -20°C, +4°C and +20°C, determined through preCOX LC-
FLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 and STX were generated and 
results were normalised to the average of replicate analysis (n=9) of samples stored at the 
reference temperature of -80°C for the duration of the study. The limits of stability from 
Figure 5-17 were generated from two times the standard deviation of the -80°C replicate 
analyses. 
The stability of all the toxins studied in this section was maintained for 9 months under all the 
temperature conditions, -20°C, +4°C and +20°C with no evidence for toxin 
biotransformations or degradation during this time. Interestingly by the last time point of the 
study (month 12) instability of dcSTX, STX and GTX5 was evident in samples under all 
storage conditions with data points falling outside the limits of stability set. GTX2,3 also 
showed the same drop in concentration in the month 12 samples under all temperature 
conditions although no data points fell outside the limits of stability. Conversely GTX1,4 
exhibited excellent stability throughout the yearlong study under all temperature conditions. 
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Figure 5-17: Long-term stability graphs by preCOX LC-FLD for freeze dried material using optimised method. 
 
The cause or causes of these instability issues for the non N-hydroxylated toxins in the month 
12 samples are unknown but may have been caused by an error in re-constituting the tissues 
prior to extraction. The concentrations of the N-hydroxylated toxins GTX1,4 after periodate 
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oxidation did not show the same decrease in concentration. The fact that all three temperature 
conditions degraded to approximately the same level in the case of each toxin is peculiar and 
could be indicative of a systematic error. Previous materials described in this thesis stabilised 
in multiple ways and indeed untreated control materials were all stable when stored at -20°C. 
The excellent stability exhibited by the freeze dried materials in the early part of the long-
term study also makes this sudden instability drop difficult to explain. The analysis of all the 
long-term stability samples was repeated using fresh reagents but results confirmed the 
instability issues in the month 12 samples. 
Freeze drying greatly improved toxin and matrix stability compared to the control material as 
can be seen from Figure 4-10. In particular the gonyautoxins 1-4 were completely degraded 
by month 3 of the study at +20°C in the control but remained stable in the freeze dried 
materials up to 9 months. Freeze drying also improved the stability of the other toxins present 
in these tissues compared to the untreated controls.  
In addition this technique showed improvements over additives spiking and heat treatment 
(Figure 4-10), particularly GTX1,4 in the heat treated and GTX2,3 in the additives spiked 
materials. This has proven freeze drying to be the most effective in stabilising the PSTs 
compared to additives spiked, heat treated or untreated controls as described in Section 4.3. 
 
PCOX LC-FLD 
Further analysis was conducted by PCOX LC-FLD on the long-term stability study extracts 
and results are presented in Figure 5-16 c-d. Limits of stability and normalised results were 
calculated as described for the preCOX analysis above.  
As in the case of the short-term study no epimerization or degradation was observed in the 
freeze dried materials stored at -20°C or +4°C for the duration of the study with results 
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falling within the limits of stability set. A small amount of epimerization was however 
observed in materials stored at +20°C which was evident after 12 months of the study. The 
only other instability issue observed at this temperature was a slight degradation of GTX3, 
evident after 3 months. 
Freeze drying significantly improved the stability of the PSTs compared to the untreated 
control (Tissue C) evident in Section 4.3.2.3 where these toxins were completely degraded by 
month 3 of the study at storage temperatures of +20°C. Improvements were also evident in 
samples stored at +4°C where epimerization of GTX2,3 was observed in Tissue C (Figure 
4-9) but these toxins remained stable in the freeze dried tissues for 12 months. Freeze drying 
also showed improvements in PST stability compared to materials spiked with additives 
(Tissue A) where epimerization of GTX2,3 could be observed after 3 months storage at +4°C 
and +20°C. 
Similar levels of stability were evident in the -20°C and +4°C freeze dried and heat treated 
(Tissue B) samples as described in Section 4.3.2.3. Although slight, the epimerization of 
GTX2,3 observed in the freeze dried materials after 12 months storage represented a minor 
deterioration in stability of toxin epimers compared to those heat treated where this 
phenomenon was not observed (Figure 4-9). Both stabilisation techniques did however show 
instability of GTX3 evident by the slight degradation of this toxin at +20°C (freeze dried) and 
+4°C (Heat treated) after 3 months. 
 
CHROMATOGRAPHIC STABILITY 
As in the case of the other techniques investigated, chromatographic stability of freeze dried 
materials, specifically those stored at +20°C was assessed in comparison to untreated control 
materials. Figure 5-18 a-f displays chromatograms generated by preCOX LC-FLD for the 
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freeze dried and untreated control (Tissue C) materials by both peroxide and periodate 
oxidation after 12 months storage at different temperatures. Chromatograms of the untreated 
control material stored at -80°C for 12 months are also shown in this figure as a visual 
comparison. 
The chromatograms generated following peroxide oxidation (Figure 5-18 a-c) show differing 
levels of stability, with the control material showing the total degradation of the toxins 
GTX2,3 by month 12 of the study. Conversely excellent GTX2,3 stability was evident in the 
freeze dried tissues stored at +20°C for 12 months with the chromatogram visually identical 
to that from the untreated control material stored at -80°C for 12 months (Figure 5-18 a+c). 
Additionally there was no visual evidence for the formation of additional chromatographic 
peaks from the freeze drying process itself.  
The chromatograms obtained following the analysis of periodate oxidised extracts used to 
quantify the N-hydroxylated toxins GTX1,4 are illustrated in Figure 5-18 d-f. Again freeze 
dried materials showed excellent chromatographic stability with the chromatogram identical 
to that observed in the untreated control stored at -80°C. The untreated control stored at 
+20°C for 12 months did not show good stability however with the chromatogram showing 
the total degradation of GTX1,4 (Figure 5-18 e). There was no visual evidence for the 
additional formation of any chromatographic peaks in the freeze dried chromatograms giving 
further evidence for the improvements this technique offers in stabilising the matrix.  
Chapter 5 
 
 
206 
 
 
Figure 5-18: Chromatograms of freeze dried and control materials under different storage conditions after peroxide or 
periodate oxidation and preCOX LC-FLD analysis. 
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5.4.5 CONCLUSIONS 
Similarly to the optimisation studies in section 5.3 freeze drying and the associated 
processing techniques developed at the MI produced homogeneous RMs with significant 
stability improvements in comparison to an untreated control as well as heat treatment and 
the use of preserving additives. Freeze drying also provided a more stable matrix as 
demonstrated by the chromatographic stability of samples stored at high temperatures. 
Whilst this study has shown compelling evidence for advantages with freeze drying, the 
technique does however require specialised equipment not readily accessible by most 
biotoxin laboratories. There is also the requirement for personnel with expertise in both the 
freeze drying process itself as well as the labour intensive processing techniques. The freeze 
drying process does also significantly alter the biological matrix compared with wet 
materials, so some researchers may debate whether such materials are ideally applicable for 
internal QC RM preparation. Materials treated by heat and chemical additives which were 
prepared from the same bulk homogenate, provide much more cost effective techniques albeit 
without providing materials with the same levels of toxin stability. Use of heat treatment or 
the preserving additives may be acceptable for the preparation of an internal QC material but 
freeze drying clearly provides a more appropriate tool for CRM production. 
Excellent short-term stability was demonstrated in these materials even at higher storage 
temperatures which indicates transport of these materials could be carried out at temperatures 
above freezing. This would provide a very significant advantage to the RM producer if 
transporting these materials globally. Long-term stability was also demonstrated by preCOX 
LC-FLD, although a potential anomaly was seen in the month 12 samples under all storage 
conditions which could not be definitively explained. 
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PCOX LC-FLD analysis of short and long-term stability study samples showed evidence for 
instability issues of GTX2,3 in the +40°C and +20°C stored samples respectively. 
Epimerization of these toxins was observed particularly in the +40°C samples in the short-
term studies with the rates of epimerization significantly reduced at +20°C in the long-term, 
thus demonstrating the significance of temperature on epimerization rates. The extent of 
epimerization of these toxins was less than that observed in the additives spiked material and 
untreated controls but interestingly heat treatment reduced these rates more than the freeze 
dried materials (Figure 4-9 a-d). This suggests that heat treating the materials prior to freeze 
drying may provide a more stable matrix less prone to epimerization issues. This 
experimental technique is described in the next section. 
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5.5 COMBINED FREEZE DRYING WITH THERMAL PRE-TREATMENT 
An additional experiment described in this section coupled this freeze drying technique with 
a thermal pre-treatment step in an effort to combine the superior stability of the PSTs 
observed in the freeze dried materials with the reduced epimerization rates of heat treated 
materials, as seen in Chapter 4. 
The material was prepared in combination with a study on the individual use of preserving 
additives together with an untreated control material as described in Chapter 4 (Section 4.2). 
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5.5.1 SOURCE TISSUES AND INITIAL TREATMENT 
The source tissues and quantities used to prepare this material can be seen in Table 4-1 and 
the preparation of this initial material is described in Section 4.2.1.1.  
The tissue was removed from the freezer, allowed to defrost in a fridge at +4°C overnight 
before being transferred to a 5L PP beaker. The beaker was covered with tin foil and sealed 
with autoclave tape, making small holes in the tinfoil lid to allow pressure release during the 
process. The tissue was autoclaved (K200E Touchclave, LTE, UK) at 121°C for 15 min, 
cooled in a fridge at +4°C before transferring 590 ± 1 g of the material to a 2L Waring™ 
goblet. The final weight was made up to 763 ± 1 g with DI water to adjust the final MC to 
~85% as the four day freeze drying programme was optimised with materials containing this 
level of moisture. The tissue was homogenised on medium power for 5.0 ± 0.1 min before 
dividing the slurry equally into two freeze drying trays at a tissue depth of ~1.0 ± 0.1 cm. The 
trays were covered with tinfoil and placed in a freezer at -20°C overnight. 
 
5.5.2 FREEZE DRYING AND MATERIAL PROCESSING 
The trays were removed from the freezer and placed into the freeze drier where the 96 hour 
programme as detailed in Table 5-5 was started. Upon completion of the freeze drying 
programme the material was removed from the instrument, processed and dispensed as 
described in Section 5.3.4. A total of 120 aliquots of this material were dispensed as 0.78 ± 
0.01 g portions (to ensure minimum retrieval of 0.75 g for extraction) and stored at -80°C 
until further use. 
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5.5.3 STABILITY AND HOMOGENEITY STUDIES 
The between-bottle homogeneity of the materials was assessed through the intra-batch 
analysis of 15 (3n
1/3
) aliquots selected through stratified random sampling of the entire fill 
series.  
All materials were stability tested over a short term (31 day) and long term (12 month) period 
following a reverse isochronous experimental design [55] as described previously. The short 
term study was conducted with triplicate samples consisting of five time points (0, 4, 8, 16 
and 31 day) and three temperature conditions (-20°C, +4°C and +40°C). The long term study 
was conducted with triplicate samples consisting of five time points (0, 3, 6, 9 and 12 month) 
and three temperature conditions (-20°C, +4°C and +20°C). The reference temperature used 
in both studies was -80°C. The stability studies were carried out as described in section 
4.2.1.4. 
At the end time point all samples were removed from storage, allowed to equilibrate to room 
temperature before removing the crimp seal and lyophilisation stopper. 0.75 ± 0.01 g of each 
tissue was weighed out immediately after the stopper was removed to minimise moisture 
uptake. The tissues were reconstituted and extracted as described in Section 5.3.5. 
Analysis was carried out by preCOX LC-FLD as per OMA AOAC 2005.06 [41] (Section 
2.3.1). PCOX LC-FLD [75] analysis was additionally performed on all samples to assess the 
presence of any epimerisation, if any, of GTX2,3 in each material. For PCOX LC-FLD 
analysis, the crude acetic acid extracts prepared according to Section 2.3.1 were deproteinated 
and analysed following AOAC 2011.02 [75]. 
PST concentrations in sample extracts were quantified against a 4 - 5-point calibration for 
each toxin and are expressed in µmol/kg with total saxitoxin equivalents calculated as an 
estimation of total toxicity. 
Chapter 5 
 
 
212 
 
The MC of these freeze dried tissues was not determined due to technical issues with the Karl 
Fischer apparatus which could not be rectified during the course of these studies. As 
determined in the optimisation studies in Section 5.3 however, the 96 hour freeze drying 
programme and associated processing and dispensing techniques produced materials with the 
required MC of ~5%. 
 
5.5.4 RESULTS AND DISCUSSION 
All the materials prepared in this section of the study were suitably homogenous for all the 
PSP toxins quantified, as evidenced through the coefficient of variances contained in Table 
5-9, which were all below 8%. The homogeneity techniques employed were therefore 
sufficient and the materials deemed suitable for the consequent study. 
Table 5-9: Homogeneity results from freeze dried material with thermal pre-treatment (n=15). 
 
dcSTX GTX2,3 GTX5 STX GTX1,4 
Total 
Toxicity 
 µg STX diHCl-eq. / kg 
Average 198.4 622.5 1.8 598.1 297.9 1718.7 
Stdev 5.6 43.6 0.1 15.2 22.2 57.1 
%CV 2.8 7.0 5.2 2.5 7.4 3.3 
Homogeneity results of Tissues 1-3 summarised in Table 4-4 compare similarly to those 
above which shows the stability of the PSTs subjected to freeze drying and thermal treatment. 
The total toxicity figures above and those of the untreated control (Tissue 3) show no 
significant toxin degradation occurred during the stabilisation processes. 
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5.5.4.1 SHORT-TERM STABILITY 
 
PRECOX LC-FLD 
Short-term stability graphs for dcSTX, STX, GTX2,3, GTX5 and GTX1,4 are presented in 
Figure 5-19 for the material prepared. Results are normalised to the -80°C freezer mean on 
day zero and are presented with error bars of the standard deviation from the triplicate 
analyses. 
Excellent stability was demonstrated at -20°C and +4°C for all the toxins studied in this 
section with all data points falling within the limits of stability set. There were some 
instability issues evidenced in samples stored at +40°C however, with dcSTX, STX, GTX2,3 
and GTX5 degrading slightly by the end of the study, as evidenced by data points falling 
outside the limits of stability. However, the calculated limits of stability, particularly for the 
toxins dcSTX, STX, and GTX5, were very tight. This was due to the low %CVs determined 
for materials stored at -80°C for the duration of the study from which these figures are 
calculated (n=9). GTX5 is also present at a very low concentration (~ 400 times less than the 
EU reg. limit) in these materials which is just above the LOQ of the preCOX LC-FLD 
method as determined through in-house validation (data not shown). GTX1,4 remained stable 
throughout the short-term study even at the elevated storage temperature of +40°C. The 
results therefore indicate again that transportation of these heat treated and freeze dried 
materials could be carried out under freezing or cooled storage conditions, but could not be 
conducted at room temperature safely. 
This combined technique also significantly improved the stability of the PSTs relative to an 
untreated control as well as antibiotic and anti-oxidant spiked materials as seen in Figure 4-3. 
These four materials were all prepared from the same bulk homogenate prepared in Section 
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4.2 so these materials can be compared for the levels of stability they provide. In terms of 
percentage difference of toxin degradation observed, this freeze drying technique with 
thermal pre-treatment provided better stability for dcSTX (9%), STX (8%) and GTX5 (48%) 
compared to the untreated control (Tissue 3) in samples stored at +40°C. 
Under the same temperature conditions the material also showed significant improvements 
over the use of antibiotics (Tissue 1) for all the PSTs except GTX2,3 where degradation of 
these toxins was observed in the freeze dried material but remained stable in the antibiotics 
spiked tissues. Similar levels of stability were observed in the antioxidant spiked material 
(Tissue 2) for the toxins dcSTX and STX but stability improvements were observed in the 
freeze dried materials for the gonyautoxins 1-5. 
The short-term stability results further emphasise the applicability of this technique in 
preparing RMs and the inclusion of a thermal pre-treatment step before freeze drying 
provides the same level of stability as freeze drying alone for most toxins, although GTX5 
showed slightly more instability issues.  
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Figure 5-19: Short-term stability graphs for PSTs present in the freeze dried material with thermal pre-treatment. 
 
PCOX LC-FLD 
Further analysis was conducted by PCOX LC-FLD on the short-term stability study extracts 
of each of the materials and results are presented in Figure 5-20 a-b. Limits of stability and 
normalised results were calculated as per the preCOX analysis. Data for the toxins GTX1 and 
GTX4 were not generated as the concentration of these toxins in each material was <LOD of 
the PCOX LC-FLD method. 
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No epimerization or degradation was observed in any materials when stored at -20°C or +4°C 
for the duration of the study with results falling within the limits of stability set. 
Epimerization was observed however in materials stored at +40°C, evident after 4 days of the 
study, which was similar to the observations made in the Section 5.4 for freeze drying alone. 
The epimerization rates were significantly reduced however in the thermally pre-treated 
materials which gives evidence for the benefits of combining the two techniques.  
Significant improvements were made over the untreated control (Tissue 3) as observed in 
Figure 4-4, with rates of epimerization reduced by ~40% in samples stored at +40°C and 
eliminated in samples stored at +4°C. Similarly this technique reduced epimerization rates in 
the antibiotic (Tissue 1) and the antioxidant (Tissue 2) spiked materials in the +40°C samples 
by ~15% in both cases. Epimerization was evident in the Tissue 1 and 2 materials stored at 
+4°C but this had been eliminated in the freeze dried material which again shows the 
advantages this technique provides. 
PCOX LC-FLD analysis of both the short and long-term stability study samples showed 
epimerisation of the β-epimer GTX3 into the more stable α-form GTX2 as expected [136]. 
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Figure 5-20: Short and long-term stability data by PCOX LC-FLD for freeze dried material with thermal pre-treatment step. 
 
5.5.4.2 LONG-TERM STABILITY 
 
PRECOX LC-FLD 
Long-term stability graphs for dcSTX, STX, GTX2,3, GTX5 and GTX1,4 are presented in 
Figure 5-21 for the material prepared in this section. Results were normalised to the -80°C 
freezer mean on day zero and are presented with error bars of the standard deviation from the 
triplicate analyses. 
Excellent toxin stability was exhibited in the freeze dried materials following the long-term 
study with none of the toxins investigated showing any signs of degradation even at the 
elevated storage temperature of +20°C. The data therefore provides evidence for the excellent 
long-term stability of these toxins in freeze dried materials which are thermally pre-treated. 
These materials could be stored at temperatures of up to +20°C without adversely affecting 
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PST content although long-term storage would always be recommended at temperatures 
below freezing. 
 
 
Figure 5-21: Long-term stability graphs for freeze dried material with thermal pre-treatment. 
 
The degradation of the toxins observed in the month 12 freeze dried samples from the 
previous section (Figure 5-17) was not evident in these materials. This shows either the 
improved stability of this combined technique or, as is more likely, the same anomaly 
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observed in that dataset was not repeated in the preparation and analysis of these dual-treated 
materials. 
The stability of the PSTs was greatly enhanced in these materials compared to the untreated 
control (Tissue 3, Section 4-2) apart from STX which displayed comparable stability to this 
material. This combined technique also showed better stability compared to the use of the 
antibiotics (Tissue 1) and antioxidant (Tissue 2) spiked materials from the same figure, 
particularly for the toxins GTX2,3 where significant increases (~30%) were observed in 
samples stored at +40°C. 
 
PCOX LC-FLD 
Further analysis was conducted by PCOX LC-FLD on the long-term stability study extracts 
of each of the materials and results are presented in Figure 5-20 c-d. Limits of stability and 
normalised results were calculated as per the preCOX analysis. 
No epimerization or degradation was observed in any materials when stored at -20°C, +4°C 
or +20°C for the duration of the long-term study with results falling within the limits of 
stability set. These results show the significant improvements the thermal pre-treatment step 
makes in reducing epimerization rates over an extended time period compared to freeze 
drying alone (Figure 5-16). This was particularly evident in the case of GTX3 which showed 
signs of degradation after month 3 of the study in materials prepared by freeze drying alone 
(Figure 5-16) with this toxin remaining stable for 12 months in the materials prepared by the 
combined techniques. 
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Significant improvements were made over the untreated control (Tissue 3) as observed in 
Figure 4-4, with rates of epimerization reduced by ~20% in samples stored at both +4°C and 
+20°C. This combined technique also significantly reduced epimerization rates compared to 
the antibiotics (Tissue 1) and antioxidant (Tissue 2) spiked materials by as much as 40% in 
the +20°C samples. 
 
CHROMATOGRAPHIC STABILITY 
The chromatographic stability of the combined freeze dried and thermally pre-treated 
material was assessed against an untreated control. Figure 5-22 a-f displays chromatograms 
generated by preCOX LC-FLD for the material described in this section and an untreated 
control (Tissue C, Section 4-2) by both peroxide and periodate oxidation after 12 months 
storage at different temperatures. Chromatograms of the untreated control material stored at -
80°C for 12 months are also shown in this figure as a visual comparison. 
The chromatograms generated through peroxide oxidation (Figure 5-22 a-c) show the 
excellent chromatographic stability of the freeze dried and thermally treated material stored at 
+20°C (a) compared to the control (c) stored at -80°C. There was no visual evidence for the 
formation of extra fluorescent components from the freeze drying process itself or from 
storage at this elevated temperature for 12 months. The control material stored at +20°C for 
12 months (b), while still maintaining the same toxin profile, did show evidence for the 
formation of extra chromatographic peaks between 2 – 7 min. Although this did not affect 
quantitation of any of the PSTs present in these materials, some of these peaks may be 
problematic in quantifying the C-toxins if they were present. 
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Figure 5-22: Chromatograms of freeze dried/thermally treated and control materials stored at different temperatures after 
peroxide and periodate oxidation and analysis by preCOX LC-FLD. 
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The periodate oxidised extract analysis used to quantify the N-hydroxylated toxins GTX1,4 
are illustrated in Figure 5-22 d-f. Again the freeze dried and thermally treated material stored 
at +20°C (d) showed excellent chromatographic stability with the chromatogram identical to 
that observed in the untreated control (f) stored at -80°C. There was no visual evidence for 
the additional formation of any chromatographic peaks in the freeze dried chromatograms 
giving further evidence for the improvements this technique gives in stabilising the matrix. 
The untreated control stored at +20°C for 12 months (e) showed the formation of two extra 
peaks in the chromatogram at ~6 min, although the toxin profile remained intact.  
 
5.5.5 CONCLUSIONS 
As demonstrated within this chapter, freeze drying is an excellent technique for preparing 
homogeneous PST RMs. Excellent stability has been observed over both short and long-term 
timeframes over a range of different temperatures. The application of a thermal treatment step 
to the source tissues prior to being freeze dried was successful in further lowering the rates of 
epimerization observed in materials prepared by freeze drying alone (Section 5-4). Both 
techniques stabilise PSTs and the matrix in different ways that combined, result in a 
procedure suitable for RM preparation. The thermal treatment of the materials sterilizes and 
therefore destroys most if not all bacteria in the source tissues which alone would produce a 
very stable material. The processing and dispensing steps are not carried out aseptically 
however so bacterial contamination of the aliquots during these steps is inevitable. The freeze 
drying of tissues lowers the water content of the final product creating an environment 
unsuitable for microbial growth. These combined techniques therefore result in the same 
desired outcome, lowering rates of degradation, epimerization or biotransformations, through 
different routes, sterilization and water removal. 
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This procedure could have specific application in the production of CRMs and is arguably the 
most appropriate technique investigated in this thesis for these purposes owing to the superior 
stability exhibited in those materials. 
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5.6 PREPARATION OF CANDIDATE PSP CRM 
The preparation of RMs, particularly those intended for internal QC, method development 
and validation use or for distribution to participants in PT exercises, can be performed 
adequately using one of the relatively simpler techniques described in Chapter 4. These 
techniques such as heat treatment or the use of preserving additives including all associated 
processing techniques have been shown successfully to produce homogenous materials, 
stable for their intended purposes. The preparation of these relatively small scale RMs does 
not therefore necessitate the use of freeze drying even with the advantages this technique 
affords the user. 
This labour intensive and significantly more costly technique does have applicability in the 
production of CRMs however where long-term stability of the toxins and matrix is of primary 
importance. CRM production is also generally carried out through dispensing large quantities 
of materials thus lowering the overall unit cost. 
The experiments conducted in this chapter so far have resulted in the development of an 
optimised freeze drying programme and processing technique that produces high quality 
homogeneous and stable materials. Using these optimised techniques a large scale freeze 
dried material was prepared in collaboration with CEFAS, UK as a candidate CRM. 
 
5.6.1 SOURCE TISSUES AND INITIAL TREATMENT 
The material was prepared from a naturally contaminated oyster tissue matrix which was 
produced through feeding experiments carried out in CEFAS facilities. The feeding 
experiments are detailed in Section 5.2.1. 
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Approximately 12 kg of homogenised oyster tissue in PP containers was sent to the MI in 
temperature controlled transport boxes. After receipt the PP containers were immediately 
transferred to a freezer at -20°C until further use. 
The tissues were initially removed from the freezer and allowed to defrost at +4°C before 
being transferred equally to 4 x 5 L PP beakers. The beakers were covered with tin foil and 
sealed with autoclave tape, making small holes in the tinfoil lid to allow pressure release 
during the process. The tissues were autoclaved (K200E Touchclave, LTE, UK) at 121°C for 
15 min, cooled in a fridge at +4°C before transferring to a 25 L PP bucket previously washed 
with Decon-90 (which contains a bactericide), followed by rinsing with DI water. 
The material was then homogenised using a Silverson BX batch mixer (Silverson, MA, USA) 
set on medium power for 30.0 ± 0.1 min (Figure 5-23). The bucket was placed in an ice-bath 
during mixing to prevent localised heating of the tissues through friction. 
 
 
Figure 5-23: Silverson BX batch mixer used to homogenise the oyster material prior to freeze drying. 
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Aliquots were taken for MC determination (n=3) using the rotary vacuum method and 
analysis by preCOX LC-FLD (n=1) as described in the materials and methods Section 2.4.1 
and 2.3.1 respectively, to give approximate PST concentrations in the bulk tissue. The bucket 
was sealed and stored in the fridge at +4°C until further use. 
The concentrations and MC of this tissue are summarised in Table 5-10. The levels 
determined for this tissue were at concentrations that would ensure the final freeze dried 
material would have total toxicity slightly higher than the current EU regulatory limit. This 
analysis also confirmed the profile of the material as containing most of the relevant PSTs. 
The MC determined was higher than the 85% normally used but the capacity of the freeze 
drier was sufficient for this quantity of water removal. 
Table 5-10: Concentrations of PSTs and MC of bulk tissue used to prepare candidate CRM. 
Material 
Concentration (µmol / kg) 
Total Toxicity                  
(µg STX diHCl-eq / kg) 
% 
Moisture 
Content dcGTX2,3 GTX-2,3 STX C1,2 GTX-1,4 NEO 
Oyster Tissue 
Homogenate  
0.74 0.48 0.31 0.23 1.94 0.72 1331 92.6 
 
5.6.2 FREEZE DRYING AND MATERIAL PROCESSING 
The container of tissue was removed from the fridge and re-homogenised using the Silverson 
BX batch mixer (Silverson, MA, USA) set on medium power for 5.0 ± 0.1 min. The 
homogenised slurry was then poured into seven freeze drying trays at a tissue depth of ~5 
mm, wrapped in tin foil and placed in a walk-in freezer at -20°C overnight. 
The trays were subsequently removed from the freezer and placed into the freeze drier where 
the 96 hour programme detailed in Table 5-5 was started. Upon completion of the freeze 
drying programme the material was removed from the instrument and the freeze dried tissue 
in each tray was manually cut up and transferred into a bag, vacuum sealed and stored at 
+4°C. The quantities of tissues pre and post freeze drying are contained in Table 5-11. 
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Table 5-11: Weights of wet and freeze dried tissues in preparation of candidate CRM. 
Freeze Drying 
Tray 
Weight of wet tissue slurry 
before freeze drying (kg) 
Weight of freeze 
dried material (kg) 
1 1.451 0.127 
2 1.388 0.123 
3 1.469 0.129 
4 1.396 0.126 
5 1.544 0.138 
6 1.472 0.132 
7 1.458 0.132 
Total 10.178 0.907 
 
As described in previous sections all equipment used to process and dispense the freeze dried 
materials was first washed in Decon-90 followed by rinsing in DI water. The equipment was 
placed in an oven at +40°C for ~4 hours to dry before being placed in a desiccator until 
further use.  
The freeze-dried material was processed in batches as follows: 
1. Two vacuum sealed bags of freeze dried tissue were taken and placed in the modified 
glove box, along with three large steel bowls containing 25 x 20 mm stainless steel balls 
and the 125 µm sieve, base plate and lid. 
2. The glove box lid was fitted and clamped and the exhaust valve opened. A cylinder of 
low moisture content argon was attached to the entry valve and the chamber was purged 
for ~5.0 ± 0.1 min before lowering the flow rate of argon. 
3. The vacuum bags of freeze dried material were opened and poured equally into the three 
milling bowls before placing the lids on top. 
4. The argon flow was stopped and the glove box lid removed. The milling bowls were 
taken and secured on the planetary ball mill (Retsch PM 100-Verder Group, The 
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Netherlands). The tissues were ground for 5.0 ± 0.1 min each before being placed back 
into the glove box. 
5. The glove box lid was fitted and clamped and the exhaust valve opened. The entry valve 
was opened and the chamber was purged for ~5.0 ± 0.1 min before lowering the flow rate 
of argon. The lids of the milling bowls were then removed and the contents of each bowl 
transferred to the 125µm sieve plate. The sieve lid was attached before opening the glove 
box. 
6. The material was placed on the motorised sieve shaker (Impact Test Equipment Ltd., 
UK) and covered with a plastic sheet, sealed with tape. A hose from a cylinder of low 
moisture argon was inserted into the sheet cover at the top of the sieve shaker, flushing 
the gas over the sieve plates. The freeze dried material was sieved for 30.0 ± 0.1 min 
before removing and placing back into the glove box. 
7. The chamber was purged with low moisture argon as described above before removing 
the sieve lid and 125µm sieve plate. The contents of the base plate were transferred to a 
vacuum bag before removing the glove box lid and vacuum sealing the bag. 
Steps 1 – 7 were repeated until all seven bags of freeze dried material had been processed 
which gave ~800 g of milled and sieved freeze dried tissue. 
The material was dispensed by transferring the amber glass vials from the dessicator into the 
glove box along with the freeze dried material, semi-automated powder dispenser and all 
other associated equipment required. The setup of the glove box is as appears in Figure 5-10. 
The glove box lid was fitted and clamped before purging the chamber with low moisture 
argon. The antistatic fan was turned on and the antistatic gun discharged to aid in dispensing 
the powders. The antistatic gun was discharged periodically throughout the dispensing 
process. 
Chapter 5 
 
 
229 
 
The vacuum bags containing the freeze dried materials were opened and transferred into a 
large PP container and continually mixed with a large spatula for 5.0 ± 0.1 min. The powder 
dispenser was calibrated to ~0.77 g aliquot sizes before the material was dispensed into pre-
labelled amber vials. After 588 aliquots had been dispensed, parafilm was placed over the 
beaker containing the remaining freeze dried material. The glove box lid was taken off and 
the amber vials were removed and placed on freeze drying trays. Lyophilisation stoppers 
were inserted halfway before placing the trays into the freeze drier. The door was sealed and 
the vacuum applied removing air from the chamber. A cylinder of low moisture argon was 
attached to the exhaust valve and a partial vacuum was released allowing argon to flow into 
the freeze drying chamber. The shelves were contracted which pushed the lyophilisation 
stoppers fully into the vials before releasing the remaining vacuum to atmosphere. The vials 
were removed and placed in boxes. 
Simultaneously to the aliquots being sealed above, empty amber vials were transferred from a 
desiccator to the glove box. The lid was put on and clamped, purging the chamber of air with 
low moisture argon and removing static build-up through use of the gun. The remaining 
material was dispensed before sealing the vials with lyophilisation stoppers as described 
above. All vials were further crimp sealed manually. 
A total of 1003 aliquots of this freeze dried material were dispensed and stored at -20°C. The 
vials were placed into boxes and transferred back to CEFAS facilities under cooled 
conditions.  
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5.6.3 ASSOCIATED STUDIES 
The stability and homogeneity studies have not been carried out on this material to date due 
to time constraints at the collaborators laboratory and the completion of another candidate 
PSP CRM stabilised through gamma irradiation [151,152]. The material is stored at -80°C 
until required for homogeneity, stability and/or certification studies. 
 
5.6.4 CONCLUSIONS 
Although no stability or homogeneity studies have been carried out on this material to date, 
the process does highlight the fact that facilities and techniques developed at the MI during 
the course of these studies are applicable in the preparation of medium scale freeze dried 
materials. 
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5.7 SUMMARY OF FINDINGS AND CONCLUSIONS 
This chapter has focused on the processing technique of freeze drying and its effects on PST 
and matrix stability for the preparation of RMs. Although this technique has previously been 
used to prepare a PST CRM it was never made commercially available. The previous study 
only covered one matrix, mussel, which contained two toxins, STX and dcSTX, and the 
freeze drying, processing and dispensing processes used were not detailed. Finally, the 
material was not prepared in parallel with an untreated control material to measure the 
effectiveness of the technique. 
For these reasons the technique of freeze drying was evaluated here specifically to ascertain 
the following: 
 The feasibility of preparing RMs by this method using MI facilities and evaluating 
multiple PSTs in a matrix other than mussel which had been previously studied. 
 Once the feasibility of carrying out this technique at the MI had been established, to 
optimise the process, including the freeze drying programme, processing and 
dispensing techniques and to determine the capabilities of the MI in terms of capacity. 
 Investigate issues arising from the initial feasibility study, specifically increased 
GTX2,3 concentrations observed in materials stored at higher temperatures. 
 Using the techniques developed, to prepare a relatively large scale freeze dried 
material as a candidate CRM. 
The initial feasibility study contained in Section 5.2 details the first biotoxin RM to be 
prepared in MI facilities and was successful in demonstrating the capabilities of equipment, 
which had been recently purchased by the MI, in preparing materials by this technique. This 
initial study confirmed freeze drying as a very effective technique in PST RM preparation 
which was carried out in a new matrix, and which contained multiple toxins, some of which 
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had not been previously evaluated. These initial studies did however highlight some stability 
issues, specifically increasing toxin concentrations, which were evident in both the short and 
long-term stability studies affecting the gonyautoxins1-4 and the C-toxins. Significant rates 
of epimerization were also observed in this initial material which affected all three pairs of 
epimers. 
The processing and dispensing techniques used to prepare these materials were then 
optimised in an effort to solve the issues highlighted above. Although the MC of this initial 
material was not determined as a KF apparatus was not available at the time of preparation, it 
seemed that moisture uptake by the highly hygroscopic material during the processing steps 
led to a final MC that was too high and therefore lead to the instability observed. This was 
due to various processing and dispensing steps being followed outside of moisture controlled 
conditions, i.e. outside of the glovebox purged with low moisture argon. 
The optimisation experiments therefore sought to develop the freeze drying process in order 
to minimise moisture uptake during the various stages of production. A KF apparatus was 
acquired for these optimisation studies and the resulting data demonstrated the suitability of 
the processing and dispensing techniques, as well as the specific freeze drying time 
programmes, to produce materials with the desired MC of ~5%. 
Two other freeze dried materials were prepared in tandem with studies on preserving 
additives and thermal treatment as detailed in Chapter 4. Full stability and homogeneity 
studies were carried out on these materials, specifically to determine if improvements were 
made from the feasibility studies, namely reduced rates of epimerization and a reduction or 
elimination of toxin biotransformations. The first material prepared by freeze drying alone 
improved the stability of the toxins, specifically increasing GTX2,3 and GTX1,4 
concentrations observed in the feasibility study materials was significantly reduced. These 
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stability improvements could be due to a lower MC in these materials compared to the 
feasibility materials although this could not be substantiated as technical difficulties with the 
KF apparatus prevented their MC being determined. The stability improvements could also 
be due to both studies being carried out in mussel and oyster tissue matrices respectively and 
the different bacterial loads each naturally contains. Although overall toxin stability was 
improved, epimerization rates were observed to take place at similar levels and to the same 
extent.  
For this reason a further technique was investigated which involved heat treating the 
materials prior to freeze drying. These techniques would combine the benefits of both, 
sterilization through heat treatment to destroy bacteria and freeze drying to lower the MC 
sufficiently to ensure conditions, for any remaining microbial activity, were as inhospitable as 
possible. The material prepared in this way showed improvements over materials previously 
prepared, specifically reducing epimerization rates over the long-term while providing the 
same level of overall toxin stability observed in materials prepared by freeze drying alone. 
Finally this chapter described the preparation of a material on a relatively large scale as a 
candidate CRM using the optimised freeze drying, processing and dispensing techniques 
developed, including initially thermally treating the materials. This material has not been 
characterised, assessed for homogeneity or stability or been certified to date. This is due to a 
gamma irradiated PST CRM being made commercially available during this time coupled to 
the fact that the biotoxin CRM market is relatively small. It is likely that the material will be 
assessed as a full CRM within the next 12 months (CEFAS, personal communication). 
From the studies contained in this chapter, freeze drying has proven to be the most effective 
technique for preparing PST RMs, providing superior stability to any of the other techniques 
investigated in the previous chapter. The applicability of the technique is, however, limited 
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solely to the preparation of CRMs and no other RM forms such as LRMs or ILRMs. This is 
due to the highly labour intensive process of freeze drying, processing and dispensing 
materials, as well as the large capital investment needed for all equipment which cost in 
excess of €250,000 in the case of the MI facilities. In terms of everyday usage in the case of 
general LRMs for internal QC/QA purposes, freeze drying would not represent a cost 
effective means of preparation and techniques such as the use of preserving additives or 
simple thermal treatment provide a better option for monitoring or research laboratories.  
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Chapter 6  
MATERIAL USE IN PROFICIENCY TESTING SCHEMES – 
QUASIMEME 
 
Chapter 6 details work described in Burrell et al. 2015, including extra data analysis not 
contained in the TrAC article. 
Stephen Burrell, Steven Crum, Barry Foley & Andrew D. Turner, 2015. Proficiency Testing 
of Laboratories for Paralytic Shellfish Poisoning Toxins in Shellfish by QUASIMEME: A 
Review. Trends in Analytical Chemistry. (Accepted Manuscript TRAC-D-15-00087) 
 
ACKNOWLEDGEMENT OF COLLABORATION 
The work in this section was carried out in collaboration with Mr. Steven Crum and Ms. Ann-
Marie Ryan at QUASIMEME. The RMs used in these exercises were all prepared by the 
author at MI facilities, including all associated homogeneity and stability studies. Materials 
were transported at -20°C to QUASIMEME facilities, Wageningen, The Netherlands where 
they were received by the collaborators and stored at -20°C until further use. All protocols 
and submission templates for results used by participants during these exercises were 
designed and written by the author. PT materials were packed and transported to participants 
by the collaborators. Participants submitted their results using an online share-point site 
operated by QUASIMEME after which the collaborators compiled all results for input into 
the Cofino software system. Participant data analysed using the Cofino model was then 
provided to the author for the analysis described in this chapter. 
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6.1 INTRODUCTION AND BACKGROUND 
As discussed in Chapter 1, an essential component in any effective monitoring program is the 
proper application of a quality management system, incorporating both quality assurance and 
quality control [153]. Proficiency testing (PT) plays a vital role in the implementation of 
these programs, and participation in these schemes is a requirement both legislatively in the 
EU [72,73] as well as by most national accreditation bodies. 
The stabilisation techniques described in Chapter 4, specifically the application of a thermal 
pre-treatment step prior to spiking with preserving additives was selected to prepare materials 
for use in these PT exercises. The techniques were chosen not only for the enhanced stability 
they provide the PSTs, especially during transport to participants laboratories, but also for the 
cost effectiveness of the preparation technique. This latter point was particularly important in 
the early rounds of this scheme in demonstrating the commercial viability of running this 
development exercise. For instance freeze drying would arguably provide superior PST 
stability but the unit cost to produce these materials in the quantities needed in these exercises 
would be too high to justify, which could jeopardise the sustainability of future exercises.  
Six rounds of PSP exercises have been delivered by QUASIMEME since 2009 with a wide 
array of different methodologies used by participants. 
 
6.1.1 METHODS OF ANALYSIS 
There are few internationally recognised methods available for determining PSP toxins and 
these have been discussed in Chapter 1. Participants of QUASIMEME exercises over the last 
six years have used a range of these plus other developed methods and the breakdown, 
including total numbers of subscribers in each round are detailed in Table 6-1. 
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Table 6-1: Total number of participants in each round including breakdown of methods used. 
Year Round 
Methods Used 
Total Number of 
Participants preCOX PCOX MBA ELISA LC-MS/MS 
2009 57 8 2 4 - - 14 
2010 61 9 5 2 - - 16 
2011 65 8 5 4 2* - 19 
2012 69 9 5 2 - - 16 
2013 72 13 6 2 - 1 22 
2014 2014-1 13 5 2 - 3 23 
*Ridascreen ELISA used by participants           
 
The methods used by QUASIMEME participants are described in section 1.8, including some 
of the major drawbacks and advantages of each method. The majority of QUASIMEME 
participants have used preCOX LC-FLD methods since these exercises began. Participation 
in these exercises is predominated by EU laboratories with approximately 60% of total 
subscriptions coming from this region. Two preCOX methods have been used to date with 
most participants using OMA AOAC 2005.06 [41]. The second closely-related method, used 
by one participant in 2014 is that described by the European Committee for Standardisation 
(CEN) and was recently published as European standard DIN EN 14526 [154]. Both methods 
involve the oxidation of toxins into iminopurine derivatives before separation and 
determination by LC-FLD. Participants using PCOX methods of analysis have increased 
since the start of this development exercise and numbers have remained steady in the 
intervening years. Most PCOX participants have used OMA AOAC 2011.02 [75] to 
determine the toxicity of QUASIMEME samples. One participant (Lab 5) used the original 
PCOX method developed by Oshima [17] for the first three years, 2009-2011. This lab did 
not submit results during the subsequent two years but submitted results again in 2014 using 
OMA AOAC 2011.02 (Table 6-4). The complexities in accurate identification of these toxins 
using either preCOX or PCOX methods are discussed in Chapter 1. To illustrate these 
complexities example chromatograms of a sample used in these exercises are contained in 
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Figure 6-1 a-d. Participants using mass spectrometry for determining PSP toxins have only 
recently submitted results using this technique in 2013 and 2014. 
 
Figure 6-1: Chromatograms of Tissue B (QST076BT, 095BT & 133BT) obtained by a) preCOX LC-FLD analysis of 
fraction 2 obtained after carboxylic acid solid phase extraction (SPE), periodate oxidised, b) preCOX LC-FLD analysis of 
C18 SPE cleaned, peroxide oxidised, c) PCOX LC-FLD analysis of GTX/STX toxins and d) PCOX LC-FLD analysis of C-
toxins. 
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6.1.2 TOXICITY EQUIVALENCY FACTORS (TEFS)  
The PSP analogues differ substantially in their toxicity and their TEFs have been derived 
from MBA data. Table 1-1 lists the TEFs reported by Oshima et al. in 1995 [17] alongside 
values compiled by the Scientific Panel on Contaminants in the Food Chain (CONTAM) of 
the European Food Safety Authority (EFSA) in 2009 [6]. The two sets of data are similar 
with the exception of dcSTX where the TEF was increased to 1.0 from 0.5131 by the 
CONTAM panel. This change would significantly affect reported total toxicities of samples 
with dcSTX as the predominant toxin present which is the case in some of the samples 
supplied by QUASIMEME. The implications of these differences are discussed in detail 
below. 
 
6.1.3 STATISTICAL METHODS FOR THE ASSESSMENT OF PROFICIENCY TESTING 
PERFORMANCE 
The assessment of laboratory performance or PT data has historically been carried out using 
ISO guide 5725: Accuracy (trueness and precision) of measurement methods and results, to 
obtain an estimate of the mean and the uncertainty of the measurement [155]. The standard 
makes the assumption that values are normally distributed and there is an equal within-
laboratory variance, and it was developed for PT studies where participants were required to 
use the same protocol. Due to the nature of PT schemes where different analytical methods 
are used, data is very often non-normally distributed and may be either positively or 
negatively skewed or bi- or multi-modal. 
Laboratories in PT studies should, in principle only participate when their methods are fully 
validated and statistically controlled and under these circumstances datasets are then 
normally distributed. QUASIMEME exercises generally have world-wide participation and 
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therefore methodologies and standards may differ between countries which may give rise to 
systematic differences in the datasets. 
In an effort to overcome issues associated with non-normally distributed data, robust statistics 
have been applied to data from PT schemes. Robust statistics are statistical methods which 
perform well for data from a wide range of probability distributions, particularly non-
normally distributed datasets containing a small number of outliers. Extreme values are not 
discarded as outliers with this approach and are down weighted to minimise the effect on the 
entire dataset. This approach works well with datasets that have 7-10% of extreme values or 
even highly skewed datasets but the robust means may be affected in datasets containing a 
small number of values (< 10) or a larger proportion of extreme values [156]. This 
breakdown in the robust model is caused by the group of down weighted values forming their 
own cluster which influences the magnitude of both the robust mean and standard deviation. 
Extreme values can generally be traced back to gross reporting errors by participants or the 
use of incorrect units and these errors can generally be identified from the dataset or through 
contact with the laboratory. Removing these extreme values adds a subjective element into 
the evaluation which the robust model sought to avoid. 
 
6.1.4 QUASIMEME’S COFINO MODEL FOR DATA ASSESSMENT 
The data assessment carried out by QUASIMEME is based on ISO guide 13528 concerning 
the proficiency testing of analytical chemistry laboratories [157] with some slight 
modifications. The assigned value and z-scores are calculated using a model developed by 
Cofino et al. [158] which was specifically designed for use in the determination of population 
characteristics [159]. Robust statistics form the basis to the ISO13528 guide to data 
assessment but this model can be limited where a high percentage of extreme values are 
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submitted. The Cofino model is unique as it can be used directly with a whole range of 
datasets including tailing or skewed data, datasets containing extreme outliers and bimodal or 
multimodal distributions. 
The model works by identifying clusters of data within a dataset exhibiting a high level of 
agreement. From this the mean, standard deviation (s.d.) and percentage of data associated 
with each cluster is calculated. A distinct advantage this model has over the standard robust 
model is that no preparation of the dataset is necessary, either by using subjective boundaries 
or outlier testing before entering it into the database for assessment. 
The Cofino model uses the concept of wavefunctions from quantum mechanics and applies 
them utilising the power of matrix algebra. The model uses probability density functions for 
each observation weighting values centred around the mean more heavily than those further 
away from the mean. The mean and variance estimators derived from this model are less 
sensitive to asymmetric, tailing datasets. The detailed, graphical information provided by the 
model can be seen in Figure 6-2 and the derivation of each is described in the QUASIMEME 
handbook [159]. The graphical information includes: 
-A plot of the population density functions (Figure 6-2a). 
-Matrix overlap (Kilt) plot which is a colour density plot very sensitive to identifying the 
structure of data, especially modality (Figure 6-2 b). 
-A ranked overview of the means and standard deviations of each data set (Figure 6-2 c). 
-Z-score plot for reviewing performance against targets (Figure 6-2 d). 
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Figure 6-2: Data plots for the toxin dcSTX found in sample QST132BT in 2012. a) Summed probability density functions 
(PDFs) for all data (black line) and for the first mode, PMF1, (blue line) with histogram of individual measurements in grey. 
Each observation from a participant is described by a PDF and is not regarded as a value using the Cofino model. b) The 
Kilt plot (Overlap matrix) showing degree of overlap of each pair of data. Areas of the map coloured white indicate 
complete overlap (agreement) for the observations concerned while black indicates no overlap. c) Ranked overview of all 
data with error bars of ± 2 s.d. d) Ranked z-score plot for all data. 
 
6.2 MATERIALS AND METHODS 
All materials were prepared by the author and designed to test the performance of 
QUASIMEME participant methods with the analysis of a wide variety of analytes, whilst 
minimising the number of samples to be tested. Materials incorporated a range of toxin 
concentration levels and different complexities in toxin profile composition. The shellfish 
tissues used were naturally contaminated with a range of different PSP toxins and prepared 
following in-house procedures to ensure homogeneity. Stabilisation of the toxins and 
matrices was achieved using a combination of heat treatment and the addition of antibiotics 
and an antioxidant [60,113] with short-term stability and homogeneity studies performed on 
all materials before distribution to participants [51]. 
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 A total of eight materials have been used over the six exercises 2009-2014, with Tissues A & 
C being incorporated into four rounds each, Tissues B & D used in three rounds, Tissue E 
used in two rounds and Tissues F, G & H used in one round only. Table 6-2 lists each of the 
materials and the rounds in which they were used, the assigned codes, predominant toxins 
present, matrices studied and the homogeneity results determined. The coefficients of 
variation were calculated from the homogeneity data in Table 6-2 and compared to expected 
levels of method variability determined through validation of the test method, below which 
the RM was deemed sufficiently homogenous. 
The exercises are true proficiency tests, meaning no standardised method protocol was 
provided by QUASIMEME and participants were requested to use the analytical method 
routinely employed at their laboratories. The only stipulation in the protocol was the use of 
the TEFs supplied and these were requested to be used in total toxicity calculations. In 2009 
(R57) and 2010 (R61), the TEFs supplied in the protocol were those reported by Oshima 
[17], while in 2011 (R65), 2012 (R69), 2013 (R72) and 2014 (R 2014-1) TEFs recommended 
by EFSA [6] were prescribed in the protocol (Table 1-1).  
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Table 6-2: List of materials used in each exercise, assigned codes, predominant toxins present, matrices studied and homogeneity results. 
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The format of the data submitted by participants is dependent upon the method employed for 
material testing. All participants are required to submit a total toxicity result for each sample, 
enabling the assessment and comparison of all methodologies. Participants using either the 
preCOX, PCOX or LC-MS/MS methods were able to submit concentration data for 
individual analogues, thereby enabling the assessment of performance for each individual 
toxin, or epimeric pair, in addition to total toxicity. This allows participants receiving less 
than satisfactory z-scores to pinpoint potential causes of method failure or operator error, if 
they relate to the determination of a particular analogue. 
 
6.3 INTERCOMPARISON RESULTS  
Up to 23 laboratories submitted data over the six exercises and Table 6-3 summarises these 
results. The table contains assigned values for each determinand and/or total toxicity, the 
number of observations or participant submissions for each determinand as well as between-
laboratory CV (%) and percentage of participants receiving satisfactory z-scores. The 
performance of laboratories was not assessed in cases where an assigned value could not be 
calculated. In these cases an indicative value was generated and no z-scores were calculated. 
Only materials where assigned values could be calculated are listed in Table 6-3. The criteria 
set out in calculating an assigned value and z-scores are contained in the QUASIMEME 
manual [159]. 
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Table 6-3: Summary data 2009-2014 
 
N.B. Codes used in table. Assigned Value, Numbers of Observations / Coefficient of Variation % (CV%), % z-scores satisfactory (|z| < 2).
Chapter 6 
 
 
247 
 
Figure 6-3 and Figure 6-5 graphically represent z-scores generated over the last six exercises 
with calculated upper and lower z-score limits for satisfactory (z ≤ |2|), questionable (z > |2| ≤ 
|3|) and unsatisfactory (z ≥ |3|) data.  
A list of the methods used by participants since 2009, including references where possible, is 
detailed in Table 6-4. It should be noted that participants 3 and 8 changed from using the 
MBA as their method of analysis in R57 (2009) to using preCOX and PCOX methods 
respectively, when they next participated in 2010 and 2011. 
 
6.3.1 TISSUE A 
This tissue was prepared at approximately half the EU regulatory limit, which is just above 
the limit of detection for the MBA and was designed to test participants at a low 
concentration level with a relatively simple toxin profile containing 3 predominant analogues. 
From the data contained in Table 6-3, 14-22 labs submitted total toxicity results in the four 
rounds this material has been used, R57, 61, 69 and 2014-1. Only total toxicity results were 
submitted in R57, while in R61, 69 and 2014-1 toxin concentrations were also requested. The 
assigned values for total toxicity showed some variability over the four rounds with 
concentrations of 461, 400, 629 and 750 µg STX diHCl-eq./kg being assigned respectively. 
This variability can mainly be attributed to changes made to the protocol which prescribed 
the use of Oshima TEFs in R57 and 61 and the use of EFSA recommended TEFs in R69 and 
2014-1. DcSTX is the predominant toxin present in this tissue so the increased TEF value 
significantly affected total toxicity results submitted, which can be clearly seen from Figure 
6-4. The precision of the participants, expressed by the between laboratory CV% has 
exhibited variability over the four rounds with values of 34.7, 44.4, 18.3 and 32.5% 
respectively.
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Figure 6-3: Distribution of participants’ z-scores for Tissues A-C used in various rounds from 2009-2014. 
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Table 6-4: Overview of methods used from 2009-2014 with references where applicable. 
 
2009 2010 2011 2012 2013 2014
1 1 1 1 1 1 1
2 1 1 1 1 1 1
3 2 - 1 1 1 1
4 2 2 2 2 2 2
5 3 3 3 - - 4
6 1 1 1 1 1 1
7 1 1 1 1 1 1
8 2 4 4 4 4 4
9 1 1 1 1 1 -
10 1 1 - 1 1 1
11 1 1 1 1 1 -
12 4 - - - - -
13 2 2 2 - - -
14 - 1 - - - -
15 4 4 4 4 4 4
16 - 4 - - 4 4
17 - 1 1 1 1 1
18 - 4 4 4 - -
19 - - 4 4 4 4
20 - - - 4 - -
21 - - 5 - - -
22 - - 2 2 - -
23 - - 2 - - -
24 - - 5 - - -
25 - - - - 4 -
26 - - - - 1 1
27 - - - - 6 6
28 - - - - - 6
29 - - - - - 1
30 - - - - - 6
31 - - - - - 1
32 - - - - - 7
33 - - - - - 1
34 - - - - - 1
35 - - - - - 2
Codes: 1. OMA AOAC 2005.06
2. OMA AOAC 959.08
3. Oshima (PCOX)
4. OMA AOAC 2011.02
5. ELISA (Ridascreen)
6. LC-MS-MS Internal method
7. DIN EN 14526
Method Used
Lab Number
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6.3.2 TISSUE B 
This material was prepared at approximately 1.2 times the EU regulatory limit and had a 
more complicated toxin profile than tissue A containing 9 predominant PSP analogues. 
14-15 labs submitted total toxicity results for this material in R57, 61 and 69 with assigned 
values in each round of 977, 950 and 986 µgSTXdiHCl-eq./kg respectively. The assigned 
values for the three rounds were consistent, even with the change to the prescribed TEFs 
made for R69. This is due to dcSTX being present in much lower quantities in this material 
compared to Tissue A which therefore has a lower overall effect on the assigned value. The 
improvement of participants over the three rounds was evident from the laboratory precision 
values of 43.8, 36.0 and 31.7 CV% respectively. 
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Figure 6-4: Assigned values determined in multiple rounds for Tissues A-E and in single rounds for Tissues F-H. 
 
6.3.3 TISSUE C 
This material was prepared at approximately 3 times the EU regulatory limit and although 
only containing 4 predominant analogues it represented a significantly more challenging 
toxin profile for participants using chemical based methods of analysis due to the presence of 
dcNEO and other decarbamoyl toxins. 
Up to 22 labs submitted total toxicity results for this material in R61, 65, 69 and 2014-1 with 
assigned values of 1886, 2670, 2734 and 3045 µgSTXdiHCl-eq./kg respectively. The 
increase in the assigned value from R61 to those calculated in R65, 69 and 2014-1 can, as in 
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the case of Tissue A, be attributed to the change in TEF values prescribed in these later 
rounds. The between lab %CVs over these four rounds were 45.4, 19.4, 19.0 and 22.1% 
which showed significant improvements from this materials early use. 
It is interesting to note that in R2014-1 (Table 6-3) the assigned values for dcGTX2 (11.20 
µmol/kg) and dcGTX3 (3.07 µmol/kg), generated from PCOX users data produces a 
significantly higher result if summed together (14.27 µmol/kg) when compared to the 
assigned value for dcGTX2,3 together (10.20µmol/kg) which was generated from preCOX 
users only. This along with the data for GTX2 and GTX3 (see Tissues D, E, G & H) suggest 
that both LC-FLD methods are not comparable when determining these epimer pairs. 
Previous studies carried out by the EU-RLMB to extend the validation of AOAC 2005.06 to 
include dcGTX2,3 found low mean recoveries (53 – 59%) from spiked mussel and clam 
tissues using this method [139]. A single laboratory validation to refine and extend the 
preCOX AOAC 2005.06 method to include additional toxins also showed differences 
between both LC-FLD methods in determining dcGTX2,3 [120]. This may explain some of 
the differences found between the dcGTX2,3 results generated by both LC-FLD methods 
above. An interlaboratory ring trial organised by CEFAS in 2011/2012 showed statistically 
significant differences between both methods in determining GTX2,3 with results generated 
by PCOX LC-FLD ~50% higher than those determined by preCOX LC-FLD [151]. This 
study did not include the toxins dcGTX2,3. 
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Figure 6-5: Distribution of participants’ z-scores for Tissues D-F used in various rounds from 2011-2014.
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6.3.4 TISSUE D 
The material was prepared at approximately 1.5 times the EU regulatory limit and 
represented a simple toxin profile for the participants, containing just STX and GTX2,3.  
Up to 21 labs submitted total toxicity results for this material in R65, 72 and 2014-1 with 
values of 1139, 1245 and 1289 µgSTXdiHCl-eq./kg assigned in each round respectively. The 
improvement in laboratory precision was again evidenced by the decrease in between 
laboratory CV% of 29.8, 10.6 and 16.6% observed over the three rounds. 
As in the case of Tissue C the individual assigned values for GTX2 and GTX3 in 2013 and 
2014 were significantly higher than those for GTX2,3 together submitted by preCOX users 
only. 
 
6.3.5 TISSUE E 
This material was prepared at approximately 1.5 times the EU regulatory limit and again 
represented a relatively simple toxin profile of only 4 predominant analogues (STX, dcSTX 
and GTX2,3). 
Up to 19 labs submitted total toxicity results for this material in R65 and 72 with assigned 
values in each round of 1187 and 1246 µgSTXdiHCl-eq./kg respectively. Improvement in 
laboratory performance was again evidenced in the CV% decreasing from 27.0% to 16.9% 
over the two year period. 
In 2013, where enough data was available to enable the generation of assigned values for 
GTX2 and GTX3 separately, these results were significantly higher than the total GTX2,3 
concentrations generated by preCOX users. 
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6.3.6 TISSUES F, G & H 
Tissues F and G were both prepared around the EU regulatory limit and Tissue H was 
prepared at approximately twice this level. All three tissues contained 6 predominant 
analogues (STX, dcSTX, GTX2,3, GTX4, NEO). 
15 labs submitted data for Tissue F in R69, 17 labs submitted data for Tissue G in R72 and 22 
labs submitted data for Tissue H in R2014-1. Values of 789, 742 and 1569 µgSTXdiHCl-
eq./kg were assigned to each material respectively in the three rounds with between lab CV% 
of 38.0, 18.6 and 15.3%. 
As previously seen in Tissue E the assigned values for GTX2 & GTX3 in Tissues G & H 
were significantly higher when summed together, than those determined as GTX2,3 together 
from participants reporting preCOX data. 
 
6.4 DISCUSSION 
 
6.4.1 IDENTIFICATION OF POOR PERFORMANCE 
The source or sources of poor performance in PT schemes can be difficult to pinpoint for 
both the participant and organiser. While it is possible to see where an inappropriate method 
has been used or the application of the method has not been carried out correctly, for example 
ELISA determination of Tissues D and E significantly overestimating total toxicity (Figure 
6-5), finding correlations between method choice and analytical performance is very difficult 
even with the large amount of data submitted by participants over the last six years. This is 
mainly due to the large number of variabilities potentially influencing PST analysis and 
results, for example changes to staff and associated training, reagents used, slight variations 
in the oxidation of toxins, and a range of other factors. 
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The majority of extreme z-scores (z ≥|6|) achieved by participants can be traced back to either 
gross calculation errors made during the conversion of concentration data into total sample 
toxicities (in some cases 2-3 orders of magnitude difference) or the misidentification of 
toxins present in chromatographic data. Adequate training of personnel, particularly new 
employees, in-house validation of methods and a comprehensive review process prior to 
submission of PT results is therefore of huge importance and would minimise, if not 
eliminate these extreme results. Experienced laboratories can also suffer from variable 
performance levels due to the recruitment of new staff requiring training or the 
implementation of new methodologies and instrumentation. 
While the causes of extreme z-scores are in general easier for participants to trace and 
remedy, unsatisfactory z-scores (z >|3 |<|6|) are a lot more difficult to account for. New 
participants to these schemes typically take two to three exercises before receiving 
satisfactory z-scores, the exact causes of which are unknown but are most likely because of 
their unfamiliarity with the submission process, reporting units requested, and analysing toxin 
profiles atypical of the participant’s geographical location. This can be seen in Figure 6-3, 
particularly for laboratories 1, 2 and 4 where initial unsatisfactory z-scores received in the 
first round were improved in subsequent exercises. The opposite of this can also be the case 
however (see laboratory 5 in Figure 6-3) therefore participants have to be continually vigilant 
to ensure satisfactory performances are maintained. 
 
6.4.2 FACTORS AFFECTING POOR PERFORMANCE 
Previous PT schemes, ring trials and interlaboratory studies for PSP toxins have highlighted 
issues related to each of the methods used [151,160–162]. The MBA is known to suffer from 
recovery issues caused by “salt” effects [160] and the presence of some metals, particularly 
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zinc can have a large suppressive effect on the bioassay [77] with underestimation of total 
toxicity particularly in samples close to the EU regulatory limit. These observations could 
explain some of the MBA results returned by participants in particular Tissues B-E where 
results were consistently below the assigned value (24 of 27 in total) with some results ~60% 
below the assigned value. 
The choice of extraction method can also have a fundamental influence on results, with 
previous studies showing that under boiling HCl conditions (MBA & PCOX methods), 
partial hydrolysis of the N-sulfocarbamoyl toxins, GTX-5 and C-1,2 transformed them into 
their carbamoyl counterparts, STX and GTX-2,3 respectively [162]. It was noted however 
that the N-sulfocarbamoyl toxins were not present at concentrations high enough to 
significantly contribute to the variability associated with the dataset. 
Other factors which may cause poor performance could include but are not limited to the use 
of inappropriate consumables, inter-batch performance of SPE cartridges or batch to batch 
issues with chromatographic columns which may cause retention and matrix issues. 
 
6.4.3 CRMS 
The lack of certified reference materials (CRMs), both solvent and matrix for all the PSP 
toxins is a problem consistently highlighted in the area, although a matrix CRM has recently 
been produced by CEFAS [152]. This lack of CRMs, particularly for the toxins GTX6 and 
C3,4, although not present in any QUASIMEME samples to date, has highlighted problems 
in the PT schemes delivered by the EU Reference Laboratory for Marine Biotoxins (EURL-
MB) [163,164]. Participants using preCOX methods can perform a hydrolysis step converting 
GTX6 into NEO and C3,4 into GTX1,4 which allows an indirect means of quantification for 
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those toxins. Although the toxicity of GTX6 is relatively low it can still contribute 
significantly to the overall toxicity of some samples [87]. 
 
6.4.4 MISIDENTIFICATION OF TOXINS 
The misidentification of toxins, particularly dcNEO, has been an issue for some participants 
and has been a source of poor performance in these exercises (see Tissue C in Figure 6-3). 
The dcNEO misidentification was particularly highlighted in the analysis of Tissue C. Users 
of PCOX methods of analysis identify this toxin as NEO due to the methods inability to 
separate both toxins unless a very long run time is utilised (>60mins). This is an accepted 
limitation of the PCOX method and presents no consumer risk in a real sample scenario 
owing to the 10-fold difference in TEF values between the two toxins. It can potentially lead 
to a significant over estimation of total toxicity owing to the differences in TEF however, and 
for the most part resulted in participants receiving unsatisfactory or extreme z-scores. This 
was not always the case however as some laboratories received satisfactory z-scores even 
with dcNEO misidentified, (see Lab 8 & 15 in 2011, 2012 and 2014 for Tissue C, Figure 
6-3). The analysis of dcNEO can also pose problems to preCOX participants as this toxin co-
elutes with dcSTX, requiring a back calculation in order to estimate toxicity. Only two 
preCOX participants (Lab 11 & 14) have failed to correctly identify dcNEO as being present 
in Tissue C. Lab 11 received an unsatisfactory z-score for this sample while Lab 14 received 
a satisfactory z-score as they significantly overestimated the dcSTX content in the sample, 
negating the fact that dcNEO was not quantified. In subsequent rounds Lab 11 correctly 
identified dcNEO in this sample and received satisfactory z-scores. Lab 14 did not participate 
in subsequent rounds. As no data is removed by QUASIMEME before assigned values and z-
scores are calculated, the onus is on participants to have a comprehensive review process of 
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final reports and z-score results to ensure that correct identification of all toxins present in the 
materials has been achieved.  
 
6.4.5 RECOVERY CORRECTION FACTORS 
The application of method recovery correction factors to results generated from preCOX 
analysis is an important issue and has been high on the agenda of the EURL-MB Working 
Group for PSP toxins over the last number of years. Only one QUASIMEME participant has 
submitted both non-recovery corrected (Lab 10) and recovery corrected (Lab 26) results in 
2013 and 2014 (Figure 6-3 & Figure 6-4), with none of the recovery corrected results 
receiving satisfactory z-scores in either round. This observation is not surprising as the 
assigned values (from which z-scores are calculated) generated for each tissue are calculated 
from the group which is weighted more heavily by non-recovery correcting participants. 
Applying recovery correction factors prior to submission of results would need to be 
stipulated in future protocols in order to ensure all participants carry out this procedure. 
 
6.4.6 METHOD DEPENDENCY AND INDIVIDUAL ANALOGUES 
Finding correlations between proficiency test performance and method choice or between 
performance and the presence of specific analogues in test samples is difficult. For instance 
the plot of the population density functions in Figure 6-6 (left) clearly shows a bi-modal 
distribution of the data in the determination of dcSTX in sample QST132BT with the smaller 
mode PMF2 (circled red) resulting from PCOX users (3 Labs). The main mode of data 
(PMF1) was shown to arise from the remaining preCOX users, although one PCOX 
participant is also contained in this main mode of data. Another sample, QST133BT used in 
the same round also showed a bimodal distribution in the determination of dcSTX (data not 
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shown). It might be easy to deduce from this and the Kilt plot (Figure 6-6 right) that there is a 
method dependency issue between both LC-FLD methods relating to the analysis of dcSTX. 
This trend however, is not consistent, as the analysis of the same two samples in 2009 and 
2010 showed no bi-modality for this toxin with the entire data set fitting a Gaussian 
distribution and results from PCOX users randomly spread throughout the entire series. 
Furthermore other samples used in these exercises that contained dcSTX showed no bi-
modality in their distributions. 
ELISA results showed variable performance levels with the only analysis of Tissue C (Lab 
24, Figure 6-3) by this method producing a satisfactory z-score, whereas ELISA analysis 
carried out on Tissues D and E (Lab 21 & 24, Figure 6-5) produced all extreme z-scores (>6). 
Tissues D and E contain the toxins GTX2,3 and STX, with Tissue E also containing dcSTX. 
This profile is relatively simple and would represent a fairly standard North European profile 
so the ELISA results if not pertaining to analyst or submission errors should be further 
investigated. 
Although LC-MS/MS has not been used extensively in PSP PT schemes to date, results 
generated by this method are encouraging with only one unsatisfactory result submitted to 
date with most receiving satisfactory z-scores. LC-MS/MS participants have also 
demonstrated the applicability of their methods to cover a variety of different toxin profiles 
with satisfactory results received from a range of different samples [165]. 
Although we have attempted to look for correlations between method choice and 
performance, no obvious or consistent patterns could be discerned from any of the PSP PT 
rounds completed to date. 
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Figure 6-6: Graphical output from the Cofino model with population measurement function (left) and kilt plot (right) 
showing two modes of data in the analysis of dcSTX in 2012. 
 
6.4.7 PERFORMANCE IMPROVEMENTS 
Overall, the development of this exercise and the performance of participating laboratories 
have improved since its inception in 2009. The numbers of participants has increased each 
year (apart from 2012) which highlights the strengthening of the exercise and its economic 
sustainability going forward. The performance of laboratories has mostly improved and this 
is clearly evidenced from Figure 6-7 which displays the averages of both the coefficient of 
variation for all samples in each round and the percentage of participants receiving 
satisfactory z-scores. The percentage of participants receiving satisfactory z-scores has 
increased most years as laboratories gain experience in these exercises and in determining 
potentially atypical toxin profiles. The precision of the laboratories as expressed by the 
coefficient of variation has also showed signs of significant improvement from the early 
exercises in 2009 and 2010. The coefficients of variations are also comparable to other more 
established shellfish biotoxin exercises organised by QUASIMEME, such as exercise BT-11 
for lipophilic marine biotoxins. Datasets in 2014 for BT-11 produced %CVs in the range 20 - 
38%, which equated to between 45 – 80% of participants receiving satisfactory z-scores. In 
the same year, the PSP development exercise generated %CVs in the range 15 – 33% with 55 
-71% of participants receiving satisfactory z-scores. Through adding PSP toxins to their 
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scope, QUASIMEME have established a comprehensive PT scheme for all EU regulated 
shellfish biotoxins. 
 
 
Figure 6-7: Improvements made over the duration of the PSP development exercise 2009-2014 with trend lines showing the 
average decrease in %CVs observed and the increase in the percentage of participants receiving satisfactory z-scores.. 
 
6.4.8 SUMMARY RESULTS FOR INDIVIDUAL TOXINS 
The graphs contained in Figure 6-8 present the data generated for the toxins STX, dcSTX and 
GTX2,3 and represent all results supplied for these toxins by participants. In R57, 2009, 
participants were requested to only submit total toxicity results so no concentrations of these 
analogues were available. The concentrations submitted by participants were normalised to 
the assigned value in that particular round such that all results could be presented in one 
figure.  
Results for all determinants, where an assigned value was calculated, were normalised in this 
way and the data was further assessed as follows. The normalised data was divided into those 
participants using preCOX or PCOX methods of analysis and some non-valid data was 
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removed where participants made gross reporting errors in calculating concentration or 
during submission. To minimise the influence of extreme results in this further statistical 
evaluation, outliers were identified and removed prior to assessment (note that non-valid or 
extreme results are not removed in the general QUASIMEME assessment as the Cofino 
model is specifically designed to cope with these scenarios). The identification of outliers 
was carried out by applying a Dixon’s test (α = 0.05), with a maximum of one result removed 
from each data set. 
In the case of the epimers, GTX2 & 3, PCOX participants submitted results for each 
individual analogue, while preCOX participants, where epimeric separation is not possible, 
submitted a result for the sum of the epimeric pair only. To compare the two methods, it was 
therefore necessary to sum the individual analogue concentrations from PCOX participants 
and normalise this concentration to the assigned value for the combined pair of epimers, 
generated from preCOX participant results only. 
Comparison of both methods was only carried out on the toxins dcSTX, STX and GTX2,3 as 
there was insufficient data submitted by participants for other toxins present in the samples.  
After the removal of non-valid data and outliers, the normalised mean and standard 
deviations were calculated for each method and all determinants. A paired t-test (two tailed, 
α=0.05) was then performed on the data to observe if there was a statistical difference 
between the two LC-FLD methods in determining the concentrations of those toxins. 
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Figure 6-8: Summary data of all determinations for STX, dcSTX and GTX2,3 normalised to the assigned values in each round. 
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The results of the paired t-test showed there to be a statistical difference between both data 
sets in the case of dcSTX and GTX2,3 but not for STX. The statistical differences observed 
could be partially explained through the extraction techniques of both methods. As discussed 
earlier, partial hydrolysis of the N-sulfocarbamoyl toxins to their carbamoyl counterparts may 
explain the higher mean values observed from PCOX participants for the toxins GTX2,3, 
although C1,2 were not present in very high concentrations. If however, hydrolysis of the N-
sulfocarbamoyl toxins statistically differentiates both methods for GTX2,3 determination 
then these differences would be expected for STX as well. Hydrolysis of GTX5 to STX 
would also be expected to take place, and although GTX5 was not present in high levels in 
these tissues, it was present at similar levels to the C-toxins. 
Another major difference between the PCOX and preCOX extraction methods is the cleanup 
method employed. Samples extracted by the preCOX method are subjected to a minimum of 
SPE cleanup using C18 cartridges and depending on the toxin profile present may also require 
further SPE cleanup with carboxylic acid cartridges. This cleanup step is not carried out in 
the PCOX extraction method, where samples, after initial extraction, follow a 
deproteinisation step using trichloro-acetic acid and centrifugation. The application of the 
SPE cleanup steps in the preCOX method would, unless recovery factors are determined and 
applied, underestimate results generated using this method, owing to losses during the 
process. Differences between both of these methods have also been highlighted in results 
from previous studies by Turner et al. [151] and in PT schemes operated by the EU-RLMB 
[163,164,166].  
 
6.5 CONCLUSIONS 
Six development exercises for PSTs have been delivered since 2009 by QUASIMEME, with 
global participation from laboratories using a range of different methods of analysis based on 
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LC-FLD, LC-MS/MS, animal toxicity and immuno-based assays. Whilst no specific and 
consistent method dependency issues could be detected from the datasets, factors affecting 
poor performance were highlighted with suggestions made on how improvements could be 
made. Data is continually monitored by QUASIMEME through their Scientific Advisory 
Board (SAB) to determine issues contributing to poor performance and any method related 
issues. Personalised feedback to participants, particularly those with unsatisfactory 
performances is not carried out by QUASIMEME owing to the large scope of determinants 
within their remit and the practicalities of extensively reviewing so many datasets. 
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Chapter 7  
CONCLUSIONS AND FURTHER WORK 
 
7.1 CONCLUSIONS 
The research detailed in this thesis describes investigations of various RM preparation 
techniques evaluated for their stabilising effects on PSTs and their applications in various 
internal and external QA/QC programmes. 
The research began similarly to any planned RM preparation, by sourcing materials 
contaminated with PSTs necessary to complete the studies. Shortly after the commencement 
of these studies a large PSP event took place in Iceland. Large quantities of contaminated 
materials were harvested and used in the RM experiments but samples were also taken 
throughout the toxic period and analysed at the MI using various methods. As PSTs had not 
been previously reported from Icelandic waters the data was compiled, including 
phytoplankton data, and presented as a first report (Chapter 3). Shellfish tissues were also 
sourced from other MI collaborators which provided samples of various shellfish species 
containing an assortment of toxin profiles. Once adequate quantities of tissues had been 
sourced, various stabilisation techniques were evaluated to observe their effects on PST and 
matrix stability. 
Freeze drying proved to be the most effective technique investigated, with the greatest level 
of PST stability demonstrated in materials prepared in this way (Chapter 5). Freeze drying 
had not previously been carried out within MI facilities so it was necessary to initially carry 
out a feasibility study on the technique to evaluate MI capabilities as well as confirming the 
stability advantages of the technique. Once the feasibility of carrying out this technique at the 
MI was demonstrated, all associated processing and dispensing steps were optimised. This 
was carried out through a series of experiments aimed firstly at gaining experience in 
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preparing materials in this way and secondly to confirm the equipment at the MI was suitable 
to prepare materials at MCs close to ~5%. Further experiments, using the optimised 
conditions, were then conducted, specifically to investigate issues arising from the feasibility 
study which related to toxin biotransformations and epimerization. Through sterilization of 
the source tissues prior to freeze drying these reactions were minimised. A final, relatively 
large scale material (>1000 aliquots), was then prepared using all the experimentally 
determined conditions to produce a material as a candidate CRM in collaboration with 
CEFAS. This material is awaiting certification and characterisation studies due to funding 
issues and the current availability of another PST CRM from CEFAS. 
The use of preserving additives, both separately and combined were also evaluated for their 
stabilisation effects and both were proven to be effective in RM preparation for various PSTs, 
specifically GTX1,4 (Chapter 4). The heat treatment of tissues was also evaluated in parallel 
with the additives study and this technique provided excellent matrix and toxin stability for 
the remaining PSTs investigated in that section, namely dcSTX, STX, GTX5 and GTX2,3. 
The results from this study indicated that combining both techniques would produce a 
material with excellent stability for all the toxins studied. Materials were prepared in this way 
and used internally at the MI in the routine QC/QA of the NMP for PSP toxins and in a 
development exercise for international PT schemes operated by QUASIMEME and 
VEREFIN. The short-term stability, demonstrated sufficiently in these materials, was an 
important prerequisite for these PT materials. 
The novel application of HPP in RM preparation was also investigated for the stabilising 
effects this technique provided (Chapter 4). The technique provided excellent matrix and 
toxin stability and was the only other technique, other than freeze drying, which could be 
considered for a feasibility study into CRM production. The HPP equipment used in this 
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section is expensive although it is available as a commercial service to paying customers. 
This may limit its’ applicability in LRM or ILRM preparation as other techniques such as 
thermal treatment or the use of preserving additives provide more cost effective stabilisation 
techniques. 
The final part of this research concerned a specific application of materials prepared through 
thermal treatment and spiking with preserving additives. The first commercially available 
PST PT scheme was operated by QUASIMEME using materials prepared using these 
techniques and results from these exercises were presented (Chapter 6). Participants used a 
range of different methodologies from animal based assays to instrument based methods of 
analysis. Participants’ results were evaluated specifically to determine if trends existed in the 
datasets and if they related to specific methods or analogues being determined. Results 
suggested many factors influence participant performance and therefore z-scores so specific 
method or analogue dependency issues could not be definitively determined. 
The studies contained in this thesis provided PST RM preparation techniques for multiple 
uses in LRM, ILRM and potential CRM production. Materials were used in the daily QC/QA 
of produce from Irish shellfish farmers and provided an excellent material for method 
development and validation studies. These studies were crucial in the movement away from 
the use of animal based assays to instrumental based methods of analysis in Ireland. The use 
of preserving additives or thermal treatment provides an extremely cost effective means for 
PST RM preparation and should be within the capacity of most monitoring or research 
laboratories. 
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7.2 FURTHER WORK 
The research contained in this thesis focused on tools that can be used in statutory monitoring 
of PSP toxins in shellfish. The research sought to gain further understanding on the 
mechanisms of PST degradation, epimerization or biotransformations taking place in 
shellfish tissue matrices and to highlight the advantages of each technique for various RM 
uses. One use for these materials is in PT development exercises and participant data was 
evaluated over a 6 year period from schemes operated by QUASIMEME. 
The findings from this research have raised some questions and have highlighted some areas 
that warrant further investigation such as the following. 
 The continued monitoring of Icelandic shellfish for marine biotoxins including 
causative organisms in water samples. This is in order to produce a thorough risk 
assessment for the occurrence of not only PSP toxins but other toxin groups present in 
Icelandic waters. Data on the timing and intensity of these algal blooms will provide a 
more comprehensive picture on toxin accumulation in Icelandic shellfish which will 
aid in setting up an Icelandic monitoring programme. 
 HPP treatment of different tissue matrices, particularly mussel, could be investigated 
to observe if the same level of stability as seen in oysters tissues is evident. 
 The certification studies should be carried out on the large scale freeze dried material 
prepared at the end of Chapter 5. The stability and homogeneity of this material could 
be determined after which the material could be made commercially available. The 
certification, if not carried out using a multi method approach, could be achieved 
through an interlaboratory exercise (consensus of expert laboratories). 
 Expand the QUASIMEME PSP exercise to include more shellfish species and toxin 
profiles in the programme. This will specifically involve sourcing various species 
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from third party suppliers or alternatively, shellfish could be fed with various species 
of phytoplankton to produce the different profiles required. The inclusion of toxins 
not covered so far in these exercises such as those predominating in shellfish from the 
South of Europe for example GTX6 and C3,4 should also be considered. The 
inclusion of these toxins could be problematic however as there are currently no 
CRMs available. 
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